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Introduction
Parkinson’s disease
Box 1  Clinical criteria of Parkinson’s Disease (Hughes et al. 1992)
A. Diagnostic criteria 
 -  Bradykinesia (slowness of initiation of voluntary movement with progressive  
reduction in speed and amplitude of repetitive actions
 -  And at least one of the following:
  · Muscular rigidity
  · 4-6 Hz rest tremor
  ·  Postural instability not caused by primary visual, vestibular, cerebellar,  
or proprioceptive dysfunction
B. Exclusion criteria for Parkinson’s disease
 -  History of repeated strokes with stepwise progression of parkinson features
 -  History of repeated head injury
 -  History of definite encephalitis
 -  Oculogyric crises
 -  Neuroleptic treatment at onset of symptoms
 -  More than one affected relative
 -  Sustained remission
 -  Strictly unilateral features after 3 years
 -  Supranuclear gaze palsy
 -  Cerebellar signs
 -  Early severe autonomic involvement
 -  Early severe dementia with disturbances of memory, language, and praxis
 -  Babinski sign
 -  Presence of cerebral tumour or communicating hydrocephalus on CT scan
 -  Negative response to large dose of levodopa (malabsorption excluded)
 -  MPTP exposure
C. Supportive prospective positive criteria for Parkinson’s disease
 -  Unilateral onset
 -  Rest tremor present
 -  Progressive disorder
 -  Persistent asymmetry affecting side of onset most
 -  Excellent response (70-100%) to levodopa
 -  Severe levodopa-induced chorea
 -  Levodopa response for 10 years or more
 -  Clinical course of 10 years or more
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Parkinson’s disease (PD) is the most common disorder in the group of parkinsonian 
syndromes, accounting for 75% of patients. The disease usually presents around the age 
of 60 years (but with a wide range), and is characterized by a slowly progressive, 
asymmetrical, dopamine-responsive hypokinetic-rigid syndrome. (Tolosa et al. 2006) 
However, although the diagnosis of PD is currently still based on the presence of such 
motor symptoms, these represent only the tip of the iceberg. (Langston 2006) 
A broad variety of non-motor symptoms can accompany the characteristic motor 
symptoms, and this includes neuropsychiatric symptoms, sleep disorders and autonomic 
symptoms. With disease progression, these non-motor symptoms increase both in 
severity and frequency, (Hawkes 2008) although they are common even in de novo 
patients with PD. Some of these non-motor symptoms, like olfactory deficits, sleep 
problems and constipation, can even precede the characteristic motor symptoms by at 
least several years. (Chaudhuri and Naidu 2008) 
Neuropathologically, PD is initially characterized by progressive loss of dopaminergic 
neurons in the substantia nigra caused by alpha-synuclein aggregations. Later in the 
course of the disease, the degeneration spreads in both brain stem and cerebrum. (Braak 
et al. 2003) Moreover, the pathology affects not only dopaminergic neurons, but also 
noradrenergic, cholinergic and serotonergic neurotransmitter systems.
The treatment of PD is only symptomatic, and no curative treatment is currently available. 
The most widely used approach is the administration of the dopamine precursor levodopa. 
In addition, drugs have been developed that stimulate dopamine receptors or that block 
the metabolism of endogenous or exogenous dopamine. Stereotactic deep brain surgery 
– and in particular deep brain stimulation with electrodes positioned in specific brain 
areas – can also improve clinical symptoms in selected patients. In addition to this medical 
management, attention is increasingly focused on a multidisciplinary team approach. (van 
der Marck et al. 2013a) No less than 19 professional disciplines can be involved, (Keus et al. 
2012) and this involves (among others) speech-language therapy, physical therapy 
and occupational therapy. Parkinson nurses also play a vital role in the management of 
PD patients. 
Evidence supporting the merits of allied health interventions is steadily growing, in 
particular for physical therapy (Keus et al. 2007; Keus et al. 2009)  and speech-language 
therapy, (de Swart et al. 2003; Fox et al. 2012) but also for other disciplines. (Sturkenboom 
et al. 2013) Whether or not extra benefits are achieved by bundling the forces of several 
disciplines into a coherent multispecialty team approach remains unclear. One recent trial 
has shown that an integrated multidisciplinary approach offers benefits to patients, 
(van der Marck et al. 2013a) helping them to maintain a good quality of life as long as 
possible. However, another recent study – that tested a different model of integrated 
multi disciplinary care – showed only small benefits in favor of the intervention group, and 
these disappeared after correction for baseline differences. (van der Marck et al. 2013b) 
More work remains needed to identify the best team composition, and in particular to 
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identify which patients can reasonably be expected to benefit most from such an intensive 
and tailor-made team approach. (Parashos 2013) 
Atypical parkinsonism
The group of atypical parkinsonism consists of multiple system atrophy, dementia with 
Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. The first two 
disorders constitute, along with PD, the so-called alpha synucleopathies, because alpha 
synuclein aggregates are found upon neuropathological examination. Progressive 
supranuclear palsy and corticobasal degeneration are caused by tau aggregates and are 
therefore called tauopathies. In addition to these disorders, most neurologists would 
regard vascular parkinsonism as a form of atypical parkinsonism. I will briefly discuss the 
main features of these forms of atypical parkinsonism below, with references to key papers 
for further reading.
Multiple system atrophy
Multiple system atrophy (MSA) is characterized clinically by a combination of a symmetrical 
hypokinetic-rigid syndrome, cerebellar ataxia, autonomic disturbances and – less 
frequently – pyramidal tract involvement. Recent work has shown that patients can also 
develop cognitive impairment, in particular frontal executive dysfunction. (Brown et al. 
2010) Patients show only a limited response to dopaminergic therapy, although initially a 
favorable response is possible. (Quinn 1989)
Clinically, MSA can be divided into two subtypes: MSA-c when the cerebellar symptoms 
are predominant, and MSA-p when the clinical picture is dominated by the hypokinetic- 
rigid symptoms. (Gilman et al. 2008) The disease typically presents around the age of 60, 
never before the age of 45, and is rapidly progressive. Within 5-6 years the majority of 
patients is wheelchair dependent. The mean disease duration is 8-10 years. (Klockgether et 
al. 1998; Watanabe et al. 2002; Wenning et al. 2013) Neuropathologically, the disease is 
characterized by alpha-synuclein inclusions in the striato-nigral (MSA-p) and/or olivoponto-
cerebellar tracts (MSA-c). (Ozawa et al. 2004)
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Box 2  Clinical criteria of Multiple system atrophy (Gilman et al. 2008)
A. Diagnostic criteria 
 -  Possible diagnosis of MSA
  · Parkinsonism  (bradykinesia with rigidity, tremor or postural instability) or 
  ·  A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia or cerebellar 
oculomotor dysfunction)  and
  ·  At least one feature suggesting autonomic dysfunction (otherwise unexplained 
urinary urgency, frequency or incomplete bladder emptying, erectile dysfunction in 
males or significant orthostatic blood pressure decline that does not meet the level 
required in probable MSA and
  · One additional feature (B)
 -  Probable diagnosis of MSA 
Autonomic failure involving urinary incontinence (inability to control the release of urine 
from the bladder, with erectile dysfunction in males) or an orthostatic decrease of blood 
pressure within 3 minutes of standing by at least 30mm Hg systolic or 15mmHg diastolic 
AND poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor or 
postural instability) OR a cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb 
ataxia or cerebellar oculomotor dysfunction)
 - Definite diagnosis of MSA 
 Histopathological confirmation of the diagnosis is obtained at autopsy
B. Additional features of possible MSA
 - Possible MSA-p or MSA-c
  · Babinski sign with hyperreflexia
  · Stridor
 - Possible MSA-p
  · Rapidly progressive parkinsonism
  · Poor response to levodopa
  · Postural instability within 3 years of motor onset
  · Gait ataxia, cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction
  · Dysphagia within 5 years of motor onset
  · Atrophy on MRI of putamen, middle cerebellar peduncle, pons or cerebellum
  · Hypometabolism on FGD-PET in putamen, brainstem or cerebellum
 - Possible MSA-c
  · Parkinsonism (bradykinesia and rigidity)
  · Atrophy on MRI of putamen, middle cerebellar peduncle or pons
  · Hypometabolism on FDG-PET in putamen
  · Presynaptic nigrostriatal dopaminergic denervation on SPECT or PET
Introduction and outline
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Dementia with Lewy bodies
Box 2  Continued
C. Features supporting MSA
 ·  Orofacial dystonia
 ·  Disproportionate antecollis
 ·  Camptocormia and/or Pisa syndrome
 ·  Contractures of hands or feet
 ·  Inspiratory sighs
 ·  Severe dysphonia
 ·  Severe dysathria
 ·  New or increased snoring
 ·  Cold hands and feet
 ·  Pathologic laughter or crying
D. Features suggestive of alternative diagnoses
 ·  Classic pill-rolling rest tremor
 ·  Clinical significant neuropathy
 ·  Hallucinations not induced by drugs
 ·  Onset after age 75 years
 ·  Family history of ataxia or parkinsonism
 ·  Dementia (on DSM-IV)
 ·  White matter lesions suggesting multiple sclerosis
Box 3  Clinical criteria of Lewy body dementia (McKeith et al. 2005)
A. Diagnostic criteria 
 -  Possible diagnosis of DLB 
Central feature with either one core feature or one suggestive feature
 -  Probable diagnosis of  DLB 
Central feature with either two core features or one core feature and one suggestive 
feature
 -  Definite diagnosis of DLB 
Criteria for clinical DLB are met and histopathological confirmation of the diagnosis is 
obtained at autopsy
14
Dementia with Lewy bodies (DLB) is a form of dementia characterized by fluctuating 
cognition, visual hallucinations, a hypokinetic-rigid syndrome that is poorly responsive to 
dopaminergic medication, and autonomic disturbances. By definition, the cognitive 
disturbances precede the motor symptoms, or occur within 12 months of onset of the 
motor symptoms.  (McKeith et al. 2005) An accompanying clinical feature is an increased 
Box 3  Continued
B. Central feature
 Dementia defined as progressive cognitive decline of sufficient magnitude to interfere 
with normal social or occupational function. Prominent or persistent memory impairment 
may not necessarily occur in the early stages but is usually evident with progression. 
Deficits of attention, executive function, and visuospatial ability may be specially 
prominent
C. Core features
 · Fluctuating cognition with pronounced variations in attention and alertness
 · Recurrent visual hallucinations that are typically well formed and detailed
 · Spontaneous features of parkinsonism 
D.  Suggestive features
 · REM sleep behaviour disorder
 · Severe neuroleptic sensitivity
 ·  Low dopamine transporter uptake in basal ganglia demostrated by PET or SPECT 
imaging
E.  Supportive features
 · Repeated falls and syncope
 · Transient, unexplained loss of consciousness
 · Severe autonomic dysfunction, e.g. orthostatic hypotension, urinary incontinence
 · Hallucinations in other modalities
 · Systemized delusions
 · Depression
 · Relative preservation of medial temporal lobe structures on CT/MRI scan
 · Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity
 · Abnormal (low uptake) MIBG myocardial scintigraphy
 · Prominent slow wave activity on EEG with temporal lobe transient sharp waves
F.  Non-supportive features
 ·  The presence of cerebrovascular disease evident as focal neurologic signs or on brain 
imaging
 ·  Other physical illness or brain disorder sufficient to account in part or total for the 
clinical picture
 · If parkinsonism only appears for the first time at a stage of severe dementia
Introduction and outline
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sensitivity to neuroleptics. The mean disease duration is 8-10 years. Neuropathologically, 
Lewy bodies can be found with alpha synuclein aggregations in the cortex, limbic system 
and brainstem. (McKeith et al. 2005)
Progressive supranuclear palsy
Box 4  Clinical criteria of Progressive supranuclear palsy (Litvan et al. 1996)
A. Diagnostic criteria 
 - Possible diagnosis of PSP 
Gradually progressive disorder, onset at age 40 or later with either vertical (upward or 
downward) supranuclear palsy or both slowing of vertical saccades and prominent 
postural instability with falls in the first year of disease onset and no evidence of other 
diseases that could explain the foregoing features, as indicated by C. Mandatory exclusion 
criteria
 - Probable diagnosis of PSP 
Gradually progressive disorder, onset at age 40 or later with vertical (upward or downward) 
supranuclear palsy and prominent postural instability with falls in the first year of disease 
onset and no evidence of other diseases that could explain the foregoing features, as 
indicated by C. Mandatory exclusion criteria
 - Definite diagnosis of PSP 
Clinically probable or possible PSP and histopathological evidence of typical PSP
B. Features supporting PSP
 - Symmetric akinesia or rigidity, proximal more than distal
 - Abnormal neck posture, especially retrocollis
 - Poor or absent response of parkinsonism to levodopa therapy
 - Early dysphagia and dysarthria
 -  Early onset of cognitive impairment including at least two of the following: apathy, 
impairment in abstract thought, decreased verbal fluency, utilization or imitation 
behavior, or frontal release signs
C. Mandatory exclusion criteria
 - Recent history of encephalitis
 - Alien limb syndrome, cortical sensory deficits, frontal focal or temporoparietal atrophy
 - Hallucinations or delusions unrelated to dopaminergic therapy
 -  Cortical dementia of Alzheimer’s type (severe amnesia and aphasia or agnosia according 
to NINCDS-ADRA criteria)
 -  Prominent, early cerebellar symptoms or prominent, early unexplained dysautonomia 
(marked hypotension and urinary disturbances)
 - Severe asymmetric parkinsonian signs
 - Neuroradiologic evidence of relevant structural abnormality 
 - Whipple’s disease
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Progressive supranuclear palsy (PSP) is classically characterized clinically by a symmetrical 
hypokinetic-rigid syndrome with postural instability, causing frequent falls early in the 
cause of the disease, cognitive deterioration (mainly frontal executive dysfunction) and a 
supranuclear gaze palsy (Steele-Richardson-Olszewski syndrome). However, an asymmetric 
variant, closely resembling PD also exists (PSP-P).  The mean age at which symptoms 
appear is between 50 and 70 years. The disease is rapidly progressive, with a mean survival 
of 6-9 years after diagnosis. (Burn and Lees 2002) The response to symptomatic treatment 
is rarely gratifying. Neuropathologically the disease is characterized by hyper-fosforylated 
tau protein depositons with loss of neurons in the midbrain and frontal lobes. (Dickson et 
al. 2007)
Corticobasal degeneration
Corticobasal degeneration is characterized clinically by an asymmetrical, non-dopamine 
responsive hypokinetic-rigid syndrome, with additional features including dystonia, and 
asymmetrical cortical dysfunction (apraxia, aphasia, stimulus-sensitive myoclonus, cortical 
sensory disturbances or an alien limb phenomenon). (Mahapatra et al. 2004) This symptom 
complex is known as corticobasal syndrome (CBS), which can be caused not only by 
CBS but also by a number of other conditions (e.g. vascular lesions or prion disease). 
Clinical differentiation can be complex, as both MSA (Batla et al. 2013) and PSP can present 
quite asymmetrically, and CBS on the other hand can present symmetrically. (Wadia and 
Box 5  Clinical criteria of Corticobasal syndrome (Boeve et al. 2003)
A. Core features 
 - Insidious onset and progressive course
 - No identifiable cause (e.g. tumor, infarct)
 -  Cortical dysfunction as reflected by at least one of the following: focal or asymmetrical 
ideomotor apraxia, alien limb phenomenon, cortical sensory loss, visual or sensory 
hemineglect, constructional apraxia, focal or asymmetrical myoclonus, apraxia of 
speech/nonfluent aphasia
 -  Extrapyramidal dysfunction as reflected by at least one of the following: focal or 
asymmetrical appendicular rigidity lacking prominent and sustained levodopa response 
OR focal or asymmetrical appendicular dystonia
B.  Supportive investigations
 -  Variable degrees of focal or lateralized cognitive dysfunction, with relative preservation 
of learning and memory, on neuropsychometric testing
 - Focal or asymmetric atrophy on CT or MRI, typically maximal in parietofrontal cortex
 -  Focal or asymmetric hypoperfusion on SPECT and PET, typically maximal in 
parietofrontal cortex and/or basal ganglia and/or thalamus
Introduction and outline
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Lang 2007) The response to symptomatic treatment is again poor. Symptoms usually 
present around the age of 60 and the disease is rapidly progressive, with a mean survival 
of 8 years after disease onset. (Wenning et al. 1998) Neuropathologically, the disease is 
characterized by asymmetrical atrophy of both frontal and parietal cortex with 
aggregations of hyper-fosforylated tau protein. (Ludolph et al. 2009)
Vascular parkinsonism
Vascular parkinsonism (VaP), is characterized by the combination of a hypokinetic rigid 
syndrome and evidence of cerebrovascular disorder. Lower body parkinsonism is the 
predominant feature in up to two thirds of the patients. Patients are older upon 
presentation than patients with PD (mean age of 70), and the mean survival is 10-12 years. 
Vascular risk factors are present in almost 90% of the patients with VaP. The course of the 
disease can be abrupt, or stepwise, but insidious courses are not uncommon (70%). Sense 
of smell is typically preserved. Over one half of the patients show at least some response 
to levodopa therapy. (Glass et al. 2012) 
Other look-alikes
There are many other diseases that can present with parkinsonism, or develop parkinsonism 
in the course of the disease. One example is the development of parkinsonism in the 
course of Creutzfeldt Jakob’s disease.  On the other hand, there are many conditions that 
may mimic (aspects) of a hypokinetic-rigid syndrome, such as the lack of facial expression 
in a patient with depression. In chapter 2 we will discuss this in more detail.
Box 6  Clinical criteria for Vascular Parkinsonism (Zijlmans et al. 2004)
A. Parkinsonism: bradykinesia and at least one of the following: rest tremor, muscular rigidity, 
or postural instability (not caused by primary visual, vestibular, cerebellar or proprioceptive 
dysfunction.
B. Cerebrovascular disease, defined by evidence of relevant cerebrovascular disease by 
brain imaging (CT or MRI), or the presence of focal signs or symptoms that are consistent 
with stroke.
C. A relationship between the above two disorders. In practice: An acute or delayed 
progressive onset with infarcts in or near areas that can increase the basal ganglia motor 
output (GPe or substantia nigra pars compacta) or decrease the thalamocortical drive 
directly (VL of the thalamus, large frontal lobe infarct). The parkinsonism at onset consists 
of a contralateral bradykinetic rigid syndrome or shuffling gait, within 1 year after a stroke. 
Or, an insidious onset of parkinsonism with extensive subcortical white matter lesions, 
bilateral symptoms at onset, and the presence of early shuffling gait or early cognitive 
dysfunction.
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Differentiating between PD and atypical parkinsonism
Clinical criteria (boxes 1-6) are available for the diagnosis of PD and for the various forms of 
atypical parkinsonism. These criteria provide a ‘possible’ and ‘probable’ diagnosis. (Litvan 
et al. 1996) This distinction is based globally on the following items: rate of progression 
(slow for PD, rapid for AP); response to dopaminergic treatment (good and sustained for 
PD; absent or at best modest but short-lived for AP; and presence of red flags (absent for 
PD; one or more for AP, with sometimes characteristic combinations). The term ‘red flags’ 
refers to all symptoms that signal the presence of AP (and at times the presence of a 
specific form of AP), such as ataxia or vertical gaze palsy.  The gold standard, however, 
remains a neuropathological confirmation. Clinicopathological studies have shown that, 
compared to this golden standard, a relatively large proportion of clinical diagnoses is 
incorrect. Up to 10% of patients diagnosed with PD during life has a different neuropatho-
logical diagnosis upon post-mortem examination. (Hughes et al. 2001a; Hughes et al. 
2001b; Hughes et al. 2002) In atypical parkinsonism, this percentage is even higher. Only 70 
% of the neuropathologically proven cases of MSA and/or PSP were correctly diagnosed 
as such during life. (Litvan et al. 1997; Osaki et al. 2002; Williams et al. 2005) Due to increasing 
awareness of these syndromes, the number of correct diagnoses is increasing. The clini-
co-pathological study performed in 2002 by Hughes et al (Hughes et al. 2002) illustrates 
this: the positive predictive value for the diagnosis of PD was 98.6% (sensitivity 91.1% 
specificity 98.4%). The diagnostic accuracy of the atypical parkinsonian syndromes has 
also increased; the use of the clinical consensus criteria leads to a sensitivity of 88.2% and 
a specificity of 95.4%. For PSP a sensitivity of 84.2% and a specificity of 96.8% were found 
and for CBS a sensitivity of 25% and a specificity of 98,6%. (Hughes et al. 2002) Moreover, 
these numbers have been validated for neurologists specialized in movement disorders 
and after extensive follow up (3 years). The diagnostic dilemma in differentiating between 
PD and AP is much greater in the first year of the disease and in general hospitals: the 
sensitivity for the diagnosis of MSA upon the first visit was only 25%, and only 50-60% after 
1 year of follow-up. (Litvan et al. 1997; Osaki et al. 2002)
Box 6  Continued
D. Exclusion criteria for VaP:  History of repeated head injury, definite encephalitis, 
neuroleptic treatment at onset of symptoms, presence of cerebral tumor or 
communicating hydrocephalus on CT or MRI scan, or other alternative explanation for 
parkinsonism.
Introduction and outline
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Aim and outline of the thesis
The overall aim of this thesis is to evaluate and optimize the differentiation between PD 
and atypical parkinsonism in a clinical setting. 
First, the clinical evaluation of a patient with parkinsonism is described in detail in chapter 2, 
including careful assessment of potential ‘red flags’. In chapter 3 we have explored the 
potential of CSF biomarkers in the differentiation between PD and different forms of 
atypical parkinsonism, as well as between different forms of atypical parkinsonism. In the 
last part of this thesis, in chapter 4, we present the results of a prospective clinical study 
in which we evaluated both clinical and ancillary investigations differentiating PD from AP. 
We will conclude with several recommendations on how to incorporate these findings 
in current clinical practice. 
2 |
2 | Clinical evaluation of a patient  
with parkinsonism 
Based on
Aerts MB, Esselink RA, Post B, van de Warrenburg BP, Bloem BR.  
Improving the diagnostic accuracy in parkinsonism: a three-pronged 
approach. Practical Neurology. 2012;12(2):77-87.
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Summary
Separating Parkinson’s disease (PD) from the various causes of atypical parkinsonism (AP) 
is a common and clinically relevant challenge in clinical practice. Distinguishing between 
the different causes of AP is even more difficult. Here we discuss a systematic, clinically 
based and three-pronged approach that can assist clinicians in establishing the correct 
diagnosis in the consulting room. The three consecutive steps include: 1. to verify that the 
clinical syndrome truly represents parkinsonism (hypokinetic-rigid syndrome); 2. to 
systematically search for the presence of ‘red flags’ (alarm signs that may signal the 
presence of AP); and 3. to integrate these two steps, as a basis for a narrow differential 
diagnosis and guide for further ancillary tests.
Clinical evaluation of a patient with parkinsonism
2
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Introduction
The presence of parkinsonism can be established in the clinical examination room, based 
on history taking and neurological examination. Parkinson’s disease (PD) is the most 
frequent cause, but the differential diagnosis is broad and includes, among others, 
multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal 
syndrome (CBS), dementia with Lewy bodies (DLB), vascular parkinsonism (VaP) and 
drug-induced parkinsonism. This wide group of ‘other’ causes of parkinsonism is here 
referred as atypical parkinsonism (AP). A list of the potential causes of parkinsonism is 
presented in Table 1a and b. 
Table 1a   Neurodegenerative diseases known to possibly present with features of 
parkinsonism
Parkinson’s Disease (idiopathic) 
Genetic parkinsonism, e.g. LRRK2, parkin, PINK1 
Atypical Parkinsonism 
 - Multiple system atrophy (MSA)
 - Progressive supranuclear palsy (PSP)
 - Corticobasal syndrome (CBS)
 - Lewy body dementia (DLB) 
Alzheimer’s Disease with parkinsonism
Frontotemporal dementia with parkinsonism (FTDP-17)
Huntington’s Disease
Spinocerebellar ataxias (SCA), e.g. SCA2, 3 and 17
Recessive parkinsonism-dystonia disorders (e.g. Kufor-Rakeb, PARK14, DYT16)
Rapid-onset dystonia-parkinsonism
Dopa-responsive dystonia
Neuroacanthocytosis
Fragile-X tremor/ataxia syndrome
X-linked dystonia-parkinsonism (Lubag)
Fahr syndrome
Neuronal intranuclear inclusion disease
Neurofilament inclusion body disease
Perry syndrome (Dynactin mutations)
Hereditary spastic paraplegia (SPG11)
Heredodegenerative diseases
 - Wilson’s disease
 - Gaucher’s disease type I
 - Mitochondrial disorders
 - NBIA (neurodegeneration with brain iron accumulation)
24
Parkinsonism is a common finding in neurological outpatient clinics. The incidence ranges 
from an estimated 0.5/1000 person-years for patients aged between 55 and 65 years to 
10.6/1000 person-years for subjects aged above 85 years. (de Lau et al. 2004) Early in the 
course of the disease, establishing a correct diagnosis can be challenging due to overlap 
in the clinical presentation between the various forms of parkinsonism (Figure 1). However, 
being able to differentiate between PD and AP is highly relevant, for several reasons. First, 
patients find it important to know which specific disease they have. Second, the prognosis 
varies greatly across the different causes of parkinsonism. In general, disease progression 
is slower in PD compared with AP. Third, an accurate diagnosis is important to prompt 
attention to disease-specific complications, such as nocturnal inspiratory stridor in MSA 
patients (which is a cause of sudden death in this disorder!), or the ‘motor recklessness’ 
and concomitant injurious falls seen in patients with PSP. Medication effects are typically 
much less in AP, with fewer patients that respond, and a more modest and temporary 
improvement for those that respond. Fourth, differentiation between PD and AP is 
Table 1b   Secondary causes of parkinsonism
Medication induced
 - Neuroleptics
 - Valproic acid 
 - Lithium
 - Calcium channels blockers
Structural
 - Vascular (vascular parkinsonism)
 - Trauma (dementia pugilistica)
 - Subdural hematoma
 - Normal pressure hydrocephalus
Toxins
 - Manganese
 - MPTP
 - Mercury
 - Methanol
 - Solvents
 - Carbon monoxide
 - Carbon disulfide
 - Cyanide
 - Organophosphates
 - Pesticides
(Post) infectious
 - HIV
 - Encephalitis lethargica
 - Japanese B encephalitis 
 - Coxsackie B virus
 - Measles
 - EBV (Epstein Barr virus)
 - West-nile virus
 - Neurosyphilis
Metabolic
 - Hypoparathyroidism
 - Hypothyroidism
 - Uremia 
 - Carbon monoxide
 - GM1 gangliosidosis
 - Addison’s disease
 - Hypoxia
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important for research purposes, as a correct diagnosis is needed to include the right 
patients for specific trials.
A recent paper in this journal carefully discussed the essentials of PD. (Lees 2010) 
Capitalizing on this paper, we here present a framework to differentiate between PD and 
AP, based on three subsequent steps.
Step 1: the core criteria of parkinsonism 
The first step is to carefully assess whether the patient truly has parkinsonism. This can be 
overlooked easily, for two reasons.  First, the motor symptoms of parkinsonism can be 
subtle early in the course of the disease, leading to a false-negative diagnosis. Second, 
some conditions mimic parkinsonism, leading to a false-positive diagnosis (Table 2). We 
will exemplify both types of misdiagnosis.
The conventional core criteria for parkinsonism (UK Brain Bank) include bradykinesia and 
at least one of the following: rigidity, rest tremor or postural instability. Hence, the presence 
of bradykinesia is a prerequisite for the diagnosis of parkinsonism. Classic bradykinesia is 
defined as a progressive decrement of both the speed and amplitude of repetitive 
movements. Clumsiness, slowness or irregularity of movements is, according to this 
definition, insufficient to fulfill the criterion ‘bradykinesia’. Indeed, patients with e.g. 
cerebellar ataxia generally exhibit irregular movements, while patients with spasticity can 
have slow movements, but both lack the classical decrement that is characteristic for true 
bradykinesia. This may explain why patients with an upper motor neuron presentation of 
amyotrophic lateral sclerosis are sometimes misdiagnosed as having parkinsonism. 
Similarly, the spasticity observed in patients with an upper motor neuron disease can be 
mistaken for the rigidity that is observed in parkinsonism. The clasp-knife phenomenon 
Figure 1   Overlapping circles depict the overlap in clinical symptoms. (A) Early in the 
course of the disease the symptoms of Parkinson’s disease (light grey) and 
atypical parkinsonism (dark grey) can closely resemble each other (10-20% 
overlap), whereas (B) late in the course of the disease a small percentage (5%) 
is still misclassified, even in the hands of experts.
A B
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(resistance building up upon passive stretch, which is suddenly giving way) and the 
speed-dependency of the increased tone (present in spasticity and absent in rigidity) can 
be used to discriminate between true rigidity and increased tone based due to spasticity.
The presence of asymmetrical resting tremor is widely perceived as a classical presentation 
of PD, but not all patients actually have parkinsonism. Studies that used nuclear imaging 
to visualize the dopaminergic pathway have identified subjects with such asymmetrical 
resting tremor but without evidence of a dopaminergic deficit upon imaging, so called 
SWEDD’s (scans without evidence of dopamine deficit). The underlying etiology of tremor 
in these SWEDD’s is often dystonia. Separating  (rest) tremor in patients with SWEDD’s 
from parkinsonian rest tremor can be very challenging. Indeed, some SWEDD’s have 
inadvertently been included in clinical drug studies designed for patients with parkinsonism. 
Table 3 summarizes certain clinical features that help to discriminate between tremor in 
PD and SWEDD’s. (Bajaj et al. 2010)
Table 2   Conditions mimicking parkinsonism
Signs and symptoms Differential diagnosis
Slow execution of movements - Decreased motor control (e.g. spasticity or ataxia)
- Cognitive causes (e.g. apathy)
- Mood (depression)
- Metabolic causes (e.g. hypothyroidism)
- Psychogenic slowness
Lack of spontaneous movements - Diminished arm swing (e.g. dystonia or  
frozen shoulder syndrome)
- Mask-like face in depression
- Psychogenic causes
Cog wheel phenomenon - Essential tremor
- Drug-induced tremor
Classical resting tremor - Dystonic tremor
Clinical evaluation of a patient with parkinsonism
2
27
Step 2: presence of ‘red flags’ 
Once the presence of parkinsonism has been established, the second step is to thoroughly 
search for the presence of additional symptoms and signs. These additional symptoms – 
which serve to signal the presence of AP – are commonly referred to as the ‘red flags’ for 
AP. Each of these additional symptoms will be described in more detail below. In addition, 
we have listed the main red flags in Table 4, including suggestions for diagnoses that can 
be considered when a specific red flag is present.
Motor symptoms 
Classically, the distribution of symptoms in PD is asymmetrical. Although these symptoms 
will inevitably present bilaterally, this asymmetrical nature persists throughout the course 
of the disease. In contrast, symptoms are generally much more symmetrical in patients 
with AP. The separation is never complete, as some patients with e.g. MSA can present 
with an asymmetric distribution. And there is one important exception to the rule: the 
asymmetry in CBS is even more pronounced than in PD. A lower-body distribution of 
symptoms – where the legs are much more affected than the arms – is the textbook 
presentation of VaP, especially when accompanied by a stepwise pattern of disease 
progression. A very pronounced axial distribution, in which the axis (i.e. neck, back) is 
much more affected than the extremities, would also be atypical for PD and more 
Table 3  Differentiating SWEDD’s and PD
Symptom PD or SWEDD’s
Bradykinesia (i.e. both slowness AND reduction of amplitude) PD
Tremor characteristics
- Resetting phenomenon (re-emergent tremor)
- Thumb extension tremor
- Head tremor
- Predominantly present in rest
- Predominantly positional
- Task-/position-specificity
- Jerkiness
PD
SWEDD’s
PD
PD
SWEDD’s
SWEDD’s
SWEDD’s
Adequate response to levodopa treatment PD >> SWEDD’s
Non-motor symptoms, including olfaction disturbances PD
PD: Parkinson’s disease; SWEDD’s: scans without evidence of dopaminergic deficits
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suggestive of PSP. Disease progression is generally slow in PD, whereas AP can progress 
more rapidly. Consequently, life-time expectancy in AP is often reduced compared to PD. 
We will next discuss several specific motor symptoms in more detail.
Tremor characteristics 
PD classically presents with an asymmetric rest-tremor, and it is important to document 
whether a true pill-rolling type (with involvement of the thumb) is present, as this is very 
supportive of a diagnosis of PD. Pill-rolling tremor does not exclude AP completely, 
because it can also be observed in drug-induced parkinsonism and MSA, although the 
tremor tends to present more bilaterally and symmetrically in these two conditions. So 
tremor symmetry is a valuable distinguishing feature, next to the nature of the tremor. 
Again, the separation is not complete, because an asymmetric, pill-rolling rest tremor can 
occur in patients with DLB and sporadically even in so called PSP-P patients. A jerky 
tremor, possibly due to polyminimyoclonus, is more suggestive of MSA.
Severe essential tremor, Holmes tremor and dystonic tremor can present with a profound 
rest component. Several elements may help in separating these tremor types from 
parkinsonian tremor. Essential tremor is very symmetrical, and no gross other neuro - 
logical abnormalities should be present (except for mild gait ataxia). Table 3 lists several 
characteristics of dystonic tremor. In addition, dystonic tremor more typically presents 
with thumb extension from the neutral position, while parkinsonian rest tremor usually 
involves thumb flexion from neutral. Holmes tremor tends to have a lower frequency (at 
around 3 Hz) than tremor is PD (generally 4-6 Hz), but reliable frequency-based 
discrimination between the various tremor etiologies is difficult due to considerable 
overlap in frequencies. (Abdo et al. 2010)
When observing rest tremor, it is important to specifically search for the resetting 
phenomenon (also referred to as re-emergent tremor): the re-emergence of tremor with 
a latency after a positional change. This latency suggests that a rest tremor has now 
reappeared in the newly acquired position, and this should not be mistaken for a positional 
tremor. Absence of this resetting phenomenon might point towards a dystonic tremor 
(Table 3). (Bajaj et al. 2010)
Myoclonus 
This concerns sudden, brief, shock-like movements, caused by muscle contractions. 
Especially when myoclonus is severe and frequently repetitive or even rhythmic, the 
 differentiation with tremor can be challenging. A useful sign is the abruptness of the 
movements, because myoclonus is typically jerky, and tremor is not. Careful examination 
of the outstretched hands can reveal subtle polyminimyoclonus without a resetting 
phenomenon and with stimulus-sensitivity (touch of the outstretched fingers); this is 
suggestive of MSA. More pronounced myoclonus, most prominent upon voluntary action 
or in response to sensory stimuli, can be observed in DLB, CBS, and rarely PSP. In CBS, the 
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observed myoclonus is generally focal and often confined to one limb. Myoclonus can 
also be observed in spinocerebellar ataxia syndromes, particularly SCA2, as well as in 
genetic parkinsonian syndromes like PARK9. (Abdo et al. 2010)
Dysphagia / dysarthria 
Mild dysphagia and dysarthria can manifest in all parkinsonian disorders. However, the 
presence of severe dysphagia early in the course of the disease is suggestive for PSP, 
CBS and MSA, especially if a percutaneous endoscopic gastrostomy is necessary. Similarly, 
early presence of severe dysarthria should prompt to MSA or PSP as possible diagnosis. 
The specific characters of the dysarthria may help to differentiate these two disorders: 
a pseudobulbar component suggests PSP, while cerebellar dysarthria suggests MSA. 
Interrater agreement for these dysarthric features is admittedly poor, perhaps with the 
exception of a high-pitched, quivery voice, which is fairly characteristic and suggestive 
for MSA. (Gilman et al. 2008)
Dystonia 
This can occur in both PD and AP. Focal dystonia can be seen in patients with PD, especially 
in patients with young-onset PD or one of the recessive forms of parkinsonism. This mainly 
involves dystonia of the foot, and can be dopamine responsive (hence the frequent 
occurrence early in the morning during a deep off phase). Different forms of dystonia are 
seen in patients with AP. Focal dystonia of the neck muscles (retrocollis) or the eyelid 
muscles (blepharospasm) occurs in PSP. Focal dystonia of the neck muscles also occurs 
in MSA, but now in the form of a mixed antecollis-laterocollis (often fixed and painful). 
MSA can also present with focal dystonia of the vocal cords (spasmodic dysphonia), or a 
segmental dystonia of trunk muscles, causing lateroflexion (Pisa sign) or anteroflexion 
(camptocormia) of the trunk. (Doherty et al. 2011) Note that a Pisa sign or camptocormia 
can also occur in PD or as a side effect of drugs (mainly neuroleptics). A full differential 
diagnosis is presented in table 4. The presence of early, fixed limb dystonia suggests a 
diagnosis CBS. (Boeve et al. 2003)
Pyramidal involvement
Pathological reflexes, including hyperreflexia and Babinski’s sign, can be seen in VP and 
MSA. The Babinski sign should be distinguished from the striatal toe, which reflects 
dystonia of the extensor halluces longus muscle (common in PD). Differentiation can be 
difficult, but generally a sustained extensor response is indicative for a striatal toe, while 
a Babinski response includes an immediate return of the big toe to the neutral position 
after striking the foot sole. The Babinski response is also associated with fanning of 
the other toes, unlike the striatal toe. Furthermore, a striatal toe can present spontaneously, 
especially during walking on bare feet.
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Table 4   Red flags and their most likely diagnosis
Signs and Symptoms Most likely diagnosis
Pattern of distribution
- Symmetrical
- Asymmetrical*
- Lower-body phenotype
PSP, MSA
CBS (very asymmetrical)
VaP
 Course of the disease
- Rapid progression (H&Y 3 < 5 years)
- Stepwise progression
- Remission
PSP, MSA
VaP
VaP, drug-induced parkinsonism
Medication
- No/insufficient response to levodopa 
(>1g per day of levodopa over 1 month)
- Early/profound levodopa intolerance
- Levodopa-induced dyskinesia*
- Non-dopa responsive pain
No response: PSP, CBS; partial response: MSA 
DLB, VaP
MSA, DLB, VaP
All forms of AP
Tremor
- Asymmetrical pill-rolling tremor*
- Irregular, jerky tremor
seldom: MSA
MSA, CBS
Myoclonus MSA (outstretched fingers), CBS, PSP, DLB, 
SCA 2, PARK9
Dysphagia and dysarthria
- Early, severe dysarthria
- Early, severe dysphagia
- Dysphonia (spasmodic)
AP
PSP, MSA
MSA
Sensory disturbances
- Cortical
- Polyneuropathy
CBS
- Drug induced: amantadine
- Intoxication : carbon-disulfide, 
manganese, solvents, carbon-monoxide
- Infectious: syphilis, HIV
- Paraneoplastic: parkinsonism and 
polyneuropathy (fast progression!)
- Endocrine: hypoparathyreoidism
- Metabolic: gangliosidosis
- Mitochondrial: MERFF, POLG mutation
- Neurodegenerative: Neuronal 
intranuclear inclusion disease
MSA
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Table 4   Continued
Signs and Symptoms Most likely diagnosis
Psychiatric symptoms
- Apathy (early)*
- Disinhibition
 ·   Emotionally
 ·    Pseudo-bulbar disinhibition
Hallucinations, delusions
PSP
Early: PSP, to lesser extent: MSA
PSP, CBS
DLB (early) 
Pyramidal involvement VaP, MSA, PARK2,9
Ataxia (cerebellar) MSA, SCA 2,3,17, Neuronal intranuclear 
inclusion disease
Eye movement disturbances
- Supranuclear palsy
- Round-the-house-phenomenon
- Saccadic eye movements
 ·   Delayed initiation
 ·   Delayed execution
- Gaze impersistance
- Square wave jerks
- Dysmetria/overshoot
- Nystagmus
- Ocular apraxia
Oculogyric crisis
PSP
PSP
CBS
PSP
MSA, SCA, PSP
MSA, SCA, PSP
MSA, SCA
MSA, SCA
CBS
Drug-induced parkinsonism (anti-psychotics, 
anti-emetics), juvenile parkinsonism, bilateral 
thalamic lesions
Dystonia
- Orofacial
- Cervical
- Axial
 ·   Pisa sign*
 ·   Camptocormia*
MSA, PSP (blepharospasm), drug-induced
MSA (antecollis), PSP (retrocollis)
- MSA
- Drug induced (both typical and atypical 
anti-psychotics, anti-depressants, anti-
emetics, choline-esterase inhibitors, 
dopaminergic medication
- Spine deformities; scoliosis
 ·   MSA
 ·   Alzheimer’s disease
 ·   Myopathy, myasthenia, CIDP)
 ·   Drug-induced
 ·   Spine deformities, arthritis
 ·   Paraneoplastic
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Table 4   Continued
Signs and Symptoms Most likely diagnosis
- Limbs*
- Generalized
- Fixed 
MSA, drug-induced
- MSA
- CBS
- Hereditary parkinsonism  
(PARK 1,2,6,7,9,14
- Hereditary dystonia syndromes  
(DYT 3,5,12,16, SCA3
- Intoxications: neuroleptics,  carbon-
monoxide, manganese
- Accumulation diseases:  
Wilson’s disease NBIA1
- Miscellaneous: hemi-parkinsonism-
hemi-dystonia, neuroacanthocytosis, 
Huntington’s disease
CBS (early), MSA (late in the course of the 
disease)
Gait and balance disorders
- Early postural instability
Use of walking aids/ wheelchair 
dependency*
PSP; to a lesser extent: MSA, CBS and VaP
< 3 yrs: MSA, PSP
3-10 yrs: other forms of AP
Sleep disturbances
- REM sleep behavior disorder
- Sleep apnea syndrome
Nocturnal inspiratory stridor
PD, MSA, DLB
MSA
MSA
Cognitive dysfunction
- Early and profound
- Relatively late*
- Relatively mild cognitive dysfunction 
- Apraxia
- Aphasia
PSP, DLB, FTD, Huntington’s Disease, NPH
CBS, VaP
MSA 
CBS, PSP (to a lesser extent)
CBS, PSP (to a lesser extent)
Autonomic dysfunction
- present early and severely
- cold, discolored extremities  
(‘cold hands sign’)
MSA, DLB (to a lesser extent)
MSA
MSA, multi system atrophy; PSP, progressive supranuclear palsy; DLB, diffuse Lewy body disease; CBS, 
corticobasal syndrome; VaP, vascular parkinsonism; FTD, frontotemporal dementia; NPH, normal pressure 
hydrocephalus; REM, rapid eye movement; SCA, spinocerebellar ataxia.  
*might also be present in Parkinson’s Disease
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Ataxia
This can result from cerebellar or sensory dysfunction, and an ataxic gait can also be 
observed in patients with frontal or vestibular pathology. The presence of ataxia, especially 
cerebellar ataxia markedly affects the differential diagnosis, and even mild ataxia calls for 
further investigation. (Gilman et al. 2008) The differential diagnosis of parkinsonism plus 
ataxia includes MSA, SCA (2, 3 and 17) and Fragile-X –tremor-ataxia-syndrome (FXTAS). 
The majority of patients with MSA present with predominant parkinsonism (MSA-p), but 
up to 20 percent of cases can present with mainly a cerebellar syndrome (MSA-c). (Gilman 
et al. 2008) In Japan, MSA-c is the more common form. Most, but not all MSA patients will 
ultimately exhibit both parkinsonian and cerebellar features, although marked bradykinesia 
and hypokinesia can make it difficult to detect ataxia in severely affected patients. 
Cerebellar features can also be observed in patients with PSP, typically as square-wave 
jerks, but also as true cerebellar ataxia in up to 15% of patients. Genetic and ethnic 
variability affect this ataxic presentation in PSP, as it is most prevalent in Japan. (Kanazawa 
et al. 2009)
Gait and balance disorders 
Disturbed gait can be observed in generally all patients with parkinsonism, especially late 
in the disease course, but the pattern varies between different diseases. Early gait 
abnormalities in PD include slowing of gait and an asymmetrically reduced arm swing. 
With disease progression, step height and length become smaller, and many patients 
develop start hesitation, festination (defined as taking increasingly rapid and small 
sequential steps during walking) and freezing (defined as debilitating episodes during 
which they are unable to start walking or, while walking, suddenly fail to continue moving 
forward). (Snijders et al. 2008) Importantly, gait remains narrow-based in PD, even until late 
in the disease, but is usually broad-based for patients with the various forms of AP, even 
early on in the disease. Freezing tends to occur much earlier and more severely in patients 
with AP, and unlike PD responds less well (or not at all) to external cueing. The exception 
is drug-induced parkinsonism, where freezing seems very rare. Ataxic gait is a key symptom 
in MSA-c. Gait in CBS is typically affected by asymmetrical and usually fixed foot dystonia.
Balance is generally not disturbed in early PD, unlike the situation in most forms of AP. Early 
falls (within the first year of the disease) are a hallmark of PSP, and are caused by a 
combination of gait and balance problems. (Litvan 2001) Most falls are backward (for 
reasons unknown), whereas PD patients mostly fall forward (due to freezing of gait). Unlike 
PD, falls in PSP often cause serious injuries – fractures of longbones and head injury – 
because many patients are also reckless, and because protective responses during falls are 
absent. Although characteristic, falls within the first year of disease are not exclusive for 
PSP, can also occur in MSA, CBS, DLB and other forms of parkinsonism. Typical for MSA is 
the presence of vertical (‘drop down’) falls due to preceding syncope (orthostatic 
hypotension), while this is rare in PD. Patients with AP often require walking aids, and may 
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become fully wheelchair-bound within the first three years of the disease. This ‘wheelchair 
sign’ would be very unusual for PD. (Gilman et al. 2008)
Gait and balance are best assessed using a combination of tests, including a proper gait 
analysis and a retropulsion test (incorporated in UPDRS III). (Jacobs et al. 2006) Another 
good test is tandem gait (performed by instructing patients to walk 10 consecutive steps 
along a thin line); the test is usually normal in PD, and taking even a single corrective side 
step points towards AP. (Abdo et al. 2006) A related test is asking whether patients are still 
able to ride their bicycle: cycling is usually preserved in early PD, but inability to cycle early 
in the disease course suggest AP. (Aerts et al. 2011a)
Eye movement disorders
Examination of the eye movements is crucial for the clinical diagnostic process, as PD 
and the different forms of AP can show different abnormalities (although these can be 
subtle). A thorough examination of eye movements involves observing fixation, voluntary 
eye movements in all directions, smooth pursuit, and saccades in both the horizontal 
and vertical direction. If a vertical gaze palsy is observed, it is important to investigate 
the doll-eye-phenomenon to localize the disorder as being either supra- or (infra)nuclear. 
An upward vertical gaze palsy can be observed in healthy elderly, albeit with preserved 
velocity of the residual saccade. Also, in PSP downgaze is usually impaired before upgaze. 
Supranuclear vertical gaze palsy is characteristic for PSP when present, but a considerable 
proportion of patients never develop this. (Litvan 2001) Overt supranuclear vertical gaze 
palsy can be preceded by slowing of vertical saccades and, even more subtle, the ‘round- 
the-house’ phenomenon (abnormal trajectory with subtle deviation from the straight 
line upon attempted vertical saccades, presumably the first stage of saccadic slowing). 
Cerebellar eye movements, including square wave jerks, can also be observed in PSP 
patients. (Kanazawa et al. 2009)
MSA patients can show cerebellar eye movements, with nystagmus, square-wave jerks and 
dysmetria, but often also hypometric saccades as a reflection of concurrent parkinsonism. In 
CBS the initiation – but not the execution – of saccades can be slowed in both the horizontal 
and vertical plane, whereas PD patients show limited spontaneous blinking and hypometric 
eye movements, but a preserved velocity of the saccades. (Kennard 2007)
Autonomic dysfunction
Symptoms of autonomic dysfunction, mostly in the form of orthostatic hypotension, 
erectile dysfunction, and urge incontinence are common, early symptoms of MSA, usually 
even preceding other symptoms. The presence of cold, discolored hands is also frequently 
seen in MSA. Autonomic dysfunction also occurs in DLB, including orthostatic hypotension 
and carotid-sinus hypersensitivity causing syncope and transient loss of consciousness. 
Urinary incontinence also has been reported early in the course of the disease. Urinary 
incontinence is also seen in PSP patients, although generally not as an early feature. In 
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contrast, symptoms of dysautonomia in PD are generally mild and are usually absent in 
the first years of the disease.
Higher cortical dysfunctions
Cognitive dysfunction 
This can be seen very early in the course of PD. PD patients generally manifest executive 
dysfunction, reduced psychomotor speed, visuospatial dysfunction and memory 
problems. However, the presence of severe cognitive impairment or profound dementia 
should lead to further investigation, as many of the AP forms (including e.g. PSP, DLB and 
VaP) demonstrate impaired cognitive function early in the disease course. Apraxia, 
non-fluent aphasia and behavioral changes can be seen in PSP and especially CBS patients. 
A particular feature in PSP is a so-called motor recklessness: risky and impulsive behavior, 
which – in combination with the early and prominent axial disability – commonly leads to 
severe fall-related injuries. Until recently, it was assumed that cognition remained 
undisturbed in MSA, in contrary to all other forms of AP. However, recent research has 
suggested that the cognitive profile of MSA patients is indistinguishable from PSP patients, 
(Brown et al. 2010) although in our own experience, the clinical impact remains much less 
pronounced compared to e.g. PSP.
Apraxia 
The term apraxia is often used inappropriately in clinical practice. Apraxia formally involves 
an inability to perform a skilled or learned act that cannot be explained by a language 
comprehension disorder or elementary motor or sensory deficit. Apraxia is subdivided 
into three main types: ideomotor apraxia, ideational apraxia and limb kinetic apraxia 
(table 5). Severe apraxia of all three subtypes can be observed in CBS, causing difficulty in 
using the afflicted extremity. Characteristically, CBS patients exhibit limb kinetic apraxia 
prominently and early in the course of the disease. Patients may complain about limited 
usability of the affected limb, or absent control over movements, and experience an alien 
limb phenomenon. (Boeve et al. 2003) Limb kinetic apraxia is generally unilateral, mainly 
involving the most affected limb, as opposed to the other two subtypes. Subtle apraxia, 
especially involving the eyes, may be seen in PSP patients. In general, apraxia is a red flag 
for the diagnosis of PD or MSA. 
Aphasia  
An important discriminating aspect is fluency, which is assessed by asking the patient to 
name as many animals (category) or words with a specified character (phonemic) in one 
minute. The presence of aphasia, especially non-fluent aphasia, prompts towards CBS or 
PSP as the underlying diagnosis. (Boeve et al. 2003; Litvan 2001)  However, disturbed 
fluency is not always due to aphasia, as it can also result from frontal executive dysfunction, 
which is often seen in (later stages of) PD.
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Psychiatric symptoms
Apathy is encountered commonly in PD, often together with depression, although it can 
present separately. In PSP patients, apathy is also common, but usually develops earlier 
and more prominently compared to PD. Other behavioral changes in PSP include 
aggressiveness and disinhibition. The latter can be identified using the clapping test: 
when a patient is asked to clap the hands three times as quickly as possible, PSP patients 
tend to clap more than the requested three times, and sometimes they cannot stop at all 
(applause sign). (Dubois et al. 2005) An abnormal clapping test can also occur in PD, so the 
test does little to help separate PD from AP. Also, emotional disinhibition can occur in PSP 
and MSA. Hallucinations are a hallmark of Lewy body dementia, especially when these 
occur prior to administration of dopaminergic therapy. The occurrence of visual 
hallucinations is associated with greater deficits in cortical acetylcholine, and this might 
predict a better response to cholinesterase inhibitors. Delusions are also seen frequently 
in DLB patients, generally of the paranoid type. (McKeith et al. 2005)
Sleeping disturbances
Various sleeping disturbances have been associated with parkinsonian disorders, caused 
either by the disease itself or by the treatment. Excessive daytime sleepiness is frequently 
seen in PD and presumably has a multifactorial origin, including poor nighttime sleep 
and adverse effects of dopaminergic medication. The presence of REM-sleep-behavior- 
disorder should prompt towards one of the α-synucleopathies (PD, MSA, DLB), although it 
can be sporadically seen in Alzheimer and other tauopathies (PSP, CBS) as well. Restless 
legs and periodic limb movements during sleep can be observed frequently in both 
Table 5   Types of apraxia
1. Ideomotor The patient knows what to do, but not how to do it; showing difficulty in 
selection, sequencing and spatial orientation.
The patient shows an inability to perform certain tasks on command 
as well as copying both meaningful and meaningless hand gestures 
(bilateral). Spontaneous performance of these tasks is remarkably better as 
well as the performance while using the actual utensil.
2. Ideational The patient does not know what to do.
The patient demonstrates a disturbance in the ‘design’ of complex tasks; 
disturbance in timing, sequencing and spatial organization of movements. 
Copying gestures can be remarkably better.
3. Limb kinetic Disturbance of fine finger movement coordination.
The patient demonstrates a unilateral difficulty in copying meaningless 
hand positions. Mimicking meaningful gestures is generally less 
troublesome. The use of real objects is typically unimpaired. 
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PD patients and patients with AP, and presumably have limited discriminative value. 
The presence of inspiratory stridor suggests a diagnosis of MSA. (Gilman et al. 2008) 
Because it is a possibly lethal complication that can (partly) be prevented, clinicians should 
always actively ask for inspiratory stridor, especially if other symptoms suggestive of MSA 
are present. Validated questionnaires are available to assess different aspects of sleep in PD, 
including the REM sleep behavior disorder screening questionnaire and the Epworth 
Sleepiness Scale. (Johns 1991; Stiasny-Kolster et al. 2007)
Response to dopaminergic medication
Patients with PD have a clear and unambiguous levodopa response and tolerate 
dopaminergic medication well. Most patients with AP react less well or not at all to 
dopaminergic therapy, even when levodopa is adequately dosed (1000 mg/day during 4 
weeks). Approximately one-third of patients with MSA and VP can demonstrate a partial 
response to levodopa, although a sustained response is rare. Patients suffering from PSP 
generally do not show a good, sustained response to levodopa. However, an adequate 
response can be observed in patients with the PSP-P phenotype (where the phenotype is 
dominated by parkinsonism). Patients with AP tolerate dopaminergic medication less well, 
and many patients become nauseous when using levodopa. Finally, the presence and 
nature of dyskinesias can help in the differential diagnosis. Dyskinesias are common in PD, 
but can be observed in MSA, although the dyskinesias are often localized cranially in MSA, 
whereas the extremities are usually dyskinetic in PD.
Step 3: The differential diagnosis
The third step is to combine the results of step 1 and 2, as a basis for the differential 
diagnosis. Table 6 summarizes the clinical signs and symptoms and their presence in the 
different types of parkinsonism. Interestingly, none of these characteristics or so-called 
red flags has the ability to fully differentiate between PD and AP. Usually, it is the 
combination of several atypical features that differentiates both groups, and this often 
involves pattern recognition (e.g. supranuclear vertical gaze palsy plus motor recklessness; 
or early autonomic failure with inspiratory stridor). Although such combinations can 
generally separate the group of PD patients from the group of patients with AP, the overlap 
between symptom clusters may be too substantial to differentiate at the individual patient 
level. Therefore, misclassifications still occur even in hands of experts in the field (5-10% 
negative predictive value in PD). (Hughes et al. 2002)
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Table 6   Signs and symptoms for each of the parkinsonisms
PD MSA PSP CBS DLB VaP
Distribution 
- Symmetrical
- Asymmetrical
- Lower body phenotype
+++
++ ++
+++
+ 
+
+++
Progression rate
- Slowly
- Quickly
- Stepwise
+++
+++
+
++ ++
+
++
+++
Medication
- Sustained reaction
- Side effects
+++
-
+
+
+ 
+
-
+
++
+++
+/-
++
Tremor
- Classical resting tremor
- Jerky tremor
+++
+
+
+++
+ +
+++
Myoclonus - + - ++ + -
Dysphagia
Dysarthria
+
+
++
+++
+++
+++
+ +
+
+
+
Dystonia ++ ++ + +++
Pyramidal tract - ++ - - - +++
Ataxia - ++ + - - -
Balance disorder
- Early
- Late 
-
++
++
+++
+++
+++
Eye movements +/- ++ +++ + - -
Autonomic dysfunction
- Early
- Late
-
++
+++
+++
-
++
-
+
++
++
+
++
Cognitive dysfunction
- Early
- Late
+/-
++
-
+/-
+
++
+
++
+++
+++
++
++
Psychiatric problems
- Hallucinations
- Depression
- Apathy
- Disinhibition
-
++
++
+/-
-
++
+
++
-
++
+++
-
++
+++ -
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The currently used diagnostic consensus criteria for AP (Boeve et al. 2003; Gilman et al. 
2008; Litvan et al. 1996; McKeith et al. 2005) have been developed mainly for research 
purposes, aiming to allocate correctly classified patients to the right studies. These criteria 
therefore are rather strict, but in daily practice, many patients do not (yet) fully comply 
with these formal criteria. Yet clinical suspicion can be strong even in such cases, based 
on the entire clinical picture and own prior experience. We share our clinical suspicion 
– including the amount of uncertainty – with the patient and family, thus creating 
transparency.
Two illustrative patient cases
To illustrate the diagnostic process we present two different cases. The first patient, a 
58-year old, right-handed man, developed a tremor of his left hand about 12 months ago. 
His symptoms increased gradually over a period of several months, but remained 
unilateral. He had not yet been treated with dopaminergic medication. Upon examination, 
he scored 29/30 points on the MMSE and 18/18 on the FAB (suggesting absence of gross 
cognitive dysfunction), and 7/39 on the HADS for depression (suggesting absence of 
depression). The patient denied symptoms suggestive of autonomic dysfunction. 
Neurological examination shows: a mask-like face, with spontaneously parted lips at rest; 
asymmetrical bradykinesia, with decrement while performing finger- and foot tapping; a 
mild rest tremor of the jaw and left hand, including a resetting phenomenon after a 
postural change; normal range and velocity of eye movements; and absence of ataxia, 
myoclonus or apraxia. The presence of an asymmetrical hypokinetic-rigid syndrome 
without red flags renders a diagnosis of PD most likely in this case.
The second patient, a 66-year old right-handed woman, developed difficulty walking 
about 24 months ago. Over the past years, her symptoms had increased gradually. She 
developed difficulty maintaining balance, but had never fallen. Just 10 days prior to the 
Table 6   Continued
PD MSA PSP CBS DLB VaP
Sleep disturbances
- Nighttime stridor
- RBD
- RLS/PLM
++
++
+++
++
++
+/-
++
+/- ++ -
PD, Parkinson’s disease; MSA, multi system atrophy; PSP, progressive supranuclear palsy; DLB, diffuse Lewy 
body disease; CBS, corticobasal syndrome; VaP, vascular parkinsonism; RBD, REM-sleep behavior disorder; RLS: 
restless legs syndrome; PLM, periodic limb movements; -, not present; +++ very often present
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examination, she started using levodopa and reported beneficial effects. She also reported 
symptoms of orthostatic hypotension and decreased libido, but no urgency or urinary 
incontinence. Examination revealed a blood pressure of 125/82 without orthostatic 
hypotension, MMSE 29/30 points, FAB 15/18 (suggesting some frontal executive 
dysfunction); and 15/39 on the HADS (indicative of depressive symptoms). Neurological 
assessment further revealed a high-pitched voice, cerebellar ataxia and poliminimyoclonus. 
Moreover, tandem walking was performed with great difficulty, necessitating a regularly 
grasping for support. In this patient, a hypokinetic-rigid syndrome was associated with 
several additional signs that were not particularly helpful for the differential diagnosis (including 
some frontal executive dysfunction and depression), but also a few clear red flags, including 
ataxia, polyminimyoclonus and subjective orthostatic hypotension (it can be difficult to 
prove this using simple sphyngomanometry). (Thijs et al. 2009) This specific combination 
of symptoms and signs most likely suggests a diagnosis of possible MSA (see table 6).
Conclusion
Establishing a clinical diagnosis of parkinsonism can be a challenge, but to differentiate 
between the different causes of parkinsonism can be even more challenging. Use of a 
systematic clinical approach, as described in this paper, enables an adequate assessment 
of the patient, and can help facilitate clinicians in establishing a correct clinical diagnosis 
early in the course of the disease. However, we do recommend that all patients with a 
parkinsonian syndrome are referred to a movement disorder expert once in the course of 
their disease.
Clinical evaluation of a patient with parkinsonism
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Summary
Differentiating corticobasal syndrome (CBS) from progressive supranuclear palsy (PSP) and 
idiopathic Parkinson’s disease (PD) can be difficult. To investigate the additional value of 
cerebrospinal fluid (CSF) biomarkers in the diagnostic differentiation of parkinsonism, we 
analyzed the CSF concentrations of total protein, lactate and brain specific proteins 
amyloid-β42 protein, tau protein (t-tau), and tau protein phosphorylated at Thr181 (p-tau), 
in CSF samples from patients with PSP (n =21), CBS (n=12), and PD (n=28). CBS patients 
demonstrated higher concentrations of t-tau and p-tau compared with PSP and PD 
patients. In discriminating CBS and PD, t-tau offered the best combination of sensitivity 
(75%) and specificity (90.9%), followed by p-tau (sensitivity 87.5% and specificity 75%). The 
p-tau/t-tau ratio resulted in sensitivity of 84.2% and specificity of 66.7% in discriminating 
PSP and CBS. In conclusion, our results suggest that CSF parameters are of additional value 
in the diagnostic differentiation of CBS and PD. 
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Introduction
Corticobasal syndrome (CBS) is an atypical parkinsonian disorder characterized by the 
combination of cortical dysfunction and extrapyramidal symptoms with profound 
appendicular dystonia and/or a poor response on levodopa therapy. The cortical 
dysfunction can comprise a variety of symptoms including the “alien-limb phenomenon”. 
Because Parkinson’s disease (PD) and other atypical parkinsonian disorders, like progressive 
supranuclear palsy (PSP), can closely resemble CBS, the initial diagnosis can be challenging, 
as reflected by the relatively poor diagnostic accuracy of the clinical diagnosis on neuro-
pathological examination. (Boeve et al. 1999; Boeve et al. 2003; Hughes et al. 2002; Litvan 
et al. 1997; Wenning et al. 1998)
Corticobasal degeneration is the neuropathological substrate of CBS, and is characterized 
by the intraneuronal aggregation of tau protein like PSP and Alzheimer’s disease (AD), 
commonly referred to as tauopathies. (Ludolph et al. 2009) In contrast, PD is characterized 
by α-synuclein inclusions in neurons of the substantia nigra and cortical areas and is 
therefore classified as an α-synucleinopathy. (Braak et al. 2003)
Currently, the distinction between CBS and other parkinsonian disorders is based mainly 
on clinical grounds, supported to a limited extent by ancillary investigations. (Abdo et al. 
2010) It would be helpful to identify new biomarkers that would facilitate the differential 
diagnosis of parkinsonism. Due to its proximity to the brain parenchyma, the composition 
of the cerebrospinal fluid (CSF) may reflect pathologic changes.
Herein, we analyzed the CSF concentrations of Amyloid-β42 (Aβ42), lactate, total protein, 
tau protein (t-tau), and tau protein phosphorylated at Thr181 (p-tau), in patients with 
CBS, PSP, and PD, to investigate the diagnostic ability in differentiating between these 
parkinsonian syndromes.
Patients and methods
In 2009, a single rater (MBA) retrospectively reassessed the clinical charts of 48 patients, 
suspected of either PSP or CBS, referred to the Department of Neurology (Radboud 
University Nijmegen Medical Centre) between 1998 and 2007, who underwent a lumbar 
puncture during their diagnostic work-up. Reassessment of the clinical diagnosis was 
performed after a mean 5-years-follow-up period according to international consensus 
criteria (UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria for PD, 
(Hughes et al. 1992) Litvan criteria for PSP, (Litvan et al. 1996) Boeve criteria for CBS 
(Boeve et al. 2003). Diagnostic evaluation included detailed medical history, systematic 
neurological examination, routine laboratory testing, and a brain magnetic resonance 
imaging-scan. In addition, many patients underwent neuropsychological assessment, 
nuclear imaging of cerebral metabolism and/or dopaminergic pathways, electro-oculog-
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raphy, and electromyography of the anal sphincter. Only patients diagnosed with either 
PSP (n=21) or CBS (n=12) and available CSF results were included in this study.
In addition, CSF data of 28 consecutive PD patients, aged older than 50 years and 49 
age-matched patients referred to our Neurology Department in that period were analyzed 
for comparison (reasons for referral: headache (n=15), memory complaints (n=6), functional 
complaints (n=10), sensory deficits (n=9), dizziness (n=4), and fatigue (n=5)). All controls 
were diagnosed as not having a neurodegenerative disorder after extensive work-up and 
had normal routine CSF parameters (normal leukocyte and erythrocyte count, normal 
protein, glucose and lactate levels, and neither oligoclonal IgG bands nor blood pigments).
The protocols of CSF analysis of Aβ42 t-tau, lactate, and total protein were described 
previously. (Abdo et al. 2004; Abdo et al. 2007) P-tau concentrations in CSF were analyzed 
using the Innotest Phospho-Tau(181)-assay (Innogenetics, Ghent, Belgium; linearity up to 
500 ng/L). The interassay variation coefficients over a period of 6 years were 8.8% for t-tau, 
6.0% for Aβ42, 4.5% for p-tau, and <3% for lactate.
Statistical analysis was performed using GraphPad Prism version 4 (San Diego, CA, USA) 
and SPSS software version 16.0 (Chicago, IL, USA). Between-groups-analysis was performed 
using a one-way analysis of variance test or Kruskal-Wallis test for non-normally distributed 
data. Correction for multiple comparisons was applied. Receiver operator characteristic 
analysis was used to evaluate the value of individual biochemical variables and their 
optimal cut-off values discriminating PSP, CBS, and PD. Multivariate logistic regression with 
backward selection procedures was used to identify variables that contributed 
independently to discriminate PSP from CBS and CBS from PD.
Results
Twenty-one patients fulfilled the diagnostic criteria of PSP (18 probable PSP, 3 possible PSP; 
according to the NINDS/SPSP criteria (Litvan et al. 1996), 12 fulfilled the CBS criteria. 
Thirteen PSP patients and 5 CBS were deceased at the time of the chart review; mean 
survival was 6.3 years after onset of symptoms in PSP patients and 4.4 years in CBS patients. 
Neuropathological confirmation of the diagnosis was not available.
Disease severity (H&Y score) at the time of lumbar puncture was significantly higher in PSP 
patients, when compared with both CBS and PD subgroups. Age, disease duration, and 
gender distribution were comparable in all 3 groups. Demographic characteristics and 
CSF parameters are shown in Table 1.
Concentrations of t-tau were significantly higher in CBS patients than in PSP patients, 
PD patients, and controls (p<0.001). P-tau concentrations were significantly higher in the 
CBS patients, when compared with PSP (p<0.05) and PD (p<0.01). Lactate concentrations 
were significantly higher in PSP than in CBS patients (p<0.05). Aβ42 and total protein 
concentrations did not differ between PSP and CBS patients. In addition, several ratios 
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were calculated. As expected, the Aβ42/t-tau ratio differed significantly between PSP and 
CBS (Table 1).
We neither established correlations between CSF parameters and age, disease duration, 
nor severity. However, mini-mental state examination (MMSE) scores correlated with Aβ42 
(r=0.481, p<0.05), t-tau (r=−0.622, p=0.002), and p-tau (r= −0.642, p=0.001) in the CBS 
subgroup. Similar results were obtained in the combined CBS and PSP subgroups.
Univariate logistic regression analysis was carried out to discriminate CBS from PSP 
revealing that neither sensitivity nor specificity exceeded 80% for individual parameters 
(Table 2). Therefore, multivariate logistic regression analysis was carried out to improve 
Table 2   ROC-analysis of CSF analysis for CBS vs. either PSP or PD
CSF variables Cut-off Sens Spec AUC (95% CI) LRa
PSP vs. CBS
Univariate
T-tau (ng/L) >322 80.0% 63.6% 0.77 (0.61–0.95) 2.20
P-tau (ng/L) >52 63.2% 75.0% 0.76 (0.59–0.93) 2.53
Aβ42 (ng/L) <655 73.7% 50.0% 0.53 (0.30–0.76) 1.47
Lactate (μmol/L) <1769 63.2% 80.0% 0.74 (0.55–0.93) 3.16
Total protein (mg/L) <539 63.2% 72.7% 0.68 (0.48–0.88) 2.32
Aβ42/t-tau <3.22 68.4% 75.0% 0.72 (0.52–0.92) 2.74
Aβ42/p-tau <7.76 94.7% 41.7% 0.64 (0.42–0.85) 1.62
P-tau/t-tau <0.18 84.2% 66.7% 0.75 (0.56–0.93) 2.53
Multivariate
Model 1b <3.95 93.8% 70.0% 0.89 (0.77–1.00) 3.13
Model 2c <1.91 68.8 % 90.0% 0.88 (0.75–1.00) 6.88
CBS vs. PD
Univariate
T-tau (ng/L) >197 75.0% 90.9% 0.91 (0.82–1.00) 8.24
P-tau (ng/L) >52.5 87.5% 75.0% 0.80 (0.64–0.97) 3.50
Aβ42 (ng/L) <658 75.0% 50.0% 0.56 (0.34–0.77) 1.50
Aβ42/t-tau <3.21 85.7% 75.0% 0.86 (0.74–0.98) 3.43
a Likelihood ratio: sensitivity/(1 − specificity) 
b Model 1: Y = −1.539 + (0.002×tau) + (0.003×lactate) + (−0.098×p-tau) + (0.004×protein)
c Model 2: Y = 0.122 + (0.003×lactate) + (−0.081×p-tau) 
ROC-analysis, receiver operating characteristic analysis; PSP, progressive supranuclear palsy; CBS, corticobasal 
syndrome; PD, Parkinson’s disease; CSF, cerebrospinal fluid; t-tau, total tau protein; p-tau, phosphorylated tau 
protein; Aβ42, amyloid-β42 protein; sens: sensitivity; spec: specificity; AUC: area under the curve; 95 CI, 95% 
confidence interval; LR: likelihood ratio.
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diagnostic accuracy in discriminating between CBS and PSP. T-tau, p-tau, lactate, and total 
protein concentrations were added to the selection procedure. The prediction model 
thus constructed reached a sensitivity of 93.8% and a specificity of 70.0%. A prediction 
model based on only p-tau and lactate reached a sensitivity of 68.8% and a specificity 
of 90.0%.
Univariate analysis demonstrated that t-tau protein offered the best combination of 
sensitivity (75%) and specificity (90.9%) to differentiate between CBS and PD. The 
concentration of p-tau showed a sensitivity of 87.5% and a specificity of 75%. Multivariate 
logistic regression analysis was performed, selecting only t-tau protein as independent 
marker to separate CBS and PD.
Discussion
This study is one of the few to compare CSF biomarkers in patients with CBS, PSP, and PD 
with extended clinical follow-up. We demonstrated that the concentrations of t-tau and 
p-tau proteins in CSF of CBS patients were significantly elevated compared with PSP and 
PD. However, the diagnostic accuracy of CSF t-tau and/or p-tau seems only sufficient in 
the discrimination of CBS vs. PD not in discriminating CBS vs. PSP.
As the sensitivity for the initial clinical diagnosis CBS is poor, the CSF profile of CBS (i.e., 
increased t-tau and p-tau) may increase awareness for the diagnosis CBS. A timely and 
correct diagnosis may result in better targeted treatment strategies, adequate patient 
counseling and —perhaps most important— early recognition of disease-specific 
complications.
In AD Aβ42, CSF concentrations are decreased, (Wiltfang et al. 2005) whereas in parkinsonian 
disorders, the data seem conflicting, (Compta et al. 2009; Holmberg et al. 2003; Verbeek et 
al. 2004) presumably due to large inter-individual variability, underpowered studies, and 
possibly different underlying pathology as neuropathological confirmation is lacking in 
most studies. (Arai et al. 1997; Borroni et al. 2008; Mitani et al. 1998; Mollenhauer et al. 2008; 
Noguchi et al. 2005; Urakami et al. 2001) T-tau and p-tau concentrations are reported to be 
increased in tauopathies, predominantly AD, (Hampel and Teipel 2004) but also—in line 
with our results—in CBS compared with controls. (Borroni et al. 2008; Mitani et al. 1998; 
Mollenhauer et al. 2008) However, other studies failed to demonstrate such elevations in 
CBS, (Arai et al. 1997; Noguchi et al. 2005) a disparity possibly caused by enrolment of more 
severely cognitively affected patients in our study, possibly reflecting more cortical 
involvement correlating with higher CSF t-tau levels (mean MMSE score 21.3 vs. 28.0). 
(Noguchi et al. 2005)
Although both PSP and CBS are neuropathologically characterized by axonal degeneration 
and the accumulation of t-tau protein in the brain, only in CBS this seems to lead to an 
increase in CSF t-tau and p-tau concentrations. (Arai et al. 1997; Borroni et al. 2008; Noguchi 
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et al. 2005; Paraskevas et al. 2005; Urakami et al. 2001) The observed difference between 
CBS and PSP may be explained by a higher rate of atrophy, a larger brain area involved and 
relative proximity of the affected brain areas to the CSF compartment in CBS. (Boxer et al. 
2006; Groschel et al. 2004; Schofield et al. 2005; Whitwell et al. 2007) Interestingly, elevated 
concentrations of t-tau protein were observed previously in MSA, an α-synucleinopathy, 
stroke, and Creutzfeldt-Jakob disease. (Abdo et al. 2004; Abdo et al. 2007; Hesse et al. 2000) 
Hence, t-tau concentrations might be a biomarker for accelerated degeneration instead of 
reflecting the pathological substrate.
This study has several drawbacks. First, due to the retrospective character of the study 
selection bias cannot be ruled out, because only patients with diagnostic uncertainty 
were included in this study, possibly leading to the selection of more atypical phenotypes. 
However, the studied population therefore closely resembles daily clinical practice in 
which ancillary diagnostic tests are applied in cases of diagnostic uncertainty. Second, the 
clinical diagnosis was not confirmed neuropathologically and therefore susceptible to 
misclassification. However, the final diagnosis was based on thorough clinical and ancillary 
investigations (including nuclear imaging and neuropsychological assessment), after 
extensive follow-up and according to international consensus criteria in a specialized 
movement disorder clinic. In addition, charts of patients with CSF parameters in over - 
lapping ranges or with Alzheimer-like CSF profiles were re-examined to assess whether 
these patients exhibited clinical features suggesting potential misdiagnosis with PSP, 
CBS, or AD; no misdiagnosed cases were identified.
In conclusion, despite these drawbacks, our results suggest that CSF analysis could aid the 
diagnostic differentiation of CBS and PD. Abnormal CSF t-tau and p-tau concentrations 
may raise awareness for the diagnosis CBS. These results warrant validation in a prospective 
study with neuropathological confirmation of the diagnosis.
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Summary
Differentiating between Parkinson’s disease (PD) and atypical parkinsonism (AP) is clinically 
relevant but challenging. A timely and correct diagnosis might result in better targeted 
treatment strategies, adequate patient counseling, and early recognition of disease-specific 
complications. We aimed to investigate whether cerebrospinal fluid (CSF) concentrations 
of α-synuclein are of additional diagnostic value.
We examined 142 consecutive patients with parkinsonism, mean disease duration 39.7 
months. (PD, n=58; MSA, n=47; DLB, n=3; VaP, n=22; PSP, n=10; CBS, n=2) Gold standard was 
the clinical diagnosis established after three years of clinical follow-up.  CSF concentrations 
of α-synuclein, blood pigments and the erythrocyte count were determined.
No differences between CSF α-synuclein concentrations of patients with PD with the 
reference values from our laboratory were observed. We neither found significant 
differences between patients with PD and AP nor between AP subgroups. Adjustment for 
age, disease severity or presence of erythrocytes or blood pigments in CSF did not alter 
these results.
Our results imply that CSF α-synuclein is currently unsuitable as biomarker to differentiate 
between PD and AP.
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Introduction
Idiopathic Parkinson’s disease (PD) is the most common neurodegenerative movement 
disorder, clinically characterized by the classical triad of bradykinesia, tremor and 
rigidity. (Daniel and Lees 1993) The initial diagnosis can be challenging, since so called 
‘atypical parkinsonian disorders’, like multiple system atrophy (MSA) can closely resemble 
PD, especially in the early phases of disease.  This challenge is reflected in the clinico - 
pathological observation that upon post mortem evaluation out of the patients 
wrongly diagnosed with MSA, 80% turned out to suffer from PD instead of MSA. (Hughes 
et al. 2002)
The differentiation between PD and atypical parkinsonism is highly important. A correct 
diagnosis might result in better targeted treatment strategies, more adequate patient 
counseling and –perhaps most important- timely recognition of disease specific symptoms 
like nighttime stridor, early dysphagia, or postural hypotension to prevent complications 
like aspiration or falls in MSA.
PD is neuropathologically characterized by α-synuclein inclusions, so called Lewy bodies, 
in dopaminergic neurons of the substantia nigra and cortical areas and is therefore 
classified as an α-synucleinopathy. Alpha synuclein is a natively unfolded, soluble protein, 
abundantly present in presynaptic nerve termini. Its precise function is still unknown. 
(Uversky 2007) Alpha synuclein may adopt a β-sheet conformation leading to its self- 
aggregation, but the mechanisms leading to the formation of these Lewy bodies are not 
fully elucidated yet. Presumably a combination of the propensity of self aggregation of 
the α-synuclein protein, α-synuclein mutations and multiplication of the coding gene 
and post-translational modifications such as phosphorylation or ubiquitination, promote 
the formation of the characteristic Lewy bodies. (Mukaetova-Ladinska and McKeith 2006) 
The group of atypical parkinsonisms is neuropathologically heterogeneous. Vascular 
parkinsonism (VaP) is presumably caused by white matter lesions in predominantly frontal 
and thalamic regions, and/or strategic lesions in the basal ganglia. (Zijlmans et al. 2004) 
Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are characterized 
by intraneuronal deposition of the tau protein, and are therefore part of the spectrum of 
tauopathies that also includes Alzheimer’s disease. (Hampel and Teipel 2004) Dementia 
with Lewy bodies (DLB) and MSA are also characterized by α-synuclein inclusions and 
are therefore, like PD, classified as α-synucleinopathies.
Since cerebrospinal fluid (CSF) directly communicates with the extracellular fluid 
surrounding brain cells, the CSF α-synuclein concentration may reflect the neuropatho-
logical changes observed in α-synucleinopathies and tauopathies. Interestingly, a recently 
published study indeed showed markedly lower levels of α-synuclein in the CSF of PD 
patients as compared to controls. (Hong et al. 2010) The potential use as a biomarker of 
α-synuclein in the differentiation between different parkinsonian disorder has, however, 
not rigorously been studied yet. In this study, we aimed to investigate the value of 
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α-synuclein as a biomarker for the differentiation of parkinsonian syndromes in a large 
cohort of consecutive patients, prospectively followed-up for three years.  
Methods
Patients 
Between January 2003 and December 2006 all patients with a hypokinetic rigid syndrome 
in which diagnostic uncertainty existed regarding the underlying etiology, referred to our 
center were asked to participate in this study. The full studyprotocol is described in chapter 
4. The patients included in the current study are a subset of the large study described in 
chapters 4 and 5. This subset of patients contains all included patients who  underwent a 
lumbar puncture. Patients also underwent an MRI, IBZM-SPECT scan and electromyogra-
phy of the anal sphincter according to study protocol. Patients were re-examined after a 
follow-up period of 3 years. 
Figure 1  Flow chart.
PD: Parkinson’s Disease; MSA: multisystem atrophy; DLB: dementia with Lewy bodies; VaP: vascular parkinsonism; 
PSP: progressive supranuclear palsy; CBS: corticobasal syndrome
* This group included 1 patient with dystonic tremor, 1 patient with neuroborreliosis, 1 patient with hydrocephalus 
and essential tremor, 1 patient with amyotrophic lateral sclerosis and 2 patients with psychogenic complaints.
154 patients
assessed
142 patients
included
58 PD
47 MSA 3 DLB 22 VaP 12 PSP/CBS
84 Atypical
parkinsonism
12 patients excluded: 
6  follow up <6 months
6 clinical diagnosis 
other than PD, MSA, DLB, 
VaP, PSP or CBS*
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Disease severity at the time of lumbar puncture was established according to the 
(modified) Hoehn and Yahr stages (H&Y) (Hoehn and Yahr 2001) and Unified Parkinson’s 
Disease Rating Scale (UPDRS). Cognitive function was assessed using the Mini Mental 
State Examination (MMSE). (Folstein et al. 1983)
Clinicopathological data have shown a high concordance between the neuropathological 
and clinical diagnosis after substantial duration of follow up (at least 2 years) by a movement 
disorder specialist. (Hughes et al. 2002)  We therefore used the final clinical diagnosis as 
gold standard in our study, which was established by consensus between two experienced 
movement disorder specialists (BB and RE) who were blinded to the CSF results, and 
always according to established diagnostic clinical criteria for PD, (Gelb et al. 1999)  MSA, 
(Gilman et al. 2008) PSP, (Litvan et al. 1996) DLB, (McKeith et al. 2005) CBS, (Boeve et al. 2003) 
and VaP. (Zijlmans et al. 2004) 
To determine reference values for the various CSF markers in a non-parkinsonian population, 
we selected age-matched controls who were referred to our Neurology Department 
between 2004 and 2007 and who had a lumbar puncture as part of a diagnostic work-up. 
All controls were diagnosed as not having a neurodegenerative disorder after extensive 
work-up, and had normal routine CSF parameters (normal leukocyte and erythrocyte count, 
normal protein, glucose and lactate levels and neither oligoclonal IgG bands nor blood 
pigments). These data have been published previously (Spies et al. 2009) Medical ethical 
approval for this study was obtained from the institutional review board. Written informed 
consent and approval by the local ethical committee were obtained.
CSF analysis
CSF samples were collected in polypropylene tubes, centrifuged, aliquoted, and stored at 
-80°C until analysis. The following CSF variables were taken into account for the present 
study: α-synuclein, blood pigments and the total erythrocyte count. The erythrocyte 
count and blood pigments were analyzed within 2 hours after CSF collection, α-synuclein 
was analyzed in the entire group at once to minimize inter-assay variability. The method of 
α-synuclein analysis and its validation have been published previously. (van Geel et al. 
2008) The linearity of the used assay ranged from 6 to 300ng/ml. The intra-assay coefficient 
of variation was 3.5% at a concentration of 49ng/ml. The number of erythrocytes was 
manually counted in a counting chamber (volume 3 µl), blood pigments were analyzed 
using spectrophotometric analysis of centrifuged CSF (Perkin-Elmer, Groningen; The 
Netherlands) and calculation of the second derivative of the signal (which is linear with the 
concentration) in the spectrum between 573 and 578 nm for hemoglobin and the 
spectrum between 460 and 478 nm  for bilirubin.
Statistical analysis
The χ2 test was used in case of 5x2 contingency tables. Between-groups analysis was 
performed using a one-way ANOVA test, or a student’s t-test in case of 2 groups in case of 
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normally distributed data. Non-normally distributed data were analyzed using a 
Kruskal-Wallis test or Mann-Whitney test in case of 2 groups. Pearson correlation coefficient 
was used to analyze correlations. Covariates were examined by linear regression (ANCOVA). 
Prior to correlation and covariate analysis, non-normally distributed data were log 
transformed to meet assumptions of normality and homogeneity. Statistical analysis was 
carried out using GraphPad Prism version 4 (San Diego, CA) and SPSS software version 16.0 
(Chicago, IL).
Results
Patients
A total of 142 consecutive patients were included in this study between August 2003 and 
December 2006. (Figure 1) Fifty-eight patients had a final clinical diagnosis of PD, 47 of 
multisystem atrophy (MSA) (25 possible, 20 probable and 2 definite MSA), 3 of dementia 
with Lewy bodies (DLB) (2 possible, 1 probable DLB), 22 of vascular parkinsonism, (VaP), 10 
of progressive supranuclear palsy (PSP) (6 possible, 3 probable and 1 definite PSP) and 2 of 
corticobasal syndrome (CBS). In 43 out of these 142 patients we were not able to complete 
the 2-years follow-up for the following reasons: 16 patients had deceased prior to 
completion of the entire follow up, neuropathological confirmation of the diagnosis was 
available in 3 of these cases (2 MSA, 1 PSP); 12 patients were too severely affected by the 
disease to enable follow up, and 15 patients were lost to follow up or declined to participate 
to the follow-up session. Chart review over the maximum available follow-up period 
Figure 2   Scatterplots of the CSF concentrations of α-synuclein (ng/L) in PD, MSA, DLB, 
VaP, PSP/ CBS and control subgroups.
Horizontal lines represent mean levels. PD: Parkinson’s Disease; MSA: multisystem atrophy; DLB: dementia with 
Lewy bodies; VaP: vascular parkinsonism; PSP: progressive supranuclear palsy; CBS: corticobasal syndrome
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was used for the final diagnosis in these 39 cases and the neuropathological diagnosis 
was used in 4 cases. The mean follow-up period for the patients lost to follow-up was 18.8 
months compared to 36 months in the patients that were not lost to follow-up. For the 
purpose of analysis, the PSP and CBS patients were combined. Demographic characteristics 
are shown in Table 1.
Age at the time of lumbar puncture and disease severity (measured by UPDRS score as 
well as Hoehn and Yahr score) were significantly lower in the patients with PD as compared 
to the patients with VaP. Disease duration however, was comparable in all subgroups. No 
significant differences in cognitive function were observed between subgroups.
CSF analysis
The results of the CSF analysis are presented in Table 2 and Figure 2. 
CSF α-synuclein data were log-transformed to meet assumptions of normality and 
homogeneity. We observed no differences in CSF α-synuclein concentrations between 
patients with PD and healthy controls. We neither observed any differences in α-synuclein 
concentrations between the PD group and the group of atypical parkinsonism, nor 
between the different subgroups of atypical parkinsonism. Furthermore, we did not 
observe any differences in α-synuclein concentration when the group of α-synucleinopathies 
(PD, MSA and DLB) was compared with the group of tauopathies (PSP and CBS). Analyzing 
patients with only probable or definite diagnosis, and analyzing only patients who 
completed the entire follow up duration did not change our results.
Correlation analysis revealed a weak correlation between both the erythrocyte count and 
the hemoglobin concentrations in CSF on the one hand and the α-synuclein concentrations 
on the other (r=0.201 and 0.191, p<0.05) in the entire group of patients. These correlations 
were not present in any of the subgroups.  
Within the PD group, α-synuclein concentrations were negatively correlated with age at 
time of lumbar puncture (r=-0.358, p<0.006). This correlation however, could not be 
established within other subgroups or within the entire group of patients. Within the MSA 
subgroup, α-synuclein concentrations were correlated with Hoehn and Yahr scores (r= 
0.409, p<0.004). The correlation was not found in the entire patient group or in the other 
subgroups. No correlations between α-synuclein concentrations and cognitive function 
(measured by MMSE) could be established, neither within subgroups, nor within the 
entire group of patients. 
Despite the aforementioned correlations, no differences in α-synuclein concentrations 
could be observed between PD patients and controls or between the various patients 
groups if only patients with a normal free hemoglobin (≤0.25 µM) and erythrocyte count 
(≤50/µl) were included, or when α-synuclein concentrations were adjusted for age or 
disease severity.
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Discussion
Our study is the first to assess the value of CSF α-synuclein concentrations in differentiating 
between PD and AP. Despite the large sample-size, we found no differences in α-synuclein 
concentrations between different patient groups. Furthermore, we could not replicate the 
previously reported decrease in CSF α-synuclein concentration in patients with PD as 
compared to controls. (Hong et al. 2010) Moreover, these findings suggest that α-synuclein 
has no value as biomarker for the differential diagnosis of parkinsonian syndrome. 
The comparability of different studies describing CSF α-synuclein levels is somewhat 
hindered by the use of different methods to measure CSF α-synuclein concentrations and 
the use of different antibodies in the respective assays to detect α-synuclein. Possibly as a 
result, previous studies have shown contradicting results.  In a recent study, α-synuclein 
concentrations were decreased in PD patients as compared to controls - in line with 
previous studies-, (Mollenhauer et al. 2008; Tokuda et al. 2006) whereas others, including 
our study, did not find significant differences. (Borghi et al. 2000; Ohrfelt et al. 2009) Besides 
different methods for detection, the observed disparity could partly be explained by 
differences in the selection of control populations, due to age effects and other possible 
confounders like coexisting neurological diseases.  Furthermore, if any, the observed 
differences were small, (Hong et al. 2010; Mollenhauer et al. 2008; Tokuda et al. 2006) with 
profound overlap between the different patients groups, resulting in insufficient sensitivity 
and specificity numbers to warrant the application of CSF α-synuclein analysis in daily 
practice.   
Currently, 4 isoforms of α-synuclein are known. (Beyer et al. 2008) Isoform α-synuclein-140 
is the best known isoform and comprises the whole transcript of the protein. The other 3 
isoforms, α-synuclein-126, α-synuclein-112 and α-synuclein-98, are the result of alternative 
splicing causing in-frame deletions of exon 3 (amino acids 41-54) and exon 5 (103-130) and 
both exon 3 and 5 respectively. (Beyer et al. 2008; Uversky 2007) Especially the deletion of 
exon 5 might prove highly relevant, since the majority of the antibodies used for the 
detection of α-synuclein are directed against these residues. (Hong et al. 2010; Mollenhauer 
et al. 2008; Tokuda et al. 2006) Therefore, both α-synuclein-112 and α-synuclein-98 isoforms 
are not routinely measured in CSF. Interestingly, differences in expression of these isoforms 
have been described in both PD and DLB patients. (Beyer et al. 2008) Perhaps the profile 
of all 4 isoforms, instead of only the concentration of exon 5 -containing α-synuclein 
protein, would distinguish between different neurodegenerative diseases. Hence, further 
research should focus on the development and validation of antibodies targeted against 
the specific isoforms, in addition to the presently available assays to detect full-length 
α-synuclein protein. 
The weak negative correlation observed between α-synuclein concentration and age in 
PD is concurrent with previous studies (Hong et al. 2010; Spies et al. 2009; Tokuda et al. 
2006) and is possibly caused by age-depended changes in the velocity of axonal transport 
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of α-synuclein and decreasing availability of soluble α-synuclein in the aging brain. 
 (Mukaetova-Ladinska and McKeith 2006)
The weak correlation between α-synuclein and free hemoglobin or total erythrocyte 
count has been described before. (Barbour et al. 2008; Hong et al. 2010) Alpha-synuclein 
in blood is present in red blood cells (RBC) and considering the fragility of RBCs, 
α-synuclein levels in CSF may be artificially elevated by CSF contamination with RBCs. 
(Barbour et al. 2008)  Hence, we also analyzed the subgroup of patients without detectable 
blood pigments in CSF and with erythrocyte counts below 50/µl, but reached similar 
conclusions.
We did observe a correlation between disease severity (as measured by H&Y score) and 
α-synuclein concentration in the MSA subgroup, as opposed to previous research. (Tokuda 
et al. 2006) Possibly the increased rate of disease progression in MSA and resulting cell 
death cause a release of the presynaptically localized α-synuclein, thus influencing the 
CSF α-synuclein concentration slightly.
The prevalence of PSP and CBS in our study population was rather low. As a result, the 
group of atypical parkinsonism in our study consisted mainly of MSA patients. Since both 
MSA and PD are neuropathologically characterized as α-synucleinopathies, the conducted 
analyses might have been dominated by the overrepresentation of α-synucleinopathies. 
Possibly a more balanced inclusion of both patients with an α-synucleinopathy and 
patients with a tauopathy might lead to different observations. 
In our specialized movement disorder center, referral and selection bias may have 
prompted the inclusion of an atypical patient population, which may have lead to more 
diagnostic uncertainty. Possibly this adds to the observed differences between our and 
previous studies. However, our study population therefore closely resembles the daily 
clinical practice in which ancillary diagnostic tests are applied in cases of diagnostic 
uncertainty. In addition, the clinical diagnosis was confirmed neuropathologically in only 
3 cases, and therefore potentially susceptible to misclassification.  However, our gold 
standard diagnosis was based on careful clinical assessment at baseline and after 2 years 
of clinical follow-up, including response to treatment and baseline cerebral MRI in all 
patients. For most patients, a proper diagnosis can be made after two years of follow-up 
and treatment with an adequate dose of levodopa. Half of the included patients were 
diagnosed according to the definite or probable diagnostic criteria. Moreover, separate 
analysis of CSF α-synuclein including only the patients with either a probable or definite 
diagnosis according to the current criteria did not yield different results, and neither did 
subgroup analysis including only patients who completed the entire follow up duration.
In conclusion, despite the aforementioned drawbacks, our results imply that CSF α-synuclein 
is currently not advocated as a diagnostic biomarker in differentiating between PD and 
atypical parkinsonism.
3.3 |
3.3 | CSF neurotransmitters in the 
differential diagnosis of 
dementia
Based on
CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from 
Alzheimer’s disease. Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, 
Verbeek MM. J Alzheimers Dis. 2011;27(2):377-84.
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Summary
Differentiating dementia with Lewy bodies (DLB) from Alzheimer’s Disease (AD) can be 
difficult because of the substantial overlap in clinical features. Since deficits in serotonergic 
and dopaminergic pathways seem more pronounced in DLB patients, we investigated 
whether cerebrospinal fluid (CSF) analysis of neurotransmitter metabolites, additional to 
brain-specific proteins, may improve the differentiation between DLB and AD.
We retrospectively compared CSF concentrations of the neurotransmitter metabolites 
homovanillic acid (HVA), 5-hydroxyindolacetic acid (5-HIAA) and 3-methoxy-4-hydroxy-
phenylethyleneglycol (MHPG) and the brain-specific proteins total tau (t-tau), phosphorylated 
tau protein (p-tau) and amyloid-β42 (Aβ42) in 45 patients with AD (mean age 71.6 years; 
34 (76%) men; 44 probable AD, 1 definite) and 23 patients with DLB (mean age 71.6 years; 
18 (78%) men; 6 possible DLB, 16 probable, 1 definite).
The concentrations of all neurotransmitter metabolites, as well as those for t-tau and p-tau 
protein, were significantly lower in DLB compared to AD, irrespective of the diagnostic 
certainty (i.e. possible or probable). The currently used combination of Aβ42,  p-tau and 
t-tau yielded a sensitivity of 92.9% and a specificity of 90%. The addition of MHPG  to 
resulted in an increased sensitivity of 97.6% and a specificity of 95% for the discrimination 
between DLB and AD. 
In conclusion, the combination of MHPG and the brain specific proteins t-tau, p-tau and 
Aβ42 in CSF were associated with the clinical diagnosis of DLB and discriminated between 
AD and DLB with high diagnostic accuracy, suggesting this combination as a potential 
biomarker for DLB.
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Introduction 
Dementia with Lewy bodies (DLB) is a common cause of dementia, accounting for up to 
20% of the dementia population. (Rahkonen et al. 2003) Core features include fluctuating 
cognition, visual hallucinations, autonomic disturbances and parkinsonism. The neuro-
pathological hallmark is the ‘Lewy body’, an intraneuronal inclusion body consisting of, 
amongst other, ubiquitin and α-synuclein, present in the substantia nigra, neocortex as 
well as limbic and forebrain structures. (D. F. Brown 1999; I. McKeith et al. 2004) 
Differentiation between DLB and Alzheimer’s disease (AD) on clinical grounds alone can be 
difficult due to substantial overlap in clinical presentation, as reflected by low sensitivity of 
the clinical criteria for DLB. (Litvan et al. 2003; I. McKeith et al. 2004; Nelson et al. 2010) 
However, early recognition is important because of the therapeutic consequences. DLB 
patients show great sensitivity to neuroleptics, which may cause physical and cognitive 
deterioration, and even increased mortality. (Aarsland et al. 2005; Henriksen et al. 2006; 
I. McKeith et al. 1992) Hence, biomarkers that improve the early recognition of DLB are 
urgently needed. 
Currently the cerebrospinal fluid (CSF) concentrations of amyloid-β42 (Aβ42), total tau 
protein (t-tau) and tau protein phosphorylated at Thr181 (p-tau) are employed to identify 
(incipient) AD patients amongst patients with dementia syndromes or MCI. (Mattsson et 
al. 2009) However, the differentiation between the different dementia syndromes based 
on CSF analysis is limited, e.g. because of considerable overlap between AD and DLB. 
(Andreasen et al. 2001; Bibl et al. 2006; Clark et al. 2003; Gomez-Tortosa et al. 2003; Kanemaru 
et al. 2000; Tschampa et al. 2001; Verbeek et al. 2003)
Deficits in serotonergic and dopaminergic pathways, associated with symptoms of 
autonomic dysfunction or parkinsonism, are more pronounced in DLB patients compared 
to AD patients. (Klein et al. 2010; Perry et al. 1991; Walker et al. 2002; Walker et al. 2007) We 
anticipated that CSF concentrations of the neurotransmitter metabolites homovanillic 
acid (HVA), 5-hydroxyindolacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylethylene -
glycol (MHPG), the catabolic end-products of dopamine and epinephrine degradation, 
are lower in DLB than in AD. (Kanemaru and Yamanouchi 2002; Langlais et al. 1993; Perry 
et al. 1993; Weiner et al. 1996) Therefore, we aimed to investigate the additional diagnostic 
value of CSF neurotransmitter metabolites compared to CSF brain-specific proteins in 
 differentiating between DLB and AD.
Methods and Materials
Patients
We included consecutive patients with a clinical diagnosis of DLB who were referred to 
either the movement disorder clinic of the Department of Neurology or the memory 
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clinic of the Department of Geriatric Medicine at the Radboud University  Nijmegen 
Medical Centre -to cover the broad clinical spectrum of DLB-, who underwent a lumbar 
puncture between December 2003 and June 2008 as part of the diagnostic work-up. 
(Figure 1)
Figure 1  Flowchart of patient inclusion in this study.
AD: Alzheimer’s disease, DLB: dementia with Lewy Bodies, CSF: cerebrospinal fluid, N: number. CSF was obtained 
during the initial diagnostic assessment upon presentation.
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The concentration of MHPG in CSF is independent of the fraction, however, since the 
concentrations of the neurotransmitter metabolites HVA and 5-HIAA do depend on the 
CSF fraction, (Brautigam et al. 1999) only patients with separate collection of the 8th-10th 
(±2) milliliter fraction were included for analysis. Diagnostic evaluation included a detailed 
medical history, systematic physical and neurological examination, routine laboratory 
testing and a brain MRI-scan. Cognitive function was assessed using the Mini Mental State 
Examination (MMSE). (Folstein et al. 1983) Additionally, 15 DLB patients underwent neuro-
psychological assessment. Symptoms of parkinsonism were assessed using the Hoehn and 
Yahr score. Hetero-anamnesis was employed to assess the presence of  visual hallucinations 
and fluctuations in cognition. The clinical diagnosis was established by either a specialized 
neurologist or geriatrician. Out of 93 eligible AD patients from the memory clinic database, 
an age and gender matched group of 45 AD patients was randomly drawn. The clinical 
diagnosis of these patients was established by a multidisciplinary team consisting of a 
geriatrician, a neurologist and a neuropsychologist. 
In April 2010 a single rater (MBA) reassessed the final clinical diagnosis by clinical chart 
review in order to improve diagnostic certainty. Reassessment of the clinical diagnosis was 
performed after a follow-up period of 12 months or longer (Table 1) according to the 
international consensus criteria for DLB (McKeith et al. 2005) and AD. (McKhann et al. 1984) 
The use of medication (serotonergic as well as dopaminergic medication), the presence of 
white matter lesions and the presence of behavioral disorders, hallucinations and 
symptoms of autonomic dysfunction were recorded to enable subgroup analysis. The 
local Institutional Review Board has approved of this study which was conducted 
according to the Helsinki Declaration.
CSF parameters
CSF samples were collected in polypropylene tubes, centrifuged, aliquoted, and stored at 
-80°C until analysis. We aimed for separate collection of the 8th-10th ml (±2) fraction for 
analysis of neurotransmitter metabolites. The following CSF variables were taken into 
account for the present study: Aβ42, t-tau, p-tau, MHPG, 5-HIAA and HVA; all parameters 
were analyzed within 4 weeks after CSF collection.
The methods of analysis of Aβ42, t-tau, p-tau, MHPG, HVA and 5-HIAA in CSF, their validation 
and reference values have been previously described. (Abdo et al. 2004; Brautigam et al. 
1999; de Jong et al. 2006) 
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Statistical Analysis 
Between-groups analysis was performed using the Student’s t-test in case of normally 
distributed data. Non-Gaussian distributed data were analyzed using the Mann-Whitney 
test. Pearson correlation coefficient was used to analyze correlations. Prior to correlation 
analysis, non-Gaussian distributed data were log-transformed to meet assumptions of 
normality and homogeneity. Logistic regression analysis was used to analyze relations 
between categorical variables.
Multivariate logistic regression and receiver operator characteristic (ROC) analysis were 
used to evaluate the diagnostic value of CSF parameters. Statistical analysis was carried 
out using GraphPad Prism version 4 (San Diego, CA) and SPSS software version 16.0 
(Chicago, IL).
Table 1   Characteristics of the diagnostic groups
Demographic characteristics DLB AD p-valueb
Number of patients 23 45
Age, yrsa 71.6 (9.3) 71.6 (9.4) NS (p=0.89)
Number of men (%) 18 (78) 34 (76) NS (p=0.88)
Disease duration, monthsa 38.8 (26.4) 33.0 (28.1) NS (p=0.42)
Cognitive function, MMSEa 23.0 (4.2) 19.5 (5.3) <0.05
Duration of follow up, months 55.9 (30.3) 49.7 (32.4) NS (p=0.75)
Vascular co-morbidity (%)a 5 (22) 12 (27) NS (p=0.73)
Autonomic dysfunction (%)a 13 (76.5) 9 (20.5) <0.001
     Orthostatic hypotension (%) 2/ (11.8) 1 (2.3) <0.001
     Urogenital dysfunction (%) 11 (64.7) 8 (18.2) <0.001
Hallucinations (%)a 13 (57) 1 (2) <0.001
Use of SSRI (%)a 4 (17) 3 (7) NS (p=0.15)
Use of L-dopa (%)a 6 (26) 0 (0) <0.001
Severity of parkinsonism, H&Y score a 2.5 (2.0-2.5) NA NA
CSF fraction analyzed, ml (lower margin)c 8.0 (7.0-9.0) 7.3 (6.8-8.0) NS (p=0.18)
CSF fraction analyzed, ml (upper margin)c 11.0 (10.0-11.5) 10.0 (9.0-10.5) <0.05
Data represent mean and standard deviation (in case of Gaussian distribution), median and interquartile 
range (in case of non- Gaussian distribution) or number and percentage.
a  At the time of lumbar puncture
b  P value for differences using student’s T-test. Gender distribution, the presence of vascular comorbidity, 
autonomic dysfunction, hallucinations and the use of medication were analyzed using χ2 test.
C  for neurotransmitter metabolite analysis
DLB: dementia with Lewy bodies; AD: Alzheimer’s disease; MMSE: mini mental state examination; SSRI: selective 
serotonine reuptake inhibitor; L-dopa: levodopa; H&Y score: Hoehn and Yahr score; NA: not applicable; 
CSF: cerebrospinal fluid
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Results
Patients
At the time of the clinical chart review, 23 patients fulfilled the diagnostic criteria for DLB 
(6 possible DLB, 16 probable DLB, and 1 definite DLB) and 45 patients fulfilled the diagnostic 
criteria of AD (44 probable AD, and 1 definite AD). None of the patients complied with the 
criteria for mild cognitive impairment (MCI). (Petersen et al. 1999) Demographic characteristics 
are shown in Table 1. Six DLB patients and two AD patients had deceased at the time of 
the chart review. 
The initial diagnoses, prior to CSF analysis were possible AD (n=18), probable AD (n=19), 
cognitive disorder not further specified (n=6), Creutzfeldt-Jakob disease (n=1) and possible 
DLB (n=1) for the AD patients; and for the DLB patients: possible DLB (n=10) , possible AD 
(n=3), Parkinson’s disease (n=5), corticobasal degeneration (n=1), multiple system atrophy 
(n=1), cerebral small vessel disease (n=2) and psychogenic complaints (n=1).  
Disease duration, gender and age at the time of lumbar puncture were similar in AD and 
DLB. MMSE score was lower in AD (p<0.05). Six DLB patients, and none of the AD patients, 
used dopaminergic therapy (median 375 mg; range 62.5-800 mg levodopa/day). 
CSF parameters
The results of the CSF analysis are presented in Figure 2. The concentrations of 5-HIAA 
(p<0.01), HVA (p<0.05) and especially MHPG, t-tau and p-tau (all p<0.0001) were lower in 
DLB as compared to AD whereas the Aβ42 concentrations tended to be higher in DLB than 
in AD (p = 0.06). We did not find an increase in median MHPG (p=0.53) or HVA concentrations 
(p=0.43) in DLB patients using dopaminergic medication relative to naïve DLB patients, 
hence these patients were not excluded from further data analysis. 
Compared to our reference values, 72.7% of AD patients had a decreased CSF Aβ42 (≤ 500 
ng/l) as opposed to 45.5% of DLB patients (p<0.05). CSF t-tau was increased (≥ 350 ng/l) in 
13.6% of DLB patients, compared to 84.1% of AD patients, whereas p-tau was increased (≥ 
85 ng/l) in 0% of the DLB patients as opposed to 70.5% of the AD patients (all p<0.0001). 
The above described differences in CSF parameters were present in AD and DLB patients 
irrespective of the certainty of diagnosis (i.e. possible or probable). 
We demonstrated no association between the occurrence of behavioral problems, use of 
serotonergic medication, presence of white matter lesions on MRI or symptoms of 
autonomic dysfunction on one hand, and levels of the three neurotransmitter metabolites 
and brain-specific proteins t-tau, p-tau, or Aβ42 on the other hand, neither in the entire 
group, nor in the DLB and AD patient groups separately. However, hallucinations were 
associated with lower MHPG (odds ratio (OR) 4.8, 95% CI 1.3-17.2 p<0.001) and HVA (OR 6.6, 
95% CI 1.5-28.6, p<0.001) in DLB patients.
Repeating the analyses while adjusting for age, disease duration and cognitive function 
did not markedly change our results.
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Diagnostic accuracy
Univariate logistic regression analysis (carried out to discriminate DLB from AD) revealed 
that the sensitivity and specificity exceeded 80% for both t-tau and p-tau (Table 2). To 
assess the diagnostic value of neurotransmitter metabolites over the currently used 
combination of t-tau, p-tau and Aβ42, we performed multivariate logistic regression 
analysis using block entry regression. 
The first block consisted of the currently used brain specific proteins resulting in a 
Nagelkerke R2 of 0.77 (p<0.001, model χ2(3)=49.8). In the second block MHPG, HVA and 
Figure 2   Scatterplots of the CSF concentrations of (A) 5-HIAA (nM), (B) HVA (nM), 
(C) MHPG (nM), (D) T-Tau (ng/L), (E) Aβ42 (ng/L) and (F) P-Tau (ng/L) in DLB and 
AD subgroups.
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5-HIAA were added. Only MHPG showed significant added value to the constructed 
model based on block 1, improving Nagelkerke R2 from 0.77 to 0.87 (p<0.001, model 
χ2(4)=59.4). ROC-curve analysis of the first model (based on t-tau, p-tau and Aβ42 
demonstrated a sensitivity of 92.9% and a specificity of 90% (AUC 0.96). The subsequent 
addition of MHPG resulted in further improvement of the diagnostic accuracy with a 
sensitivity of 97.6% and a specificity of 95% (AUC 0.99).
Discussion 
We found that CSF concentrations of 5-HIAA, HVA, MHPG, t-tau and p-tau were significantly 
lower in DLB than in AD, whereas CSF Aβ42 tended to be higher in DLB. Most important, 
the combination of MHPG, p-tau, t-tau and Aβ42 analysis discriminated between AD and 
DLB with high diagnostic accuracy. 
 
Figure 3  ROC curves of the models 1 and 2.
Model 1:  y= -13.965 + 0.072x p-tau, + 0.021x t-tau + 0.143x MHPG – 0.006x Aβ42. AUC: 0.99 (0.97-1.0)
Model 2:  y= -5.098 + 0.005x p-tau, + 0.020x t-tau – 0.002x Aβ42. AUC: 0.96 (0.92-1.0)
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We are the first to rigorously investigate CSF MHPG in a large group of DLB patients. Only 
one earlier study examined CSF MHPG concentrations in DLB and, although the sample 
size was small (n = 8 subjects) findings are consistent with ours. (Weiner et al. 1996) Moreover, 
our findings of lower concentrations of CSF MHPG are consistent with previous neuro-
pathological studies, demonstrating degeneration of the locus coeruleus (Mann et al. 
1980) and decreased concentrations of norepinephrine in putamen and neocortex, as 
compared to controls and AD patients. (Ohara and Kondo 1998)  Moreover, these findings 
are also compatible with the neuropathologically observed degeneration of nigrostriatal 
dopaminergic neurons in DLB, (Dickson et al. 2009) because reduced availability of 
dopamine results in a decrease of dopamine-derived neurotransmitter metabolites. 
Interestingly, even though 5-HIAA and HVA were significantly lower in DLB as compared 
to AD, both did not contribute significantly to the constructed model, possibly because 
the direction of the effects were similar to MHPG and and the strong correlation between 
CSF HVA and MHPG r 0.618, p< 0.001. 
The brain specific proteins t-tau, p-tau and Aβ42 have been studied abundantly in both AD 
and DLB. We confirmed previous results that CSF Aβ42 concentrations are low in DLB and 
close to the levels observed in AD patients, (Andreasen et al. 2001; Bibl et al. 2006; Clark et 
al. 2003; Gomez-Tortosa et al. 2003; Kanemaru et al. 2000; Tschampa et al. 2001; Verbeek et 
al. 2003) possibly reflecting the AD-like pathology observed in a proportion of the DLB 
patients upon post-mortem examination, substantially limiting its discriminating 
properties. We also found increased t-tau levels in AD, but generally normal levels in DLB. 
Previous studies demonstrated conflicting results; some studies found elevated t-tau 
concentrations in DLB patients, (Andreasen et al. 2001; Kanemaru et al. 2000) whereas 
other studies showed normal t-tau concentrations, (Clark et al. 2003; Kasuga et al. 2010; 
Tschampa et al. 2001) as we did. In our study, as in two other reports (Kasuga et al. 2010; 
Parnetti et al. 2001) p-tau concentrations were normal in DLB, although conflicting results 
were also reported. (Buerger et al. 2002) These discrepancies underscore the importance 
of additional CSF parameters, in order to compose a more comprehensive and robust CSF 
profile.
Our results imply that the addition of CSF MHPG to the currently used analysis of 
brain-specific proteins can further improve the diagnostic differentiation between DLB 
and AD. The recent observation that up to 18% of patients suffering from dementia are 
treated with neuroleptics (Guthrie et al. 2010) further stresses the importance of diagnostic 
accuracy in early disease stages, because the use of neuroleptics in DLB patients is contra-
indicated for fear of increased physical and cognitive deterioration, as well as increased 
mortality. (Aarsland et al. 2005) 
Cognitive dysfunction is often assessed using the MMSE score. This score, however, has 
certain disadvantages, as it is an inaccurate method of cognitive assessment. For example, 
it is known that, as cognition is known to fluctuate in DLB, test – re-test variability is 
substantial. However, the MMSE is easy to perform and still the most commonly used 
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cognitive screening assessment in daily practice, and therefore used in this study as well. 
The slightly lower MMSE scores in the AD subgroup might reflect the often more 
pronounced amnestic and orientation problems observed in AD. 
This difference in MMSE likely does not affect the results for CSF t-tau, p-tau and Aβ42, 
since it is known that CSF biomarker levels are hardly dependent on disease state and 
severity, especially in AD. It is, however, unknown whether this also applies to DLB and to 
CSF neurotransmitter metabolite levels. Therefore, to acknowledge these differences in 
MMSE score, but also in age and sex, between AD and DLB we included these parameters 
in our models, but this modification did not result in an altered AUC.
This study has several potential drawbacks. First, the retrospective design may have 
introduced selection bias. Only DLB and AD patients who underwent a lumbar puncture 
as part of their diagnostic workup were included in this study, possibly leading to selection 
of more atypical phenotypes. However, we included a substantial number of probable 
and even definite DLB patients, who showed similar CSF patterns. Second, the clinical 
diagnosis was not confirmed neuropathologically in most patients. Misclassification may 
therefore have occurred. However, accuracy of the final clinical diagnosis was optimized 
using the following approach: thorough clinical and ancillary investigations at baseline; 
extensive follow-up (53 months for DLB and 50 months for AD patients) to monitor disease 
progression and development of new diagnostic signs; and establishing the diagnosis 
according to international consensus criteria in a specialized clinic. Third, the proposed 
model based on CSF biomarkers warrants validation in an independent and larger cohort. 
Despite these drawbacks, our results underline the importance of CSF analysis for the 
differentiation between dementia syndromes, specifically between AD and DLB. Moreover 
the addition of CSF MHPG to the currently used analysis of the brain-specific proteins 
t-tau, p-tau and Aβ42 may further improve this diagnostic differentiation. These results 
warrant validation in a prospective study with preferably neuropathological confirmation 
of the diagnosis and inclusion of patients with other types of dementia.
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Summary
In everyday practice, differentiating between Parkinson’s disease (PD) and atypical 
parkinsonism (AP) is challenging due to overlap in clinical presentation. Various ancillary 
investigations are available to facilitate the differential diagnosis, but have not yet been 
compared within one study. We will conduct a prospective study to investigate the 
individual and relative value of electromyography (EMG) of the anal sphincter, analysis of 
cerebrospinal fluid (CSF), magnetic resonance imaging of the brain (MRI) and 123I-iodo-
benzamide Single Photon-Emission Computed Tomography (IBZM-SPECT) for 
discriminating between PD and AP. Our aim is to develop a diagnostic model based on 
baseline clinical characteristics, and ancillary investigations.
Consecutive patients with parkinsonism referred to our outpatient department are invited 
to participate. Baseline assessment includes extensive neurological examination, MRI, anal 
sphincter EMG, IBZM-SPECT and lumbar puncture. The clinical diagnosis after 3-year 
follow-up will serve as the silver standard diagnosis, based on additional neurological 
signs, rate of progression and treatment response. Two movement disorder specialists will 
establish this silver standard diagnosis in consensus. Univariate and multivariate analysis 
will be performed to determine which of the baseline assessments best predicts the silver 
standard diagnosis. 
This study has the potential to clarify the individual and relative diagnostic value of MRI, 
EMG, IBZM-SPECT and CSF analysis for discriminating between PD and AP. 
A prospective study to evaluate the diagnostic approach in parkinsonism
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Introduction
Differentiation between Parkinson’s Disease (PD) and the various forms of atypical 
parkinsonism (AP) such as multiple system atrophy (MSA), progressive supranuclear palsy 
(PSP), and corticobasal syndrome (CBS) can be difficult due to overlap in clinical symptoms, 
especially early in the course of the disease. Although the clinical diagnosis after several 
years of follow-up highly correlates with the neuropathological diagnosis upon 
post-mortem examination, the diagnostic accuracy of the initial diagnosis varies greatly 
and can be as low as 30%. (Hughes et al. 2002; Litvan et al. 1996; Litvan et al. 1997) While 
difficult, a correct diagnosis is important for adequate treatment and patient counseling, 
as well as for research purposes.  
Various ancillary investigations are available to facilitate the differential diagnosis, but 
different modalities of ancillary investigations have not yet been compared in one study. 
We sought to investigate the diagnostic accuracy of four different tests, which have all 
been proposed as a diagnostic tool for the neurologist in daily practice. These tests 
include brain magnetic resonance imaging (MRI), electromyography (EMG) of the anal 
sphincter, analysis of the cerebrospinal fluid (CSF) and 123I-iodobenzamide Single 
 Photon-Emission Computed Tomography (IBZM-SPECT).
MRI characteristically does not show abnormalities in PD, whereas specific signs mark AP, 
such as the hummingbird sign (midbrain atrophy) for PSP, the putaminal rim (putaminal 
atrophy) and hot cross bun sign (atrophy of pontine fibres) for MSA, and the asymmetrical 
cortical atrophy in CBS. (Schrag et al. 2000) A recently published study describes the pilot 
data of this study. (Meijer et al. 2012)  
EMG of the anal sphincter can detect denervation of the external anal sphincter due to 
degeneration of Onuf’s nucleus in up to 70% of PSP and MSA patients. (Papp and Lantos 
1994; Scaravilli et al. 2000) Such abnormalities are only rarely observed in PD patients in 
the early phase of the disease, (Podnar and Fowler 2004; Vodusek 2005; Winge et al. 2010) 
but can be present later in the course of the disease. (Paviour et al. 2005) 
CSF analysis of brain specific proteins and neurotransmitter metabolites in PD patients are 
generally within normal range, whereas in especially MSA a characteristic profile with 
elevated brain specific proteins, especially tau protein and neurofilaments, is seen. (Abdo 
et al. 2007; Aerts et al. 2011b) The observed abnormalities in CSF possibly reflect the 
increased neuronal damage as observed in AP, as elevated concentrations of especially 
the brain-specific proteins can be observed in other quickly progressive neurodegenera-
tive diseases like Creutzfeldt-Jakob disease. (van Eijk et al. 2010)
IBZM-SPECT enables imaging of the post-synaptic dopamine D2 receptors. PD patients 
generally show up-regulation of these D2 receptors in the striatum, whereas both MSA and 
PSP patients show decreased density of dopamine D2 receptors in the striatum. (Churchyard 
et al. 1993; Kim et al. 2002; Plotkin et al. 2005) However, sensitivity can be limited due to 
overlapping ranges between PD and AP. (Seppi et al. 2004; Verstappen et al. 2007)
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The studies cited above demonstrate the potential merits of the various investigations 
when used in isolation. However, it is more difficult to compare different sorts of ancillary 
investigations in their ability to discriminate between PD and AP. Consequently, it remains 
uncertain which ancillary investigation(s) to choose first when the clinician is uncertain 
about the underlying etiology of a patient with parkinsonism. We therefore have designed 
a prospective clinical trial to investigate the individual and relative value of three types of 
ancillary investigations in discriminating PD and AP. (Figure 1)  
Methods
Design  
Prospective, longitudinal study design
Participants and setting
Consecutive new patients with a hypokinetic-rigid syndrome, referred between September 
2003 and November 2006 to the movement disorders clinic of the Department of 
Neurology at the Radboud University Nijmegen Medical Centre, were invited to participate. 
Inclusion and exclusion criteria are provided in Table 1. The clinical examinations and 
ancillary investigations are performed in this hospital.
Figure 1  The study design.
At baseline several ancillary tests are performed. After follow up a silver standard diagnosis is performed. Looking 
back, the predictive value of the ancillary tests at baseline is analyzed. MRI: magnetic resonance imaging; 
CSF: cerebrospinal fluid; IBZM-SPECT: 123I-iodobenzamide Single Photon-Emission Computed Tomography; 
EMG: electromyography
Parkinsonism
but
uncertain diagnosis
Silver standard diagnosis:
* rate of progression
* new signs
* levodopa response
Ancillary tests
* MRI
* CSF analysis
* IBZM spect
* anal sphincter EMG
3-years follow up
Predictive value?
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Medical ethical approval is obtained by the local Institutional Review Board (2002). 
All patients have to sign the informed consent form after detailed explanation of the 
procedures.
Methods
After informed consent and within 6 weeks of the initial visit, all patients undergo a 
structured interview, detailed and standardized neurological examination, magnetic 
resonance imaging (MRI) scan, a lumbar puncture, IBZM-SPECT and electromyography 
(EMG) of the anal sphincter. After three years all patients will be re-examined by the initial 
investigator. The final clinical diagnosis will be established in consensus and according to 
the clinical criteria by neurologists specialized in movement disorders. These neurologists 
are blinded for the results of the ancillary investigations, except MRI because this is now 
nearly routinely used in clinical practice. Previously published data show a very high 
concordance between the neuropathological diagnosis and the clinical diagnosis after at 
least 2 years follow up by a movement disorder specialist (PPV 99%). (Hughes et al. 2002) 
Hence, this final clinical diagnosis serves as a surrogate ‘silver standard’ to calculate the 
diagnostic accuracy of CSF analysis, IBZM-SPECT and anal sphincter EMG to differentiate 
between PD and AP. (Flowchart 1)
Interview and neurological examination
Interview and neurological examination are performed by two independent physicians, 
not directly involved in patient care (WFA, RAJE). Using a structured interview the following 
items are assessed: medical history, used medication, presenting complaints and 
progression of the disease, most affected body site, balance and fear of falling, activities in 
daily living, and quality of sleep. In addition, the following clinimetric scales are scored: 
Unified Parkinson’s Disease rating scale (UPDRS) III and IV and Hoehn and Yahr score, 
(Hoehn and Yahr 2001) International Cooperative Ataxia Rating Scale (ICARS), (Trouillas et 
al. 1997) and Mini mental state examination (MMSE), (Folstein et al. 1983) for cognitive 
assessment. Definitions can be found in Table 2.
Table 1   Inclusion and exclusion criteria
Inclusion criteria
- Hypokinetic rigid syndrome of 
neurodegenerative origin
- Aged >18 years
Exclusion criteria
- Instable comorbidity
- Patient unfit to consent
- Thrombopenia
- A medical history of brain surgery
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MRI
All patients receive a brain MRI at first presentation performed on a 1 or 1.5 Tesla MRI 
scanner. The scanning protocol is not standardized as the studies are made in the clinical 
setting, and not for research purposes. All MRI scans will be evaluated by an experienced 
neuroradiologist (FJAM) blinded for clinical symptoms and outcome in a systematic 
fashion. To assess interrater variability, a second neuroradiologist, also blinded for clinical 
symptoms and outcome, will evaluate a consecutive subset of MRI studies.  The presence 
of the following abnormalities will be noted: putaminal T2 hypo- and hyperintensity 
changes, putaminal rim sign, putaminal atrophy, frontal lobe and parietal lobe atrophy, 
lateral, third and fourth ventricle dilatation, midbrain and pontine atrophy, hummingbird 
sign, atrophy of the cerebellum and cerebellar vermis, atrophy of the medulla oblongata, 
pontine T2 hyperintensity and hot cross bun sign, dilated perivascular spaces, lacunar 
infarctions and white matter changes. White matter changes are scored according to the 
Figure 2  Flowchart study design.
MRI: magnetic resonance imaging; UPDRS: unified Parkinson’s Disease rating scale; ICARS: International Cooperative 
Ataxia Rating Scale; MMSE: mini mental state examination; battery; IBZM-SPECT: 123I-iodobenzamide Single Photon- 
Emission Computed Tomography; CSF: cerebrospinal fluids; EMG: electromyography
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•  Neurological examination
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age related white matter changes criteria. (Wahlund et al. 2001) For validation purpose the 
scoring system proposed by Yekhlef (Yekhlef et al. 2003)  combining several MRI 
abnormalities in cortical, putaminal, midbrain and pontocerebellar regions  will be used. 
In accordance with these criteria, a cut-off value of 8 is set to discriminate PD from AP. 
Analysis of these data is published recently. (Meijer et al. 2012) 
Table 2   Definitions of the clinical parameters
History All indicators are derived from the history taking. Hence, 
these are questions asked to the patient, not observations 
by the examiner.
Age Continuous parameter
Course of the disease Either stable, slowly progressive, or quickly progressive 
Use of walking aids Walking with a stick, walker or wheelchair
Cognitive dysfunction Whether the patient felt that cognition had declined more 
than compared to people the same age (yes or no)
Presence of falls Whether the patient falls or has fallen the past year  
(yes or no)
Presence of night time stridor Whether the patient has inspiratory stridor at night time 
(yes or no)
Hypersalivation Does the patient experience night hypersalivation  
(yes or no)
Ability to cycle Is de patient still able to cycle despite the disease (yes or no)
Autonomic dysfunction Does the patient experience urgency, urge incontinence, 
erectile dysfunction or lightheadedness upon standing  
(yes or no)
Independence of care Is the patient fully independent in daily self care (yes or no)
Dysphagia Does the patient have trouble swallowing (yes or no)
Neurological examination All indicators are derived from the neurological examination. 
Hence, these are observations by a trained examiner
Romberg The patient is asked to stay with the eyes closed and feet 
together. Romberg’s test is disturbed when balances is lost 
when closing the eyes. (yes or no)
Pathological reflexes Two or more of the following reflexes: glabellar, snout gasp, 
palmomental, masseter reflex
Cognitive assessment
MMSE
Fluency
Cognitive assessment (Folstein et al. 1983) (range 0-30)
The average of two phonetical ( the patient is asked to 
name as many words with both S and T as starting vowel) 
and one categorical trial (naming as many animals as 
possible). Each trial lasts 60 seconds.
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Table 2   Continued
Ataxia
Dysarthria
Finger- nose test
Heel shin test
Tandem gait
ICARS total score
Score of separate items, see ICARS reference below
Presence of slurred speech, 
Patient is asked to point the finger to the nose; assessed for 
dysmetria tremor. 
Patient is asked to bring the heel to the other legs shin and 
slide down; assessed for dysmetria and tremor
The patient has to walk 10 consecutive staps in tandem, not 
one single side step is allowed. (range 0 (without side steps) 
– 4 (not able to perform)
International Cooperative Ataxia Rating Scale (Trouillas  
et al. 1997)
UPDRS axial score Composite score of all axial parameters tested in the UPDRS 
including speech and face assessment, axial rigidity, rising 
from a chair, posture, gait and assessment of postural 
stability
Disease stage Disease stage: 0: normal, 1: disturbed gait but walking 
independently; 1.5: disturbed gait, intermittent use of 
walking aids; 2: disturbed gait, permanent use of walking 
aids; 2,5: disturbed gait, intermittent use of wheelchair; 3: 
disturbed gait, permanent use of wheelchair; 4: death.
Schwab and England score Disease severity (Fahn and Elton 1987)
Myoclonus Brief, shock-like movements (yes or no)
Autonomic dysfunction
Early orthostatic hypotension
Late orthostatic hypotension
A drop of 30 mmHg in systolic or 15 mmHg in diastolic 
blood pressure directly after standing
Similar after 3 minutes of standing
Eye movements
Saccadic intrusions
Slow saccades
Multistep saccades
Supra nuclear palsy
The disturbance of smooth pursuit by saccadic intrusions 
(yes or no)
Slowed velocity of saccadic eye movements
(yes or no)
The saccadic eye movements cannot be performed in 
one attempt, multiple shorts saccadic eye movements are 
needed (yes or no)
Limited range of vertical eye movements (yes or no)
A prospective study to evaluate the diagnostic approach in parkinsonism
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CSF
CSF samples are collected in polypropylene tubes, centrifuged, aliquoted, and stored at 
-80°C until analysis. We aim for separate collection of the 9th-11th ml fraction for analysis of 
neurotransmitter metabolites.  All CSF analysis is performed by laboratory technicians 
blinded for clinical symptoms and outcome. The following CSF variables are analyzed: 
Amyloid β42 (Aβ42), total tau protein (t-tau), tau protein phosphorylated at Thr181 (p-tau), 
α-synuclein, neuronspecific enolase (NSE), S-100B, Glial fibrillary acidic protein (GFAP), 
myelin basic protein (MBP), neurofilament light chain (NFL), neurofilament heavy chain 
(NFH), L-dopa, 3-Methoxy tyrosine (3MT), 3-methoxy-4-hydroxyphenylethyleneglycol 
(MHPG), 5-hydroxyindolacetic acid (5-HIAA), homovanillic acid (HVA), lactate, total protein, 
blood pigments and the total erythrocyte count; The erythrocyte count and blood 
pigments are analyzed within 2 hours after CSF collection, all other parameters are 
analyzed within 4 weeks after CSF collection. 
Aβ42 concentrations in CSF are analyzed using the Innotest amyloid β42 assay 
(Innogenetics, Ghent, Belgium; linearity up to 2000ng/L, interassay variation coefficient 
(ICV) 6.4%). T-tau concentrations in CSF are analyzed using the Innotest hTau assay 
(Innogenetics, Ghent, Belgium; linearity up to 1200ng/L, ICV 8.3%). P-tau concentrations in 
CSF are analyzed using the Innotest Phospho-Tau(181) assay (Innogenetics, Ghent, Belgium; 
linearity up to 500ng/L, ICV 3.8%).  Both NSE and S-100B concentrations in CSF are analyzed 
in an immunoluminometric assay (Byk Sangtec, Dietzenbach, Germany) by using the 
Liaison automated analyzer (Byk, Sangtec). The assays are linear up to 100 µg/L (NSE) and 
30 µg/L (S-100B). CSF GFAP is analyzed by using a homemade sandwich ELISA (linear up to 
250 µg/L; ICV <14%). (van Geel et al. 2002) MBP is analyzed using a commercial ELISA (DSL, 
Webster, Texas; linearity up to 10 µg/L, ICV <10%. NFH is measured according to previously 
described methods (Abdo et al. 2007; Van Geel et al. 2005) ICV <18% for both NFH and 
NFL), NFL is measured by a commercial 2-site solid phase sandwich ELISA (UmanDiagnos-
tics, Umea, Sweden; Detection limit: 31ng/L linearity up to 10 µg/L,  ICV <6 %, L-dopa and 
3MT are analyzed using HPLC with fluorimetric detection; excitation 278nm and emission 
at 325nm (linear up to 160 nM; ICV <7%). MHPG, HVA and 5-HIAA in CSF are measured 
according to previously described methods. (Abdo et al. 2004; Brautigam et al. 2002) 
Because the concentrations of HVA and 5-HIAA vary in the different fractions of CSF, 
(Brautigam et al. 2002) the 9th-11th milliliter CSF fraction is used for analysis. The assays are 
linear within the following ranges: HVA, 0 to 4 µM; 5-HIAA, 0 to 2 µM; MHPG, 0 to 125 nM. 
ICV is ≤4.8% in all three assays. The method of α-synuclein analysis and its validation is 
published previously. The linearity of the used assay ranges from 6 to 300ng/ml. The ICV is 
3.5% at a concentration of 49ng/ml. The number of erythrocytes is manually counted in a 
counting chamber (volume 3 µl), blood pigments are analyzed using spectrophotometric 
analysis of centrifuged CSF (Perkin-Elmer, Groningen; The Netherlands) and calculation of 
the second derivative of the signal (which is linear with the concentration) in the spectrum 
between 573 and 578 nm is performed to quantify hemoglobin and the spectrum 
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between 460 and 478 nm is used for quantification of bilirubin. Lactate concentration is 
determined by the enzymatic conversion of lactate into pyruvaat and hydrogen peroxide 
in the presence of lactate oxidase and the subsequent conversion of hydrogen peroxide 
with 4-aminoantipyrine and N-ethyl-N-sulfopropyl-m-anisidine to quinoneimine in the 
presence of peroxidase, measured at 550nm. Total protein concentration is determined with 
the Lowry reaction and absorption measured at 720 nm. Both lactate and total protein are 
analyzed with an automated analyzer (Mira Plus; ABX, Eindhoven, The Netherlands).
For a comprehensive analysis of the various CSF parameters, we developed a scoring 
system. Only the best documented CSF parameters, based on own experience and 
literature, we have added in this model. Other parameters (e.g. cell count) are used to 
exclude other causes of disease, or are aimed for cross-sectional – post hoc analysis (e.g. 
α-synuclein). Moreover, we sought to weigh slightly abnormal values less heavily than 
significantly abnormal values. (Table 3) The individual cut-off values are assessed based on 
prior studies as well as the currently used cut-off values in our laboratory.
The following CSF parameters are incorporated in the model: T-tau, probably the best 
documented CSF parameter to discriminate PD and AP, with a first cut-off of >225ng/l 
(slightly elevated) (Abdo et al. 2007) and >350 ng/l as a second cut-off (significantly 
elevated); NFL,  with a first cut-off of >2500ng/l (based on prior analyses (Abdo et al. 2007)) 
and >3000 ng/l as a second cut-off; Aβ42, with a first cut-off of <500ng/l and <350 ng/l as 
a second cut-off; (Aerts et al. 2011c) MHPG with a first cut-off of <43ng/l and <38ng/l as a 
Table 3   CSF analysis paradigm
CSF parameter Individual cut-off value Score
T-tau > 225
> 350
1
2
A β42 < 500
< 350
1
2
NFL > 2500
> 3000
1
2
MHPG < 43
< 38
1
2
HVA 
And
5-HIAA
< 70 
And
< 100
1
Total score 9
T-Tau: total Tau ; A β42 : Amyloid β 42; NFL: neurofilament light chain ; MHPG: 3-methoxy-4-hydroxyphenyl-
ethyleneglycol; HVA: Homovanillic acid; 5-HIAA: 5-hydroxyindolacetic acid
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second cut-off; (Aerts et al. 2011c) and lastly the combination of HVA (<70mmol/l) and 
5-HIAA (<100mmol/l). (Aerts et al. 2011c) In total, 9 points can be obtained. The cut-off for 
the discrimination between PD and AP is determined at 3 points, with a score below the 
cut-off leading to a CSF-based diagnosis of PD.
IBZM-SPECT
Cerebral SPECT imaging is performed 90 minutes after slow (30s) intravenous injection of 
185 MBq 3-[123]iodo-6-methoxybenzamide, (iodobenzamide or IBZM, GE Healthcare, 
Eindhoven, the Netherlands) with a dual head gamma camera. The first 34 scans are made 
on a Siemens MultiSpect camera connected to an ICON computer (Siemens AG, Erlangen, 
Germany), the remaining on a Siemens ECAM (Siemens AG, Erlangen, Germany) connected 
to a HERMES work station (HERMES, Nuclear Diagnostics, Stockholm, Sweden). The cameras 
are especially calibrated for quantification using a traveling phantom and fitted with 
low-energy high-resolution collimators using a 15% energy window centered on the 159 
keV photon energy-peak of iodine-123. Both heads perform a 180 degree circular motion 
and collected 64 projections (40 seconds per view) in a step-and-shoot mode using a 128 
x 128 matrix with a zoom factor of 1.23. During scanning the patient’s head is positioned 
in a head holder and the patient’s head and shoulders are fixated to minimize movement 
during the scan. The radius of the detector orbit is kept as small as possible, usually 
11-15cm.
Transaxial images will be reconstructed using filtered back projection with post-recon-
struction filtering (Butterworth 8th order, cutoff 0.6) without attenuation or scatter 
correction. The head is reoriented to the canthus-meatus plane. The three consecutive 
slices with the highest striatal uptake (total thickness 14.6 mm) are selected for quantitative 
analysis. Fixed size regions of interest (derived from an anatomical brain atlas) are bilaterally 
drawn over the striatum and the occipital cortex enabling the calculation of striato-occip-
ital ratio’s. (van Royen et al. 1993) All drugs known to interfere with scanning will be 
withdrawn prior to scanning. (Table 4) Dopamine agonists  and levodopa have to be 
discontinued for at least one week and >12 hours respectively. Quantitative and qualitative 
analysis of the IBZM-SPECT scans are performed by an independent nuclear medicine 
physician, blinded for clinical symptoms and outcome. 
EMG of the anal sphincter
Standard needle EMG procedure will be performed. (Podnar and Fowler 2004) Subjects 
lay on their right side, with knees and hips flexed.  A 37 mm long standard disposable 
concentric EMG needle with a diameter of  0.46 mm and a recording area of 0.07 mm2 will 
be used. (Medelec Elite disposable concentric needles, Viasys Healthcare, Carefusion, San 
Diego, California, U.S.A.). The needle is placed into the subcutaneous external anal 
sphincter (EAS) muscles. On each side, one skin penetration and EMG analysis of at least 
two different positions in the EAS muscle will be performed. 
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The EMG activity of the EAS muscles is assessed in rest, during relaxiation and contraction. 
The EMG signals are amplified and filtered between 20Hz and 3 kHz and stored using the 
liveplay feature of the Medelec Synergy EMG equipment. (Synergy, Viasys Healthcare, 
Carefusion, San Diego, California, U.S.A.; software version 14, Oxford Instruments Medical, 
UK). 
Visual inspection of these needle EMG investigations is performed at different gains 
by an independent clinical neurophysiologist (GD), blinded for clinical symptoms and 
outcome. A sensitivity of 20 µV/div with an acquisition duration of 100ms at rest, 100 µV/
div with an acquisition duration of 100ms during moderate contraction, and a sensitivity 
of 200 µV/div with an acquisition duration of 1s during relaxation and full contraction 
are used. 
Follow up
Three years after the inclusion visit, patients will be again seen on the outpatient clinic 
for a repeated structured interview and neurological examination by an independent 
physician, (WFA) blinded for test results and clinical records of the treating neurologist.  
Table 4   Medication interfering with IBZM-SPECT scanning
Amfetamine Penfluridol (Semap)
Alizapride (Litican) Pergolide (Permax)
Apomorfine (Apo-go) Pimozide (Orap)
Benperidol (Frenactil) Pipamperone (Dipiperon)
Bromocriptine (Parlodel) Pramipexol (Sifrol)
Cabergoline (Dostinex) Prochloorperazine (Stemetil)
Chloorpromazine (Largactil) Promazine (Sparine)
Cinnarizine Promethazine (Phenergan)
Clozapine (Leponex) Perphenazine (Decentan)
Cocaine Quetiapine
Flufenazine (Anatensol) Quinagolide (Norprolac)
Flunarizine (Sibelium) Raclopride
Flupentixol (Fluanxol) Risperidone (Risperdal)
Haloperidol (Haldol) Ropinirol (Requip)
Lisuride (Dopergin) Rotigotine (Neupro)
Methylfenidaat (Ritalin) Sulpiride (Dogmatil)
Metoclopramide (Primperan) Zuclopentixol (Cisordinol)
Olanzapine (Zyprexa)
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Clinical diagnosis
The clinical diagnosis is established in a systematic fashion by two movement disorder 
specialists, blinded for test results. All patient data are anonimized and sequentially 
presented to this panel: 1) clinical data and clinimetrics (UPDRS, MMSE, ICARS) upon 
inclusion, 2) disclosure of MRI results, 3) description of the reaction to dopaminergic 
medication, 4) disclosure of the clinical data and clinimetrics (UPDRS, MMSE, ICARS) after 3 
years follow-up, and 5) disclosure of ancillary investigations. Each time the panel -in 
consensus- establishes a diagnosis (either PD or AP (not otherwise specified) and the 
corresponding degree of uncertainty (on a 0-100% rating scale), followed by a more 
specific diagnosis (e.g. IPD, MSA or PSP) always according to the international clinical 
criteria. (UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria for PD, 
(Hughes et al. 1992) NINDS-SPSP criteria for PSP, (Litvan et al. 1996) Boeve criteria for CBS, 
(Boeve et al. 2003) McKeith Criteria for DLB, (McKeith et al. 2005) Gilman criteria for MSA, 
(Gilman et al. 2008) and Zijlmans criteria for VaP. (Zijlmans et al. 2004) The diagnosis prior 
to disclosure of the ancillary investigations (as defined above under (4)) is used as the silver 
standard to compare the ancillary investigations with.
Statistical analysis
Research questions
The objective of the study is to evaluate the added value of ancillary investigations to the 
clinical evaluation in the discrimination of PD and AP. Research questions include:
1. Evaluation of the initial clinical diagnosis as compared to the final diagnosis 
2. The development of a diagnostic model based on baseline characteristics and clinical 
variables 
3. The evaluation of the contribution of MRI scan variables, IBZM, CSF and EMG to the 
diagnostic accuracy in discriminating between PD and AP
4. The development of a diagnostic model based on baseline characteristics, clinical 
variables and ancillary investigations
In this article, we describe the overall design of the study including detailed methods, 
present baseline characteristics and the statistical methods for the proposed research 
questions. 
Outcome measures
The primary outcome measure is the number of correct diagnoses (i.e. PD or AP) at the 
first diagnosis. Secondary outcome measures will include the number of correct specific 
AP diagnoses. 
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Analysis plan
We will analyze the diagnostic power of potential identifiers of atypical parkinsonism, 
obtained from history and neurological assessment, both for each identifier separately 
and for combinations of identifiers. Missing data points are imputed as normal. The 
discriminative power of an identifier or a combination of predictors is quantified using the 
area under the receiver operating curve (AUC). 
Logistic regression with stepwise model selection is used to identify combinations of 
parameters that had optimal diagnostic power. In order to reduce inflation of the error 
rate due to the selection procedure and to limit the number of parameters in the model, 
a p-value of 0.01 is used as criterion for incorporation in the final prediction model. As 
stepwise selection methods lead to optimistic estimates of the AUC, we use cross 
validation to adjust the AUCs for optimism. Finally, in an attempt to simplify the final 
model, we also investigate the diagnostic performance of a diagnostic rule based on the 
two most powerful parameters of the model. Subanalysis, including only patients who 
completed the entire duration of the follow up and without missing data will be performed 
to assess robustness of the model.
Results
Baseline characteristics of the studied population
Between September 2003 and November 2006, 164 patients presenting with a hypokinetic 
rigid syndrome at our movement disorder clinic complied with inclusion criteria and 
consented to participation in this study. The demographic and baseline characteristics of 
the included patients are presented in Table 5.
Suspected clinical diagnosis at baseline was Parkinson’s Disease in 73 patients, Multiple 
System Atrophy in 43, Progressive Supranuclear Palsy in 9, Dementia with Lewy bodies in 
3, Vascular Parkinsonism in 30 and Corticobasal Syndrome in 6 patients.
Discussion
The large, prospective longitudinal study presented here has the potential to evaluate the 
diagnostic accuracy of various tests to differentiate between PD and AP in clinical practice. 
The diagnostic value of each of the selected ancillary investigations has been studied 
previously, predominantly in case-control studies. However, even the combination of 
these previous studies does not tell clinicians which ancillary investigation to choose 
when confronted with a patient with a hypokinetic-rigid syndrome of uncertain clinical 
etiology. This study is especially designed to evaluate the predictive value of ancillary 
investigations performed at baseline with the final diagnosis after follow up.
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Moreover, in addition to providing directions for the neurologist in daily practice, our 
study (with comprehensive assessment using validated questionnaires and clinimetric 
scales, both at baseline and at follow-up) will yield new insights into disease progression, 
succession of symptoms and may even unveil biomarkers that determine the prognosis.   
Table 5   Demographic characteristics of the included patients at baseline
Characteristics Patients (n=164)
Age 61.3 (54.6-68.8; SD 10.2) 
Males, n (%) 104 (63%)
First symptom/complaint
- Tremor
- Bradykinesia
- Rigidity
- Dystonia
- Gait/balance disorder
- Clumsiness
- Speech
- Pain
- Cognitive dysfunction
- Depression
- Fatigue
- Writing disturbances
- Urogenital symptoms
- Other 
53  (32.3%)
19 (11.6%)
16 (9.8%)
3 (1.8%)
23 (14%)
6 (3.7%)
3 (1.8%)
14 (8.5%)
1 (0.6%)
1 (0.6%)
6 (3.7%)
7 (4.3%)
4 (2.4%)
8 (4.9%)
Disease duration, months 40.6 (18.0-48.0; SD 34.3)
Disease severity
- H&Y
- UDPRS (III)
- ICARS
- MMSE
2.4 (2.0-3.3; SD 0.9)
28.7 (17.0-37.0; SD 14.0)
6.9 (1.0-11.0; SD 8.0)
27.7 (27.0-30.0; SD 2.5)
Use of medication
- Amantadine
- Dopamine agonist
- Levodopa
- Other 
- No medication
11 (6.7%)
39 (23.8%)
38 (23.2%)
2 (1.2%)
74 (45.1%)
Care dependencya 64 (39%)
Use of walking aidsb 31 (18.9%)
N: number; H&Y: Hoehn and Yahr score; MMSE: mini mental state examination; ICARS: International Cooperative 
Ataxia Rating Scale; UPDRS: Unified Parkinson’s Disease Rating Scale; NS: not significant
a number of individuals that are care dependant. 
b either walking stick, walker or wheelchair. 
Data represent either number and percentage or mean, interquartile range (25 - 75%) and standard deviation.
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Out of potential 1056 patients with a hypokinetic-rigid syndrome presenting at our 
movement disorder clinic, only 164 were included. This large attrition is partly explained 
by the function of our hospital as a tertiary referral center. Many patients are seen only 
once in the process of a second or even third opinion, or are referred to our clinic with a 
specific question regarding medication or the need for allied care by different health 
professionals such as physiotherapists and occupational therapists. These patients are 
therefore not rendered eligible for inclusion. However, although the included 164 patients 
only form a small and likely biased sample of the total population, our power analysis 
demonstrated that this sample is large enough to permit valid conclusions.
The gold standard for diagnosis of PD and the AP remains neuropathological confirmation 
of the clinical diagnosis upon post-mortem examination. However, prior research has 
demonstrated that neuropathological data show a high concurrence between the clinical 
diagnoses after three years follow-up and established by a movement disorder specialist 
with neuropathological examination post-mortem. (Hughes et al. 1992) Therefore, we use 
the clinical diagnosis at follow-up as the silver standard with which we compare the 
results of ancillary investigations in individual patients, for practical purposes. In order to 
minimize the potential misdiagnosis that might occur using the clinical diagnosis instead 
of the neuropathological diagnosis, we require the clinical diagnosis to be established in 
consensus by two neurologists highly experienced in movement disorders and according 
to the international guidelines.  
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Summary
Various ancillary investigations can assist clinicians in the differential diagnosis of patients 
with  parkinsonism. It is unknown which test offers greatest diagnostic value in clinical 
practice.  
We included 156 consecutive patients with parkinsonism but an initially uncertain 
diagnosis. At baseline, all patients received the following ancillary investigations: brain 
magnetic resonance imaging (MRI); 123I-iodobenzamide Single Photon-Emission 
Computed Tomography (IBZM-SPECT); analysis of cerebrospinal fluid (CSF); and anal 
sphincter electromyography (EMG). The “silver standard” diagnosis (Parkinson’s disease 
(PD) n=62 and atypical parkinsonism (AP) n=94) was established after 3-year follow-up by 
two movement disorder specialists, according to international consensus criteria. We 
determined the diagnostic value by correlating the baseline clinical parameters and 
ancillary studies with the silver standard diagnosis. 
Out of a potential 138 parameters, univariate analysis identified 35 parameters that 
discriminated PD from AP, with an AUC of 0.55-0.81. Stepwise logistic regression showed 
that the combination of tandem gait, axial UPDRS subscore, slow saccadic eye movements 
and dysphagia yielded an AUC of 0.93, adjusted for optimism. The combination of tandem 
gait and axial UDPRS subscore yielded an AUC of 0.90. None of the ancillary investigations 
improved this clinically based diagnostic accuracy, not even in a subgroup of patients 
with the greatest diagnostic uncertainty at baseline. 
Our study demonstrates that a comprehensive set of clinical tests provides good accuracy 
to differentiate PD from AP. Our results also suggest that routine MRI, IBZM-SPECT, CSF 
analysis and anal sphincter EMG do not improve this diagnostic accuracy. Future work 
should evaluate the possible diagnostic value of more advanced diagnostic tests.
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Introduction
Due to overlap in clinical symptoms, it can be difficult to differentiate between Parkinson’s 
disease (PD) and the various forms of atypical parkinsonism (AP), such as multiple system 
atrophy (MSA), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB) 
and corticobasal syndrome (CBS). This differential diagnosis is especially challenging early 
in the course of the disease. The clinical diagnosis after several years of follow-up correlates 
well with the neuropathological diagnosis upon post-mortem examination. However, the 
diagnostic accuracy of the initial diagnosis varies greatly in PD, with accuracies of 76% in 
the hands of a general neurologist to up to 90% by movement disorder specialists. 
(Hughes et al. 1992; Hughes et al. 2002) The diagnostic accuracy is even lower for patients 
with a form of AP, e.g. 41-88% in PSP; (Litvan et al. 1996) and 50-66% in MSA. (Litvan et al. 
1997) This uncertainty hampers optimal disease management, because a correct diagnosis 
is important for patient counseling and for optimizing treatment. 
Various ancillary investigations are available to improve the differential diagnosis of PD 
and AP, including magnetic resonance imaging (MRI), (Mahlknecht et al. 2010) 123I-iodo-
benzamide Single Photon-Emission Computed Tomography (IBZM-SPECT), (Vlaar et al. 
2008), analysis of the cerebrospinal fluid (CSF), (Hall et al. 2012), and electromyography 
(EMG) (Winge et al. 2010) of the anal sphincter. Each of these ancillary investigations has 
been studied in selected patient populations in case-control studies. (Hall et al. 2012; 
Mahlknecht et al. 2010; Vlaar et al. 2008; Winge et al. 2010) However, the diagnostic value 
of these ancillary tests relative to clinical examination has not been studied in a design 
that reflects actual daily practice. Moreover, the diagnostic value of the various ancillary 
tests relative to each other remains unknown. Such knowledge could help clinicians to 
make an informed decision in selecting the best available test, knowing that many tests 
are time-consuming and expensive. Some tests are invasive, and not all tests are 
ubiquitously available.
In a prospective study involving a cohort of 156 consecutive patients with parkinsonism 
but an initially uncertain diagnosis, we evaluated the diagnostic accuracy and added 
value of detailed clinical examination and various ancillary investigations (MRI, IBZM, anal 
sphincter EMG and CSF analysis, all performed at baseline). Our aim was to develop a 
prediction model for the discrimination between PD and AP.
Methods
Patients
Between January 2003 and December 2006, all consecutive patients who had been 
referred to our center because of diagnostic uncertainty about the etiology of their 
 hypokinetic-rigid syndrome were asked to participate. Our aim was to replicate everyday 
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clinical circumstances in general neurology clinics. For this purpose, diagnostic uncertainty 
was defined as being present when the community physician who referred the patient to 
our tertiary movement disorder centre was uncertain about the diagnosis (even when the 
patient in our view fulfilled the probable criteria for one of the parkinsonian syndromes). 
After informed consent all patients underwent a structured interview, detailed and 
standardized neurological examination (see chapter 4.1 for detailed information), and, 
within six weeks after the initial visit, brain MRI, IBZM-SPECT, lumbar puncture and anal 
sphincter electromyography. After three years all patients again underwent a structured 
interview and the same standardized examination. Using these findings at 3-year 
follow-up, the final diagnosis was established by consensus agreement between by two 
movement disorders experts (BRB and RJE), according to current diagnostic criteria for PD, 
(Hughes et al. 1992) NINDS-SPSP criteria for PSP, (Litvan et al. 1996) Boeve criteria for CBS, 
(Boeve et al. 2003) McKeith Criteria for DLB, (McKeith et al. 2005) Gilman criteria for MSA, 
(Gilman et al. 2008) and Zijlmans criteria for VaP. (Zijlmans et al. 2004) In addition, they 
scored diagnostic certainty on a visual analogue scale ranging from 0% (completely 
uncertain) to 100% (completely certain), which enabled us to perform a planned subgroup 
analysis in patients with the greatest diagnostic uncertainty at baseline (diagnostic 
certainty of <75%). A “gold standard” diagnosis (based on post-mortem brain examination) 
was reached in only three patients, confirming the clinical diagnosis in all cases. We used 
this clinically based diagnosis after 3-year follow-up as a “silver standard” standard 
diagnosis. Details of the study protocol can be found in chapter 4.1 of this thesis. 
Written informed consent was obtained from the participants prior to participation of the 
study. All clinical investigations have been conducted according to the principles 
expressed in the Declaration of Helsinki. The local Institutional Review Board (“Commissie 
Mensgebonden Onderzoek region Arnhem-Nijmegen”) approved of this consent 
procedure.
Ancillary investigations
Details of the MRI scan, IBZM-SPECT, lumbar puncture and anal sphincter EMG can be 
found in chapter 4.1 of this thesis. Each analysis resulted in a dichotomous outcome, i.e. 
compliant with either PD or AP.
Statistical analysis
We analyzed the diagnostic power of all individual parameters, obtained from history and 
neurological assessment, both for each parameter separately and for combinations of 
parameters by quantification of the area under the receiver operating curve (AUC). Missing 
data points were imputed as normal. 
Logistic regression with stepwise model selection was used to identify combinations of 
parameters that had optimal diagnostic power. To reduce inflation of the error rate due to 
the selection procedure and to limit the number of parameters in the model, a p-value of 
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0.01 was used as criterion for incorporation in the prediction model. As stepwise selection 
methods lead to optimistic estimates of the AUC, we used cross validation to adjust the 
AUCs for optimism. Finally, to simplify the final model, we also investigated the diagnostic 
performance of a diagnostic rule based on the two most powerful parameters. Subgroup 
analysis, including only those patients who completed the entire duration of the follow-up 
and who had no missing data, was performed to assess robustness of the model. Next, we 
used the AUC to quantify the additional value of each of the ancillary investigations, both 
in the entire group of patients and in a subgroup of patients with diagnostic certainty of 
<75%. 
 
Results
Patient characteristics
In total 164 patients were enrolled. We excluded eight patients in whom we established a 
diagnosis other than neurodegenerative parkinsonism: essential tremor (n=1), dystonic 
tremor (n=1), neuroborreliosis (n=1), amyotrophic lateral sclerosis (n=1), psychogenic 
movement disorder (n=2), and pure MSA-C without signs of parkinsonism (n=2)). The final 
diagnoses (n=156 patients) were PD (n=62) or AP (n=94).
Forty-six patients did not complete the follow-up assessment. Reasons were as follows: 
too severely disabled (n=16), death (n=16), consent withdrawal (n=7), and loss to follow-up 
(n=7). The final diagnosis in the 110 patients who completed the 3-year follow-up were PD 
(n=62), MSA (n=51; 28 possible, 21 probable and 2 definite), PSP (n=12; 6 possible, 5 
probable and 1 definite), CBS (n=2), DLB (n=3; 2 possible and 1 probable) and vascular 
parkinsonism (n=26). (Figure 1)
Baseline characteristics are shown in Table 1. Patients with a final diagnosis of AP were 
older and were more severely affected at baseline. Baseline characteristics showed that, 
compared to patients who completed the follow-up, patients lost to follow-up had a 
longer median disease duration and greater disease severity (reflected by the Hoehn and 
Yahr stages). However, the final diagnosis, using a ‘last-observation-carried-forward 
approach’ in the group of patients lost to follow-up, did not differ between both groups. 
(Table 2) 
Out of the 110 patients who completed the 3-year follow-up, 106 patients (96.4%) 
underwent at least two ancillary investigations, 94 (85.7%) underwent three ancillary 
investigations and 58 (52.7%) underwent all four investigations. 
Five patients did not receive a lumbar puncture (the main reason being use of oral 
anticoagulants), 20 did not receive IBZM-SPECT (the main reason being inability to 
withdraw medication that was incompatible with IBZM-SPECT), 20 patients did not receive 
an anal sphincter EMG (the main reason being previous rectal or urogenital surgery or 
rupture during childbirth) and 27 patients did not receive an MRI (the main reasons being 
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claustrophobia and metal implants; these patients received a CT-scan instead). No significant 
differences were observed regarding proportions of completed ancillary investigations 
between the PD and AP subgroups.
Table 1   Demographic and baseline characteristics
Parkinson’s Disease     
(n= 62)xx
Atypical Parkinsonism 
(n=94)xx
p-value
Age 56.6 (10.7) 65.0 (7.8) <0.001
Number of men (%) 42 (67.7%) 58 (61.7%) NS
First symptom/complaint
Tremor
Bradykinesia
Rigidity
Dystonia
Gait/balance disorder
Clumsiness
Speech
Pain
Fatigue
Depression
Writing disturbances
Urogenital symptoms
Other 
25 (40.3%)
9 (14.5%)
3 (4.8%)
2 (3.2%)
7 (11.3%)
2 (3.2%)
0 
7 (11.3%)
2 (3.2%)
0 
3 (4.8%)
0
2 (4.8%)
25 (26.6%)
10 (10.6%)
13 (13.8%)
1 (1.1%)
15 (16%)
2 (2.1%)
3 (3.2%)
7 (7.4%)
4 (4.3%)
1 (1.1%)
4 (4.3%)
4 (4.3%)
5 (5.3%)
NS
Distribution patternx
Asymmetrical
Symmetrical
27 (43.5%)
35 (56.5%)
8 (8.5%)
86 (91.5%)
<0.001
Disease duration, monthsx 24 (12.7-48) 36 (18-54) NS 
Disease severityx
H&Y
1
2
2.5
3
4
5
UDPRS (III)
ICARS
MMSE
8 (12.9%)
41 (66.1%)
8  (12.9%)
2 (3.2%)
1 (1.6%)
0 
24.1 (11.6)
2.3 (2.6)
28.4 (1.7)
7 (7.4%)
15 (16.0%)
35 (37.2%)
23 (24.4%)
12 (12.7%)
2 (2.1%)
32.7 (13.9)
10.2 (8.7)
27.2 (2.9)
<0.001
<0.001
<0.001
0.002
Care dependencyx 13 (21.0%) 31 (33.0%) NS 
Use of walking aidsx 0 29 (30.9%) <0.001
H&Y: Hoehn and Yahr score; MMSE: mini mental state examination; ICARS: International Cooperative Ataxia 
Rating Scale; UPDRS: Unified Parkinson’s Disease Rating Scale
x At the time of inclusion
xx Final diagnosis after follow up
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The initial clinical diagnosis
In 92 out of the 110 patients who completed the 3-year follow up, the initial classification 
of either PD or AP at baseline was correct. Twelve patients were incorrectly diagnosed 
with PD at baseline, and six patients, initially classified as having AP, were diagnosed with 
PD upon follow-up. Moreover, the specific diagnosis (i.e., MSA, PSP, DLB, VaP or CBS) at 
baseline was incorrect in 33% of patients. (Table 3ab) All diagnoses (n=5) at baseline that 
were scored as ‘probable’ diagnosis remained unaltered at follow-up examination. (Figure 2)
Univariate analysis
The structured interview, neurological assessment and clinimetric scales yielded 138 clinical 
parameters that were potentially able to differentiate between PD and AP. Univariate 
analysis identified the following eight parameters that discriminated PD from AP with 
an AUC of at least 0.70: higher age (0.72), rapid disease progression (0.74), autonomic 
Figure 1  Flowchart of included patients.
PD: Parkinson’s Disease; MSA: multiple system atrophy; DLB: dementia with Lewy bodies; VaP: vascular parkinsonism; PSP: 
progressive supranuclear palsy; CBS: corticobasal degeneration
156 patients included
at baseline
 110 patients seen
in follow up
94 Atypical
parkinsonism
61 Atypical
parkinsonism
49 PD
1 CBS9 PSP17 VaP1 DLB33 MSA
62 PD
46 patients not seen in follow up:
- deceased (16)
- lost to follow up (7)
- withdrew consent (7)
- too severely affected for 
 further participation (16)
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Table 2   Comparison of demographic characteristics and final diagnosis between 
patients who completed follow up and patients lost to follow up
Included in follow up 
(n=110)
Lost to follow up 
(n=46)
p-value
Agex 61.5 (10.2) 62.1 (9.4) NS
Number of men (%) 72 (65.5%) 28 (60.9%) NS
Diagnosis 
PD
AP
49 (44.5%)
61 (55.5%)
13 (28.3%)
33 (71.7%)
NS
 Disease duration, monthsx  28 (18-48) 40 (24-60) <0.05
Disease severityx
H&Y
1
2
2.5
3
4
5
UDPRS (III)
ICARS
MMSE
12 (10.9%)
45 (40.9%)
35 (31.8%)
12 (10.9%
5 (4.5%)
1 (0.9%)
28.5 (13.3)
6.1 (7.2)
28.0 (2.3)
3 (6.5%)
11 (23.9%)
8 (17.4%)
13 (28.2%)
8 (17.4%)
1 (2.2%)
31.3 (3.5)
8.9 (9.2)
27.0 (2.9)
<0.05
NS
NS
<0.05
N: number; H&Y: Hoehn and Yahr score; MMSE: mini mental state examination; ICARS: International Cooperative 
Ataxia Rating Scale; UPDRS: Unified Parkinson’s Disease Rating Scale; PD: Parkinson’s disease; AP: atypical 
parkinsonism; NS: not significant
x At the time of inclusion
Table 3a   Initial clinical diagnosis compared to the final diagnosis
Clinical diagnosis at baseline
Fi
na
l d
ia
gn
os
is
  (
af
te
r 
fo
llo
w
 u
p)
PD MSA PSP DLB VaP CBS Initially  
Misclassified  
patients (n)
PD 43 3 0 0 3 0 6  (5%)
MSA 6 19 1 0 6 1 14 (13%
PSP 0 1 3 0 4 1 6 (5%)
DLB 0 0 0 1 0 0 0 (0%)
VaP 6 3 1 0 7 0 10 (9%)
CBS 0 0 0 0 1 0 1 (1%)
Total 55 26 5 1 21 2 37 ( 33%)
N: number; PD: Parkinson’s Disease; MSA: multiple system atrophy; PSP: progressive supranuclear palsy; DLB: 
dementia with Lewy bodies; VaP: vascular parkinsonism; CBS: corticobasal syndrome
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dysfunction (0.75, impaired tandem gait (0.81), abnormal fluency (0.70), higher ICARS total 
score (0.82), (Trouillas et al. 1997) higher UPDRS axial score (0.79) and higher disease stage 
(0.70). (Trouillas et al. 1997) All significant univariate parameters are listed in Table 4. 
Multivariate analysis
Impaired tandem gait, higher axial UPDRS subscore, presence of slowed saccadic eye 
movements and the presence of dysphagia were combined into a model with an AUC of 
0.95 (Figure 3). After correction for optimism, the AUC was 0.93. With a cut-off value of 14.5 
for this model the sensitivity was 0.88 and the specificity was 0.92. A simpler diagnostic 
rule with only tandem gait and the axial UPDRS subscore yielded an AUC of 0.92 (0.90 
corrected for optimism) and (at a cut-off value of 13.5) a sensitivity of 0.73 with specificity 
of 0.92.
Subgroup analysis was performed to assess validity. Analysis of all patients, including those 
lost to follow-up, or including only patients who completed the follow-up assessment 
without any missing data, did not affect our results.  Table 5 demonstrates the dependency 
of both positive and negative predictive values as a function of the prevalence of atypical 
parkinsonism. 
The additional value of ancillary investigations
None of the ancillary investigations (IBZM, MRI, CSF analysis, anal sphincter EMG) increased 
the AUC of the clinical model. We expected the diagnostic value of ancillary investigations 
to be greater for patients with a higher degree of clinical diagnostic uncertainty at baseline. 
However, none of the ancillary investigations increased the diagnostic accuracy as 
compared to clinical evaluation alone in the subgroup with a baseline clinical certainty 
below 75% (N=61) (Table 6). Detailed data of the ancillary investigations can be found in 
Tables 7-9.
Table 3b   Initial clinical diagnosis compared to the final diagnosis; PD vs AP
Clinical diagnosis at baseline
Fi
na
l 
di
ag
no
si
s 
PD AP Misclassified patients (n)
PD 43 6 6  (5%)
AP 12 49 12 (10%)
Total 55 55 18 ( 15%)
N: number; PD: Parkinson’s Disease; AP: Atypical parkinsonism
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Table 4   Univariate analysis of parameters that discriminate between PD (n=62) and 
atypical parkinsonism (n=94)
Parameters AUC p-value 
History
Age 0.72 <0.0001
Course of the disease 0.74 <0.0001
Use of walking aids 0.65 <0.0001
Cognitive dysfunction 0.61 0.0009
Presence of ≥ 1 falls 0.68 <0.0001
Presence of night time stridor 0.55 0.0077
Hypersalivation 0.61 0.0094
Ability to cycle 0.67 <0.0001
Independence of care 0.62 <0.0001
Autonomic dysfunction 0.75 <0.0001
Dysphagia 0.64 0.0002
Neurological examination
Romberg 0.55 0.0077
Pathological reflexes 0.63 0.0002
Cognitive assessment
MMSE 
Fluency
0.61
0.70
0.0041
<0.0001
Ataxia
Dysarthria
Finger-nose test
Heel-shin test
Tandem gait
ICARS total score
0.59
0.60
0.58
0.81
0.82
0.0022
0.0005
0.0015
<0.0001
<0.0001
UPDRS axial scorexx 0.79 <0.0001
Disease stagex 0.70 <0.0001
Schwab and England score 0.69 <0.0001
Myoclonus 0.55 0.0077
Autonomic dysfunction
Orthostatic hypotension (directly)
Orthostatic hypotension (after 3 min)
0.61
0.63
0.0002
<0.0001
Eye movements
Saccadic intrusions
Slow saccades
Multistep saccades
Supranuclear palsy
Nystagmus
0.68
0.66
0.62
0.58
0.55
<0.0001
<0.0001
0.0004
0.002
0.0077
AUC: area under the curve; MMSE: mini mental state examination; ICARS: International Cooperative Ataxia 
Rating Scale; UPDRS: Unified Parkinson’s Disease Rating Scale
x     Disease stage: 0: normal, 1: disturbed gait but walking independently; 1.5: disturbed gait, intermittent use 
of walking aids; 2: disturbed gait, permanent use of walking aids; 2.5: disturbed gait, intermittent use of 
wheelchair; 3: disturbed gait, permanent use of wheelchair; 4: death.
xx  Axial UPDRS: a composite score of all axial parameters tested in UPDRS including: speech and face 
assessment, rigidity of the neck, rising from a chair, posture, gait and assessment of postural stability.
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Figure 3   ROC curves for the discrimination of Parkinsons’disease and atypical Parkinsonism.
3A Receiver operating characteristic (ROC) curve analysis discriminating PD and atypical parkinsonism based on 
model 1: score = 11*tandem gait + UPDRS axial subscore +14* slow saccades + 5.9*dysphagia.  A cut-off score  of 
12.5 resulted in a sensitivity of 90% and a specificity of 83%. A cut-off score of 14.5  resulted in a sensitivity of 88% 
and a specificity of 92%. The optimal cut-off score was calculated using the youden index.
3B ROC curve analysis discriminating PD and atypical parkinsonism based on model 2: score = 9.8*tandem gait + 
UPDRS axial subscore. A cut-off score of 9.5 resulted in a sensitivity of 89% and a specificity of 75%. A cut-off score 
of 13.5 resulted in a sensitivity of 73% and a specificity of 92%.
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Table 5   Positive and negative predictive values under different assumptions of 
prevalence
Prevalence of atypical 
parkinsonism
Scenario 1
20%
Scenario 2
40%
Scenario 3*
60%
Scenario 4
80%
Model 1**
PPV 0.73 0.88 0.94 0.98
NPV 0.97 0.92 0.83 0.66
Model 2***
PPV 0.70 0.86 0.93 0.97
NPV 0.93 0.84 0.69 0.46
* Scenario 3 represents the sample of the present study
**Model 1: 11*tandem gait + UPDRS axial subscore +14* slow saccades + 5.9*dysphagia 
***Model 2: 9.8*tandem gait + UPDRS axial subscore
PPV: positive predictive value; NPV: negative predictive value
Table 6   Diagnostic accuracy of ancillary investigations in patients with initial 
diagnostic certainty < 75% (N=61)
Method of investigation AUC alone AUC combined with the 
clinical model
p-value
Clinical model 0.91
IBZM scan 0.51 0.93 NS
CSF analysis 0.61 0.92 NS
MRI scan 0.63 0.90 NS
Anal sphincter EMG 0.69 0.95 NS
AUC: area under the curve; N: number; IBZM-SPECT: 123I-iodobenzamide Single Photon-Emission Computed 
Tomography; CSF: cerebrospinal fluids; MRI: magnetic resonance imaging; EMG: electromyography; NS: not 
significant
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Table 7   CSF parameters differentiating PD and AP
Parameter PD (n=47) AP (n= 58) P value
Tau (ng/l) 226 (139-285) 262 (169-315) NS (0.22)
NFL (ng/l) 1226 (726-1612) 2816(1024-3460) <0.001
Aβ42 (ng/l) 825 (701-942) 851 (701-1020) NS (0.54)
MHPG (mM) 45.5 (37·0-51·0) 48.1 ( 38.0-54.5) NS (0.28)
5-HIAA (mM 94.9 (70·0-115) 111 (67.0-145) NS (0.08)
HVA (mM) 171 (99·0-205) 236 (134·0-274) NS (0.07)
Data represent mean and 25-75% quartile range·
PD: Parkinson’s disease; AP: atypical parkinsonism; n: number; NS: not significant; NFL: neurofilament light 
chain, Aβ42: Amyloid β42; MHPG: 3-methoxy-4-hydroxyphenylethyleneglycol; 5-HIAA: 5-hydroxyindolacetic 
acid; HVA: Homovanillic acid
Table 8   Sphincter ani EMG parameters differentiating PD and AP
Parameter PD (n=40) AP (48)
Spontaneous activity
- None
- Yes
37 (92.5%)
3 (7.5%)
40 (83.3%)
8 (16.7%)
NS (p=0.4)* 
Duration of the action potential
- Normal (<10ms)
- Slightly increased (10-15ms)
- Increased /(>15ms)
33 (82.5)
7 (17.5)
0
31 (64.6)
14 (29.2)
3 (6.2)
NS (p=0.1)**
Amplitude of the action potential
- Normal (<500uA)
- Slightly increased (500-1000uA)
- Increased (>1500uA)
34 (85%)
5 (12.5%)
1 (2.5%)
27 (56.3)
16 (33.3)
5 (10.4)
P = 0.01**
Activity pattern in contraction
- Poor
- Intermediate
- Interference
10 (25)
10 (25)
20 (50%)
24  (50%)
12 (25)
12 (25%)
P= 0.03**
* as measured by Fisher’s exact test
** as measured by χ2 test
Data represent number and percentage. 
PD: Parkinson’s disease; AP: atypical parkinsonism; n: number; NS: not significant
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Discussion
We prospectively evaluated the diagnostic value of various ancillary investigations in a 
large cohort of PD and AP patients with an initially uncertain diagnosis. Our results suggest 
that the combination of tandem gait and the axial UPDRS subscore have a high predictive 
value to discriminate between PD and AP. Relative to this combination of clinical tests, 
none of the ancillary investigations (brain MRI, IBZM-SPECT, CSF analysis, anal sphincter 
EMG) further increased the diagnostic accuracy of PD versus the various AP syndromes. 
The ancillary tests were neither helpful in the subgroup of patients with greatest clinical 
insecurity at baseline, where one might expect most benefit from these ancillary 
investigations.
Out of all clinical parameters, tandem gait performance proved to be the best parameter 
for differentiating between PD and the group of AP syndromes (AUC 0.81). A preliminary 
analysis including a subset of the current cohort (36/62 PD and 49/94 AP patients) also 
demonstrated the diagnostic value of tandem gait assessment. (Abdo et al. 2006) 
However, these prior analyses were derived from a smaller population, and without 
confirmation of the silver standard diagnosis based on the extensive follow up that is 
presented here. A possible explanation for this finding is the presence of mediolateral 
postural instability, which is typically more pronounced in the various AP syndromes than 
in PD, and certainly early in the course of the disease. This mediolateral postural instability 
in AP can be attributed to the presence of extranigral lesions, in particular within the 
cerebellum, the brainstem, or their connections. (Bloem and Bhatia 2004) The diagnostic 
accuracy of tandem gait improved further by combination with the UPDRS axial score, i.e. 
the sum score of the following UPDRS part III items: face, speech, neck rigidity, rising from 
a chair, posture, gait, and postural instability. The UPDRS tests for gait and balance have 
been criticized for various reasons, (Bloem et al. 1998; Jacobs et al. 2006) but apparently 
still offered diagnostic value. The combination of tandem gait plus UPDRS axial score 
yielded a high diagnostic accuracy (AUC 0.92) that exceeded previously advocated clinical 
Table 9   IBZM-SPECT parameters differentiating PD and AP
Parameter PD (n= 40) AP (n=53) p-value
Normal 16 (40%) 21 (39.6%) NS* 
Symmetrically decreased 13 (32.5%) 19 (35.8%)
Asymmetrically decreased 11 (27.5%) 13 (24.6%)
Data represent number and percentage. 
PD: Parkinson’s disease; AP: atypical parkinsonism; n: number; NS: not significant
* as measured by χ2 test
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motor and non-motor tests for the differentiation of PD and healthy controls, including 
the UPSIT-40 test for olfaction (AUC 0.89), the pegboard test (AUC 0.83) finger-tapping 
(AUC 0.75) and the Berg balance scale (AUC 0.62). (Bohnen et al. 2008) Moreover, this 
combination of tandem gait and axial UPDRS performed only slightly less than the 
diagnostic accuracy of FDG-PET (AUC for distinction between PD and AP of 0.93-0.97). 
(Tang et al. 2010) However, obvious disadvantages of FDG-PET are the high costs, its 
invasive character and limited availability. 
The diagnostic accuracy of each of the ancillary investigations (brain MRI, IBZM-SPECT, CSF 
analysis, anal sphincter EMG) was poor and did not add to the clinical prediction model. 
The pathophysiological and clinical heterogeneity between the different AP syndromes 
may have contributed to this. For example, patients with MSA might have a hot cross bun 
sign on MRI, reduced tracer binding on IBZM-SPECT, elevated concentrations of CSF NFL 
protein and anal sphincter denervation. However, neither of these abnormalities are 
obligatory in other forms of AP. Hence, most investigations have a high specificity for 
diagnosing AP, but with a limited sensitivity. (Savoiardo 2003; Schrag et al. 2000; Yekhlef et 
al. 2003) Moreover, the various forms of AP may demonstrate different and sometimes 
even opposing abnormalities. Lumping all forms of AP therefore carries the risk of yielding 
a lower “net” diagnostic accuracy for each of the ancillary investigations. However, we did 
observe added value for brain MRI performed at baseline, in particular to improve the 
accuracy of the diagnosis ’vascular parkinsonism’. This demonstrates that dedicated 
ancillary investigations can aid in the differential diagnosis when used to answer a specific 
question. Current guidelines recommend using brain MRI in patients who newly present 
with parkinsonism, (Berardelli et al. 2013) and our results provide no reason to change this. 
Note that the present results were based on routine brain MRI, obtained using 
predominantly 1.5 Tesla scans. Future studies should evaluate the merits of more advanced 
MRI techniques, including high resolution scans (7 Tesla), diffusion-weighted images and 
diffusion tensor imaging.
Our study has several strengths. First, the study design was prospective, with a 
comprehensive set of clinimetric parameters and a battery of ancillary investigations 
(all obtained at baseline). Prior work typically examined the diagnostic merits of single 
ancillary tests, but we compared their relative value by applying all tests in a single cohort. 
Second, we included a large population of patients in whom the referring neurologist was 
uncertain about the diagnosis. Prior studies usually evaluated a diagnostic test in patients 
with a typical clinical profile and a probable diagnosis, and this may explain why the 
diagnostic tests performed better in those advanced populations than in our early stage 
patients. Third, the silver standard diagnosis in our population was established after long- 
term follow-up using a comprehensive, standardized assessment. We then determined 
which baseline test best predicted this careful follow-up diagnosis. In contrast, previous 
studies typically had a cross-sectional design. Finally, the sample size (n=156) was larger 
than most previous studies of diagnostic tests.
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The gold standard diagnosis of PD and AP remains neuropathological confirmation after 
post-mortem brain examination. Only three patients came to post-mortem examination 
in this study, and the clinically based diagnosis was confirmed in all three. As an acceptable 
surrogate for a definite neuropathological diagnosis, we used the clinical diagnosis after 
3-year follow-up as our “silver standard” reference diagnosis, as previous research has 
shown that the clinical diagnosis after three years of follow-up (and established by a 
movement disorder specialist) correlates well with neuropathological examination 
post-mortem. (Hughes et al. 2002) This silver standard diagnosis after three years was 
based upon the rate of disease progression, the treatment response, and development of 
any red flags, but did not include any of the baseline ancillary tests (to avoid circle 
reasoning). We acknowledge that a comparison of clinical parameters (obtained at 
baseline) to a final clinical diagnosis (established at follow-up) carries the risk of introducing 
circularity to the argument. Presumably, this did not affect the results much, because the 
clinical data at baseline and at follow-up were obtained by a single, independent examiner 
who was blinded to the final diagnosis (that was established in consensus by two 
experienced movement disorders experts who did not perform any of the clinical tests at 
baseline or follow-up). Moreover, the silver standard diagnosis was always established 
according to the international guidelines, and this does not include tandem gait as 
criterion. In addition, all ancillary investigations were assessed by specialists who were 
blinded to the clinical symptoms and the final diagnosis. Using a cut-off established at the 
outset of the study, these experts rated the outcome of the ancillary tests according to a 
dichotomous outcome, i.e. compliant with either PD or AP, to improve reliability.
Our study also had several shortcomings. First, the study cohort was not representative of 
the overall PD population. Out of a potential of 1056 patients with a hypokinetic-rigid 
syndrome who presented at our movement disorder clinic, only 164 were included. This 
high attrition is partly explained by the function of our hospital as a tertiary referral center. 
Moreover, the prevalence of patients with AP in our study was 60%, which is higher than 
expected based on previous epidemiological reports in the general population. (de Lau 
et al. 2004) The high proportion of AP patients reflects the atypical population of a 
neurological centre specialized in movement disorders, and this might overestimate the 
diagnostic accuracy of the proposed model. However, after statistical correction for 
background prevalence in the population, the diagnostic accuracy remains high (PPV 
70%, NPV 93% at a prevalence of AP of 20%). Second, a substantial proportion (n=46; 
29.5%) of patients were lost to follow-up, mainly due to death and severe disability. Based 
on their latest available assessment, 33 of these 46 drop-outs had a diagnosis of AP, which 
is understandable because of their rapid disease progression and increased mortality. 
Patients without complete follow-up had a shorter disease duration and greater disease 
severity than those with complete follow-up, and this may have affected our analyses. 
However, we obtained similar results when we analyzed all patients in the study using a 
last-observation-carried-forward approach. Finally, not all patients received all ancillary 
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investigations, because of contraindications such as use of anticoagulants. However, this 
is inevitable in a cohort of elderly subjects with age-related co-morbidity, and reflects 
common clinical practice.
Despite these limitations, our study suggests that when patients are referred to a 
specialized movement disorders center because of an uncertain diagnosis of parkinsonism, 
careful clinical investigations – and in particular tandem gait and the axial UPRDS subscore 
– suffice to distinguish AP from PD. These observations help to reduce the use of 
redundant, expensive and potentially harmful ancillary investigations. The high diagnostic 
accuracy and the simplicity of the proposed model justifies further external validation in 
a new cohort. In addition, further work remains needed to examine the diagnostic merits 
of newer and more advanced ancillary investigations, such as FDG-PET, (Tang et al. 2010) 
advanced MRI techniques, (Seppi and Schocke 2005) and transcranial sonography. (van de 
Loo et al. 2010)
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Differentiation of Parkinson’s disease from atypical parkinsonism is important clinically, for 
adequate patient counselling, and scientifically, to ascertain proper inclusion in clinical 
trials. The differential diagnosis remains challenging, even with current clinical insights and 
modern ancillary investigations. (Litvan et al. 2003) Here, we suggest that the answer to one 
simple question-”Can you still ride a bicycle?”-offers good diagnostic value for separating 
Parkinson’s disease from atypical parkinsonism.
We did a prospective observational study in 156 consecutive patients with parkinsonism, 
but without a definitive diagnosis. At baseline, patients received a structured interview, 
comprehensive neurological assessment, and cerebral MRl. The interview included a 
standard question about whether, when, and why cycling had become impossible. The 
gold standard was the diagnosis after 3 years, which was based on the clinical follow-up 
including repeat neurological examination, response to treatment, and MRl. All assessments 
were done by a single, experienced examiner. All patients gave informed consent, as 
approved by the local ethics committee.
Before their first disease manifestation, 111 patients rode a bicycle (table 1). 45 went on to 
develop a gold- standard diagnosis of Parkinson’s disease and 64 a form of atypical 
parkinsonism. At the time of inclusion (median disease duration 10 months), 34 of the 64 
patients with atypical parkinsonism had stopped cycling, as opposed to only two of the 
45 patients with Parkinson’s disease (sensitivity 52%, specificity 96%; AUC 0.74, 95% cl 
0.64-0.83). The loss of cycling abilities was present for all forms of atypical parkinsonism. 
Regression analysis revealed no significant effect of age, parkinsonism, or ataxia on the 
ability to cycle, suggesting that this was an independent marker of atypical parkinsonism.
We suggest that loss of the ability to cycle after disease onset might serve as a new red 
flag, signalling the presence of atypical parkinsonism. The diagnostic value of the “bicycle 
sign” was good: its presence was highly specific for the diagnosis of atypical parkinsonism. 
This observation does not stand alone. Patients with Parkinson’s disease have little balance 
problems moving sideways, (Carpenter et al. 2004) their gait is typically narrow-based, 
(Charlett et al. 1998) their tandem gait is usually normal, (Abdo et al. 2006) and they can 
show a remarkable ability to ride a bicycle. (Snijders and Bloem 2010) Cycling requires 
a highly coordinated interplay between balance, coordination, and rhythmic pedalling 
of the legs. This skilled task is probably sensitive to subtle problems with balance or 
coordination, caused by the more extensive extranigral pathology in atypical parkinsonism. 
Simply asking about cycling abilities could be added to the list of red flags that can assist 
clinicians in their early differential diagnosis of parkinsonism.
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Table 1   Clinical characteristics
Parkinson’s 
disease (n=45)a
Atypical 
parkinsonism 
(n=66)a
P value
Disease subtype (%)a
- Multiple system atrophy 35 (31.5%)
- Progressive supranuclear palsy 9 (8.1%)
- Lewy body dementia 3 (2.7%)
- Corticobasal syndrome 2 (1.8%)
- Vascular parkinsonism 17 (15.3%)
Ageb 55.5 (10.7) 65.0 (7.3) 0.001
Patients unable to cycle (%)b 2 (4.4 %) 34 (51.5%) 0.001
Disease duration (months)b 36 (20–60) 24 (12–36) 0.01
Disease severity (%)c
- Stage 1 5 (11.1%) 7 (10.6%) 0.001
- Stage 2 34 (75.6%) 12 (18.2%)
- Stage 2·5 6 (13.3%) 21 (31.8%)
- Stage 3 0 18 (27.3%)
- Stage 4 0 8 (12.1%)
PIGD score (UDPRS)b 1.1 (0.7) 2.6 (1.3) 0.001
Posture and gait ataxia (ICARS)b 0.5 (0.7) 4.5 (4.1) 0.001
Oculomotor ataxia (ICARS)b 0.2 (0.4) 1.3 (1.2) 0.001
Limb ataxia (ICARS)b 1.3 (2.0) 3.8 (4.7) 0.001
Speech disorder (ICARS)b 0.1 (0.2) 0.7 (1.3) 0.001
Data represent means and SDs (p value assessed by use of Student’s t test), medians and IQRs (Mann-
Whitney), and number and percentage (Fisher’s exact). ICARS:international cooperative ataxia rating scale, 
PIGD:postural instability gait difficulty. UDPRS: unified Parkinson’s disease rating scale.
a Gold standard diagnosis, after 3 years’ follow-up.
b At baseline, when patients were included.
c Modified Hoehn and Yahr stages.
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Clinical evaluation of parkinsonism
In the first part of this thesis, we sketched the background of the clinical evaluation of 
Parkinson’s disease (PD) and atypical parkinsonism (AP), and we provided a stepwise 
approach to improve the clinical differentiation.
Establishing a clinical diagnosis of parkinsonism can be difficult, but to differentiate 
between the different causes of parkinsonism can be even more challenging. The use of 
a systematic clinical approach, as described in chapter 2, may enable an adequate 
assessment of the patient’s disorder, and may help clinicians in establishing a correct 
clinical diagnosis, even early in the course of the disease. This systematic approach 
includes three consecutive steps: 
1.  To verify that the clinical syndrome truly represents parkinsonism (i.e. a hypokinet-
ic-rigid syndrome)
2.  To systematically search for the presence of ‘red flags’ (alarm signs that may signal the 
presence of a form of AP)
3.  To integrate these two steps, as a basis for a narrow differential diagnosis and guide 
for a tailored set of further ancillary tests. The importance of a careful and thorough 
clinical examination is reflected by the recently published EFNS/MDS-ES guideline 
which states that the ‘diagnosis of PD is still largely based on correct identification of 
its clinical features’.(Berardelli et al. 2013)  
Biochemistry 
In the second part of this thesis we explored the diagnostic accuracy of several 
cerebrospinal fluid (CSF) biomarkers, including tau protein and α-synuclein for the differ-
entiation between PD and AP. The choice of CSF parameters in these chapters was strongly 
influenced by the pathophysiological mechanisms in parkinsonism. The underlying 
pathophysiological mechanisms in PD and AP involve disturbances in the aggregation of 
tau protein and α-synuclein resulting in either tauopathies (corticobasal syndrome (CBS), 
progressive supranuclear palsy (PSP)) or α-synucleinopathies (PD, multiple system atrophy 
(MSA) and dementia with Lewy bodies (DLB)).
Tau protein
In chapter 3.1 we analyzed the CSF concentrations of total protein, lactate and the brain 
specific proteins amyloid-β42 protein (Aβ42), tau protein (t-tau), and tau protein 
phosphorylated at Thr181 (p-tau). These analyses were performed  in CSF samples from 
patients with a clinically based diagnosis of PSP (n = 21), CBS(n = 12), and PD (n = 28). The 
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‘silver’ standard was the clinical diagnosis established after a mean clinical follow-up of 
five years (range 3 to 9 years) . A ‘gold’ standard diagnosis (post-mortem confirmation) was 
not available for these patients.
We demonstrated that the concentrations of t-tau and p-tau proteins in CSF of CBS 
patients were significantly elevated compared with both PSP and PD. The diagnostic 
accuracy of CSF t-tau and/or p-tau seems only sufficient for the discrimination of CBS vs. 
PD, but – as was perhaps to be expected – not for discriminating CBS vs. PSP (which are 
both tauopathies). However, the CSF concentrations of t-tau protein could not adequately 
discriminate between PD and PSP. As t-tau protein is also elevated in MSA, which is not a 
tauopathy, (Abdo et al. 2004) t-tau concentrations might be a biomarker for accelerated 
axonal degeneration in parkinsonism instead of reflecting the pathological substrate.
Some studies suggested that a decreased ratio of t-tau isoforms (33/55kD t-tau) is a good 
biomarker for the diagnosis of PSP (Borroni et al. 2008), especially when combined with 
mid-sagittal midbrain-to-pons atrophy ratio. (Borroni et al. 2010) However, attempts to 
reproduce these findings have not been successful (Kuiperij and Verbeek 2012), questioning 
the value of the proposed biomarker in clinical practice.
α-synuclein 
In chapter 3.2 we aimed to investigate whether cerebrospinal fluid (CSF) concentrations 
of α-synuclein have additional diagnostic value in differentiating PD from AP. One hundred 
and forty two consecutive patients with parkinsonism were included in this prospective 
study. (PD, n=58;  MSA, n=47; dementia with Lewy bodies (DLB), n=3; vascular parkinsonism 
(VaP), n=22; PSP, n=10; CBS, n=2) Silver standard was the clinical diagnosis established after 
three years of clinical follow-up. CSF concentrations of α-synuclein, blood pigments and 
the erythrocyte count were determined.
We found similar CSF α-synuclein concentrations in patients with PD and patients with AP. 
This was unlikely to be a power problem given the relatively large sample size, although in 
our study the majority of AP were patients with MSA (an α-synucleinopathy like PD). 
Nevertheless, our findings suggest that α-synuclein has no value as a biomarker for the 
differential diagnosis of parkinsonian syndrome. However, after publication of our results, 
several more studies have evaluated the potential of α-synuclein for the differentiation 
between PD and AP. Most studies suggest a lower concentration of α-synuclein in 
α-synucleinopathies. (Hall et al. 2012; Hong et al. 2010; Kasuga et al. 2010; Mollenhauer et 
al. 2008; Mollenhauer et al. 2011; Mollenhauer et al. 2013)  The comparability across these 
different studies describing CSF α-synuclein levels (including our own) is hindered by the 
use of different methods to measure CSF α-synuclein concentrations, and by the use of 
different antibodies in the respective assays to detect α-synuclein.  Several isoforms of 
α-synuclein are known. However, not all isoforms are measured in the various assays that 
have been used. The most widely applied ELISA design/antibody combination for the 
quantification of total α-synuclein levels detect only full length α-synuclein and the splice 
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variant α-syn126 (see Figure 1). Perhaps the profile of all 4 isoforms, instead of only the full 
length α-synuclein and the splice variant α-syn126, would distinguish between different 
neurodegenerative diseases. Possibly as a result, studies have shown contradicting results.
Besides different methods for detection, the observed disparity could partly be explained 
by differences in the selection of study populations and/ or controls, due to age effects 
and other possible confounders like coexisting neurological diseases. Furthermore, if any, 
the observed differences were small (Hong et al. 2010; Mollenhauer et al. 2008; Tokuda et 
al. 2006) with a profound overlap between the different patients groups, resulting in 
insufficient sensitivity and specificity to warrant the application of CSF α-synuclein analysis 
in daily practice. Recently, CSF α-synuclein was compared in de novo PD patients and 
healthy controls, resulting in a highly significant decrease (Mollenhauer et al. 2013) 
compared α-synuclein in de novo PD patients with healthy controls, describing a highly 
significant decrease. Nonetheless, the corresponding AUC was only 0.65 with a sensitivity 
of 91% and a specificity of only 25%.  In another study the diagnostic accuracy was slightly 
higher, albeit not convincingly relevant for daily practice, with a sensitivity of 92% and a 
specificity of 58%.  (Hong et al. 2010) Hence, it remains doubtful whether these lower 
α-synuclein concentrations have true value for the clinician in daily practice. 
Neurotransmitter metabolites
DLB is a disease characterized not only by parkinsonism, but also by progressive dementia. 
In chapter 3.3 we used CSF parameters to distinguish DLB and Alzheimer’s disease (AD), 
as this can be equally challenging as discriminating PD and AP. We retrospectively 
compared CSF concentrations of the neurotransmitter metabolites homovanillic acid 
(HVA), 5-hydroxyindolacetic acid (5-HIAA) and 3-methoxy-4-hydroxy-phenylethylenegly-
col (MHPG) and the brain-specific proteins t-tau, p-tau and Aβ42 in 45 patients with AD 
(mean age 71.6 years; 34 (76%) men; 44 probable AD, 1 definite) and 23 patients with DLB 
(mean age 71.6 years; 18 (78%) men; 6 possible DLB, 16 probable, 1 definite). We found that 
CSF concentrations of 5-HIAA, HVA, MHPG, t-tau and p-tau were significantly lower in DLB 
than in AD, whereas CSF Aβ42 tended to be higher in DLB. Most importantly, the 
combination of MHPG, p-tau, t-tau and Aβ42 analysis discriminated between AD and DLB 
with high diagnostic accuracy (sensitivity 92.9%, specificity 100%). In a separate patient 
cohort we have confirmed that addition of MHPG to Aβ42, t-tau, and p-tau improves the 
discrimination of DLB from AD, (Herbert et al. 2013) but  not the differentiation of DLB from 
VaD or FTD. Still, CSF analysis could add to the recognition of DLB in the differential 
diagnosis of dementia. 
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Prospective evaluation of diagnostic accuracy
In the third part of this thesis, we presented both the design and results of a prospective 
study to investigate the individual and relative value of clinimetrics as well as several 
ancillary investigations.  
Study design
In chapter 4.1 we present the study design of a prospective study to investigate the 
individual and relative value of electromyography (EMG) of the anal sphincter, analysis 
of cerebrospinal fluid (CSF), magnetic resonance imaging of the brain (MRI) and 123I- iodo-
benzamide Single Photon-Emission Computed Tomography (IBZM-SPECT) for discriminating 
between PD and AP. 
The large, prospective longitudinal study was designed with the potential to evaluate the 
diagnostic accuracy of various tests in differentiating between PD and AP in clinical 
practice.  The diagnostic value of each of the selected ancillary investigations has been 
studied previously, predominantly in case-control studies that included patients with a 
clinically unambiguous presentation. However, from these previous studies it cannot be 
derived which type(s) of ancillary investigation are most helpful when a clinician is 
confronted with a patient with a hypokinetic-rigid syndrome of uncertain clinical etiology. 
Our trial was therefore designed with the aim to evaluate the predictive value of various 
ancillary investigations performed at baseline, and with the final diagnosis after follow-up. 
Strong elements of the design comprised the inclusion of patients with diagnostic 
uncertainty at baseline (in the eyes of the referring physician), the detailed and standardized 
Figure 1  Illustration of the different α-synuclein isoforms. (Figure courtesy of dr. H.B. Kuiperij)
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clinical work-up both at baseline and at follow-up, the use of a ‘silver standard’ diagnosis 
after three years of follow-up (using rate of disease progression, response to treatment 
and development of any red flags) and, in particular, the fact that multiple tests were 
directly compared with each other in a single design.
The results
In chapter 4.2 we demonstrated that the combination of tandem gait and the axial 
UPDRS sub-score has a high predictive value to discriminate PD from AP. Out of a potential 
138 parameters at baseline, univariate analysis identified eight parameters discriminating 
PD and AP with an area under the receiver operating curve (AUC) of at least 0.70. Stepwise 
logistic regression showed that the combination of tandem gait, axial subscore of the 
UPDRS, the presence of slowing of the saccadic eye movements and dysphasia resulted in 
an AUC, adjusted for optimism, of 0.93. The combination of tandem gait and the axial 
subscore of the UDPRS resulted in an AUC of 0.90. Interestingly, none of the ancillary 
investigations (CSF analysis of different biomarkers, MRI, IBZM-SPECT, and anal sphincter 
EMG) increased the diagnostic accuracy in differentiating PD from AP, not even in the 
subgroup of patients with the largest clinical insecurity of diagnosis at baseline, where 
one would expect the largest benefit from complementary testing.
Prior studies described a relatively high diagnostic accuracy for the various ancillary tests 
that are currently available (chapters 3.1-3.3). (Hall et al. 2012; Mahlknecht et al. 2010; Vlaar 
et al. 2008; Winge et al. 2010) At first sight, this appears to contrast with our observation 
that none of the evaluated ancillary investigations added much to the diagnostic accuracy 
of clinimetrics alone in differentiating between PD and AP. On the one hand, this might be 
explained by the high accuracy of clinimetrics in our study. Circularity can be a potential 
cause of this; however, prior studies (Hughes et al. 1992; Hughes et al. 2002) have 
demonstrated that –  provided that the duration of follow-up is at least 2 years, and that 
the diagnosis is established by a movement disorder specialist - the correlation between 
the clinically based diagnosis and neuropathological findings is high (95%). As the follow-up 
in our study was 3 years, and since two movement disorder specialists established the final 
diagnosis in consensus, we have ensured at least a silver standard diagnosis to compare 
our data with. 
Another explanation lies within the ancillary investigations itself, as the pathophysiological 
and clinical heterogeneity between the different AP syndromes may have contributed to 
this. For example, patients with MSA might have a hot cross bun sign on MRI, reduced 
tracer binding on IBZM-SPECT, elevated concentrations of CSF NFL protein and anal 
sphincter denervation. However, neither of these abnormalities are obligatory in other 
forms of AP. (Box 1) Hence, most investigations have a high specificity for diagnosing AP, 
but with a limited sensitivity. (Hall et al. 2012; Mahlknecht et al. 2010; Vlaar et al. 2008; 
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Winge et al. 2010) Moreover, the various forms of AP, which includes a group of 
biochemically heterogeneous disorders (e.g. both tauopathies and α-synucleinopathies), 
may appear clinically similar despite the different underlying pathophysiology, and may 
demonstrate different, and sometimes even opposing, abnormalities in the various 
ancillary test. Lumping all forms of AP, therefore, carries the risk of yielding a lower “net” 
diagnostic accuracy than for each of the ancillary investigations, since the high specificity 
of ancillary tests for AP syndromes may be lost in this way.
Box 1   Typical results of ancillary investigations in PD and atypical parkinsonism
Parkinson’s Disease
- MRI 
- CSF 
- EMG
- IBZM-SPECT
Normal 
Decreased α-synuclein, normal t-tau, normal Aβ42, normal NFL,  
normal MHPG
Normal 
Increased striato-occipital ratio
Multiple system atrophy
- MRI
- CSF
- EMG
- IBZM-SPECT 
Structural: putaminal rim, hot cross bun sign, decreased middle 
cerebellar peduncle (MCP) width, decreased pons diameter, decreased 
fractional anisotropy of the MCP
Decreased α-synuclein, increased t-tau, normal Aβ42, increased NFL, 
decreased MHPG
Denervation pattern
Decreased striato-occipital ratio
Dementia with Lewy bodies
- MRI
- CSF
- EMG
- IBZM-SPECT
Normal/mild atrophy of frontal, temporal and/or hippocampal region 
Normal/mildly decreased α-synuclein, normal t-tau, decreased Aβ42, 
moderately increased NFL, decreased MHPG
Mild neurogenic denervation pattern
Increased striato-occipital ratio
Progressive supranuclear palsy
- MRI
- CSF
- EMG
- IBZM-SPECT
Hummingbird sign, decreased sagittal midbrain-pons ratio
Normal α-synuclein, normal t-tau, normal Aβ42, increased NFL
Mild neurogenic denervation pattern
Decreased striato-occipital ratio
Corticobasal syndrome
- MRI 
- CSF
- EMG
- IBZM-SPECT
Asymmetric cortical frontal or frontoparietal atrophy
Decreased α-synuclein, increased t-tau, normal/mildly decreased Aβ42, 
increased NFL
No data
Decreased striato-occipital ratio
MRI: magnetic resonance imaging; CSF: cerebrospinal fluid; EMG: electromyography of the anal sphincter; 
IBZM-SPECT: 123I-iodobenzamide Single Photon-Emission Computed Tomography
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However, we observed added value for brain MRI performed at baseline as compared to 
clinical / neurological investigations alone, in particular to improve the accuracy of the 
diagnosis ’vascular parkinsonism’. This demonstrates that dedicated ancillary investigations 
can aid in the differential diagnosis when used to answer a specific question. Current 
guidelines recommend using brain MRI in patients who newly present with parkinsonism, 
(Berardelli et al. 2013) and our results provide no reason to change this. 
Taken together, it seems to become clear that ancillary investigations are hampered by 
the widely used approach to lump the different diseases together as one homogeneous 
form of AP. Such an approach lowers the discriminative sensitivity due to fundamental 
pathophysiological differences within the group of AP. One exception that we identified 
in this setting was the bicycle sign, which is not dependent on the specific nature of the 
pathophysiological disease process, but which acts as a global marker for mediolateral 
balance instability caused by extranigral lesions (this latter feature is a common 
denominator among the various forms of AP). In a research setting, this approach to lump 
the various forms of AP is almost inevitable. The number of patients needed to differentiate 
PD from any of the AP as well as all the AP independently in a prospective study would be 
enormous to ascertain enough patients with the individual diagnoses after follow-up. 
Nonetheless, our clinical algorithm was designed to differentiate between PD and AP, but 
not to clarify which specific form of AP a patient has. To solve this problem, one should use 
the clinical examination to narrow the differential diagnosis down to two diseases, in 
which ancillary investigations can then be used to shift the balance. Hence, based on the 
prior case control studies (Hall et al. 2012; Mahlknecht et al. 2010; Winge et al. 2010) the 
only rational approach to employ ancillary investigations would be to employ these to 
answer a specific dilemma, such as differentiating PD from MSA. This approach stresses 
the importance of clinical assessments. In a future study, we will design and evaluate a 
structured clinical assessment to aid the clinician in this respect.
Illustration
The importance of clinical examination and history taking is illustrated in chapter 4.3. 
Simply asking about whether or not a patient had stopped cycling yielded a high 
diagnostic accuracy to discriminate PD and AP. Before their first disease manifestation, 111 
patients rode a bicycle. 45 went on to develop a silver-standard diagnosis of PD and 64 a 
form of AP. At the time of inclusion (median disease duration 10 months), 34 of the 64 
patients with atypical parkinsonism had stopped cycling, as opposed to only two of the 
45 patients with Parkinson’s disease (sensitivity 52%, specificity 96%; AUC 0.74, 95% cl 
0.64-0.83). The loss of cycling abilities was present for all forms of atypical parkinsonism. 
This might be explained by the observation that balance deficits in PD are dependent on 
direction. Mediolateral stability is relatively preserved in patients with idiopathic PD, as 
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was demonstrate in dynamic posturography experiments where patients were exposed 
to multidirectional balance perturbations; maintaining balance sideways was hardly 
affected in PD patients, whereas maintaining balance in the backward was less compared 
to controls. (Carpenter et al. 2004) This preserved mediolateral stability could also explain 
why PD patients typically walk with a narrow-based gait and why tandem gait is preserved 
in most patients. (Abdo et al. 2006; Carpenter et al. 2004) In contrast, in patients presenting 
with a form of AP, mediolateral stability is much more affected, possibly due to more 
extended lesion load in AP disorders, extending beyond the nigrostriatal system.
 
Future perspectives
One can argue that the ancillary investigations evaluated in our study are outdated. This 
might be true for IBZM SPECT scanning, however, the other methods are still used in daily 
practice. The rationale behind these investigations was to evaluate different categories, 
namely structural evaluation (brain MRI), functional evaluation (IBZM-SPECT), biochemical 
evaluation (CSF) and clinical neurophysiological evaluation (EMG of the anal sphincter). 
After the design and subsequent start of the study, new techniques have become 
available such as diffusion tensor imaging (DTI) and functional MRI techniques,18F-fluoro-
deoxyglucose (FDG) positron emission tomography (PET), as well as DJ-1 analysis in CSF. 
FDG PET is a novel technique, visualizing the metabolic activity in the brain. Specific 
disease related networks with abnormal metabolic activity have been defined for not only 
PD, but also MSA and PSP. In one large cohort study, FDG PET yielded high diagnostic 
accuracy (sensitivity >84% and specificity >91% ) in the differentiation between PD and 
AP. (Tang et al. 2010) However, limited availability and the use of radioactive tracers remain 
notable disadvantages.
MRI DTI is a technique to visualize the orientation and integrity of white matter tracts, as 
well as gray matter areas. Another novel technique is the 7T-MRI, which enables the 
detailed visualization of specific brain areas such as the substantia nigra. Both techniques 
are not used in daily patient care yet, but have demonstrated promising results in research 
setting. (Kwon et al. 2012; Vaillancourt et al. 2009)  
DJ-1 and the newer MRI techniques mentioned before will be subject of our future 
research. However, chances are that these more up-to-date ancillary investigations are 
hampered in exactly the same way as the investigations that were evaluated in the current 
study. 
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Conclusion 
A thorough clinical evaluation remains of the utmost importance to narrow down the 
differential diagnosis of parkinsonism, and ancillary investigations should not be used in 
every patient as part of a standardized work-up. Nonetheless, this is often still the case in 
daily practice. In this thesis, we have established that this is not a rational approach, as the 
contribution over and above the clinical diagnosis is low. Moreover, most ancillary 
investigations are costly, invasive and some are potentially even harmful.
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Introductie
Dit proefschrift gaat over patiënten met de ziekte van Parkinson (ZvP) en ziekten die daar 
op lijken (atypische parkinsonismen, AP). De ziekte van Parkinson is een neurologische 
ziekte waarbij zenuwcellen in een bepaald deel van de hersenen afsterven door insluitsels 
van een bepaald eiwit,  α-synucleïne, in die hersencellen. Deze cellen zijn een belangrijke 
bron van dopamine, een signaalstof in de hersenen die cellen gebruiken om met elkaar te 
communiceren. Patienten met ZvP zijn vaak stijf (rigiditeit), hebben moeite met het 
vloeiend en snel uitvoeren van bewegingen en ook met het uitvoeren van minder 
automatische bewegingen zoals mimiek van het gelaat (brady-/hypokinesie). Deze 
combinatie wordt ‘hypokinetisch rigide syndroom’ genoemd. Trillen (tremor), vaak van 
een hand of been, is een ander bekend symptoom. In de loop van de ziekte ontwikkelen 
patienten vaak houdingsproblemen. Deze klachten zijn (gedeeltelijk) te behandelen met 
tabletten die dopamine bevatten. De ziekte zelf kan vooralsnog niet geremd worden. 
Er zijn ziekten die lijken op de ziekte van Parkinson maar het niet zijn (AP). Om een aantal 
redenen is het belangrijk om deze ziekten van ZvP te onderscheiden. Ten eerste is het 
verloop van deze AP veelal veel sneller en ernstiger dan bij ZvP. Ook kent ieder van de 
verschillende AP zijn eigen complicaties waarop je als patient en als behandelend arts 
bedacht zou moeten zijn. Ook voor voorlichting naar patiënten toe is dit zeer belangrijk. 
Ten tweede is de te verwachten respons op medicatie verschillend voor de verschillende 
ziektebeelden. Als laatste is het voor verder onderzoek enorm belangrijk om patiënten juist te 
diagnosticeren, zodat de juiste patiënten in de juiste studies geincludeerd kunnen worden.
 
Atypische parkinsonismen
De groep atypische parkinsonistische syndromen omvat Multipele Systeem Atrofie (MSA), 
Dementie met Lewy Bodies (DLB), Progressieve Supranucleaire Paralyse (PSP) en het 
Corticobasaal syndroom (CBS).
Bij MSA en DLB ontstaat schade, net als bij ZvP door insluitseltjes van α-synucleïne in 
bepaalde hersencellen, die hierdoor beschadigd raken en afsterven. Deze ziekten worden 
daarom samen ook wel α-synucleopathieen genoemd. Bij PSP en CBS is het niet het 
α-synucleïne eiwit dat problemen oplevert maar ontstaat stapeling en insluitsels van tau- 
eiwit op bepaalde plekken. Deze ziekten worden samen ook wel tauopathieen genoemd.
Hieronder volgt een korte beschrijving van de verschillende ziektebeelden die aan de 
orde komen in dit proefschrift.
Multiple systeem atrofie
Multipele Systeem Atrofie (MSA) wordt klinisch gekarakteriseerd door een combinatie van 
een symmetrisch hypokinetisch-rigide syndroom, cerebellaire ataxie (problemen met de 
coördinatie, gelijkend op dronkenschap), autonome functiestoornissen (o.a. problemen 
met plassen en duizeligheid bij overeindkomen) en, minder frequent, piramidebaan-
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verschijnselen. De patiënten reageren over het algemeen slecht tot matig op dopamine 
therapie, hoewel initieel een goede respons mogelijk is. Er wordt onderscheid gemaakt 
tussen 2 subtypes, MSA-c wanneer cerebellaire symptomen op de voorgrond staan en 
MSA-p wanneer de parkinsonistische symptomen de overhand hebben. De ziekte openbaart 
zich meestal rond het 50ste levensjaar en is over het algemeen snel progressief. Gemiddeld 
worden patiënten binnen 5-6 jaar rolstoelafhankelijk. De ziekteduur is gemiddeld 8-9 jaar. 
Dementie met Lewy bodies
Dementie met Lewy bodies (DLB) is een dementieel syndroom gekarakteriseerd door 
sterk wisselende cognitie, visuele hallucinaties, een hypokinetisch-rigide syndroom en 
autonome functiestoornissen. Een bijkomend symptoom is een verhoogde gevoeligheid 
voor bepaalde medicijnen. 
Progressieve supranucleire paralyse
Progressieve Supranucleaire Paralyse (PSP) wordt klinisch gekarakteriseerd door een 
hypo kinetisch-rigide syndroom met houdingsinstabiliteit, leidend tot frequent vallen 
vroeg in het ziektebeloop, cognitieve achteruitgang en problemen met het in verticale 
richting bewegen van de ogen. De leeftijd waarop de symptomen zich openbaren 
varieert van 50 tot ongeveer 70 jaar. De ziekte is snel progressief, met een gemiddelde 
overleving van 6-9 jaar na stellen van de diagnose.  
Corticobasaal syndroom
Corticobasaal syndroom (CBS) wordt klinisch gekarakteriseerd door een asymmetrisch, 
slecht dopa-responsief hypokinetisch-rigide syndroom, dystonie (afwijkende stand van 
ledematen) en asymmetrische corticale dysfunctie (zoals problemen met de juiste volgorde 
van handelingen, of minder controle over de ledematen.) De ziekte komt gemiddeld zo rond 
het 60ste jaar tot uiting en is snel progressief met een gemiddelde overleving van 8 jaar. 
De evaluatie van een patient met parkinsonisme in  
de klinische praktijk
In het eerste gedeelte van dit proefschrift schetsen we de achtergrond van het klinisch 
onderzoek bij een patient met parkinsonisme in de dagelijkse praktijk.  
Het stellen van een klinische diagnose ‘parkinsonisme’ kan lastig zijn maar om onderscheid 
te maken tussen de verschillende oorzaken van parkinsonisme is vaak nog veel lastiger. 
Het hanteren van een systematische benadering, zoals beschreven in hoofdstuk 2, maakt 
het voor de behandelend arts gemakkelijker om belangrijke klachten en verschijnselen 
niet over het hoofd te zien en leidt in het algemeen tot meer nauwkeurigheid bij het 
stellen van een diagnose vroeger in het ziektebeloop. 
Nederlandse samenvatting
7
143
Deze gestructureerde benadering bestaat uit 3 stappen. De eerste stap is, voor de hand 
liggend maar zeer belangrijk, om te kijken of de patient daadwerkelijk een hypokinetisch-
rigide syndroom heeft. De tweede stap is dan om de patient nauwkeurig en systematisch 
te onderzoeken en specifiek te kijken naar ‘rode vlaggen’; bepaalde symptomen die niet 
goed passen bij ZvP maar mogelijk duiden op een van de genoemde AP. De derde stap is 
het integreren van de eerste 2 stappen om zo te komen tot een einddiagnose die dan 
indien gewenst bevestigd of versterkt kan worden met bepaalde vormen van aanvullend 
onderzoek.
Biochemisch onderzoek
In het tweede deel van het proefschrift is gekeken naar de mogelijke bijdrage van het 
onderzoek van hersenvocht om de waarschijnlijkheidsdiagnose na het klinisch onderzoek 
te bevestigen. We hebben hiervoor gekeken naar diverse eiwitten in het hersenvocht van 
patiënten die van belang lijken te zijn bij de pathofysiologie van de verschillende ziekten. 
In hoofdstuk 3.1 hebben we gekeken naar de concentraties van onder andere tau eiwit 
bij patiënten met ZvP (n=28)  maar ook met PSP (n=21) en CBS (n=12), beide tauopathieen. 
We hebben met dit onderzoek laten zien dat de concentratie van vormen van dit tau eiwit 
in het hersenvocht bij patiënten met CBS significant hoger is dan bij patiënten met PSP of 
ZvP. Het onderscheidend vermogen van deze bevinding lijkt echter alleen voldoende om 
patiënten met CBS te onderscheiden van patiënten met ZvP, en niet PSP en CBS patiënten 
onderling, of patiënten met PSP en patiënten met ZvP .
In hoofdstuk 3.2 hebben we gekeken we naar verschillen in de concentraties van 
α-synucleine in het hersenvocht van 142 patienten met een hypokinetisch-rigide 
syndroom. Na 3 jaar follow up bleken 58 patienten ZvP te hebben, 47 patienten MSA, 3 
patienten DLB, 22 patienten vasculair parkinsonisme, 10 patienten PSP en 2 patienten CBS. 
We hebben laten zien dat we, ondanks deze relatief grote patiëntengroep, geen verschil 
konden aantonen tussen de verschillende groepen patiënten. Vooralsnog heeft 
α-synucleine analyse van het hersenvocht dus niet voldoende onderscheidend vermogen 
om de verschillende ziekten van elkaar te onderscheiden. 
In hoofdstuk 3.3 hebben we gekeken naar verschillende eiwitten en neurotransmitter-
metabolieten (afbraakproducten van signaalstoffen die hersencellen gebruiken om 
prikkels door te geven) in het hersenvocht van patiënten met DLB (n=23) en patiënten 
met de ziekte van Alzheimer (n=45), een andere belangrijke veroorzaker van dementie. 
We hebben laten zien dat de concentraties van drie belangrijke neurotransmitter-
metabolieten 5-HIAA (serotonine afbraakproduct), HVA (dopamine afbraakproduct) en 
MHPG (noradrenaline afbraakproduct) verlaagd waren in patiënten met DLB. Door deze 
neurotransmittermetabolieten te combineren met de eiwitten β-amyloid en tau kon met 
zeer grote nauwkeurigheid onderscheid gemaakt worden tussen deze ziektebeelden.
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Over het geheel genomen zijn de resultaten van de analyse van deze eiwitten, met name 
tau eiwit en α-synucleine in het hersenvocht teleurstellend als het gaat over het 
onderscheiden van ZvP versus AP. Gedeeltelijk is dit misschien te verklaren doordat in 
de groep AP verschillende ziektebeelden bijeen genomen worden die wat betreft patho-
fysiologie niet altijd even goed vergelijkbaar zijn. Kleine nuanceverschillen kunnen 
hierdoor verloren zijn gegaan.
De combinatie van klinisch neurologisch onderzoek en 
aanvullende onderzoeken
In het derde deel van het proefschrift beschrijven we de opzet (hoofdstuk 4.1) en 
resultaten (hoofdstuk 4.2) van een grote studie gericht op het vroeg onderscheiden van 
ZvP en AP. We vergeleken in deze studie de individuele waarde van verschillende vormen 
van aanvullend onderzoek, namelijk analyse van hersenvocht, MRI-scan van de hersenen, 
IBZM scan (beeldvorming van dopamine receptoren) en electromyografisch onderzoek 
van de sluitspier. Belangrijker dan deze individuele waarde is wellicht nog de relatieve 
waarde van de verschillende onderzoeken in vergelijking met elkaar en als aanvulling op 
het klinisch neurologisch onderzoek.
Als eerste stap werd het klinisch neurologisch onderzoek gestandaardiseerd en werden 
138 verschillende parameters geïdentificeerd, variërend van de aanwezigheid van trillen 
van een van de ledematen tot leeftijd en geslacht. Uit deze groep van parameters bleek 
een aantal parameters op zich al redelijk te voorspellen of een patient ZvP of AP had. Een 
van de beste voorspellers bleek of een patient al dan niet 10 stapjes voetje voor voetje 
over een lijn kon lopen (koorddansers-gang). De combinatie van deze koorddansers-gang 
met een subscore van de UPDRS (het gestandaardiseerde onderzoek gericht op ZvP) 
bleek een AUC (area under the curve) te hebben van 0.90. 
Geen van de genoemde vormen van aanvullend onderzoek bleek in staat dit verder te 
verhogen. Zelfs in de groep patiënten waar de neuroloog het moeilijk vond om de 
diagnose te stellen bleken deze vormen van aanvullend onderzoek niet bij te dragen. 
De belangrijkste conclusie van deze grote studie is dan ook dat een nauwkeurig en 
 gestandaardiseerd neurologisch onderzoek de sleutel lijkt te zijn voor een snelle en goede 
diagnose. Dit wordt geïllustreerd in hoofdstuk 5 waarin wij de observatie beschrijven dat 
patiënten met ZvP tot lang in de ziekte nog goed kunnen fietsen, terwijl patiënten met AP 
daar veelal meer moeite mee hebben en daarom stoppen met fietsen. De vraag ‘fietst u 
nog’ kon bij een eerste bezoek van een patient met hypokinetisch-rigide symptomen op 
onze polikliniek goed voorspellen of deze patient als uiteindelijke diagnose ZvP of AP zou 
krijgen. Een mooi voorbeeld van het belang van anamnese en neurologisch onderzoek! 
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Box 1   Take home messages
· Naast de ziekte van Parkinson bestaan er ziekten die daar sterk op lijken (atypische 
parkinsonismen)
· Onderscheid is belangrijk voor adequate zorg, voorlichting en voor onderzoeksdoeleinden
· Een nauwkeurig neurologisch onderzoek is de kern van goede en snelle diagnose
· Aanvullend onderzoek zoals in deze studie verricht draagt hier niet of nauwelijks aan bij.
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Lieve Anke, meester in het combineren van opleiding, onderzoek en het hebben van een 
gezin. Dank voor je goede voorbeeld en voor alle tips and tricks. Ik ben heel blij dat jij hier 
op dit moment als paranimf naast mij staat!
Lieve Nathalie, nog altijd snap ik niet wat ons bezield heeft om naar Israël te gaan maar 
wat was het een goed idee! Ik hoop dat we nog heel lang eindeloos kunnen kletsen. 
Ik ben enorm blij dat jij vandaag naast mij wil staan als paranimf! 
Vrienden en (schoon)familie, dank voor alle ontspannen momenten en lekkere etentjes. 
Lieve pap en  mam, bedankt! Gewoon omdat jullie er altijd voor mij waren, zijn en hopelijk 
nog heel lang zullen blijven. Maarten, lieve broer, ik hoop dat je nog heel lang ‘even 
gezellig een kopje koffie’ komt doen. 
Marvin en Lauke, lieve schatten, wat heb ik geboft met jullie in mijn leven. Ik houd boelveel 
van jullie!
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Marjolein Berdina Aerts was born on January 27th 1984 in Meyrin (Switzerland). She 
finished her secundary education at Augustinianum, Eindhoven in 2002 (cum laude). She 
started medical school afterwards at the Radboud University in Nijmegen. After travelling 
and doing volunteer work in South Africa, she obtained her doctoral degree in 2006 (cum 
laude).  After the regular clerkships Marjolein performed a scientific elective at the Sourasky 
Medical Centre, in Tel Aviv Israel in 2008 with a scholarship of the Huygens Talents Program. 
Here she learned Hebrew and worked with prof. Nir Giladi investigating promotor 
manifestations of Parkinson’s disease. After graduation in 2008 (bene meritum) she 
worked one year as a resident in the Intensive Care department of the Elizabeth Hospital 
in Tilburg. In 2009 she started her PhD on improving the diagnostic aproach of PD and 
atypical parkinsonism in the Neurology department of the Radboud University Medical 
Centre under supervision of prof. Bas Bloem, dr. ing. Marcel Verbeek and dr. Rianne Esselink. 
In 2011 she started her training as a neurological resident, also in Nijmegen under 
supervision of prof. GWAM Padberg, which she hopes to finish in 2018. During the past 
years she has combined research and clinical training. Marjolein is married to Marvin 
Berrevoets. Together they have one daughter, Lauke.
Marjolein Berdina Aerts is geboren op 27 januari 1984 in Meyrin (Zwitserland). Ze volgde 
Voorbereidend wetenschappelijk onderwijs aan het Augustinianum in Eindhoven (cum 
laude). In 2002 begon zij aan haar studie Geneeskunde aan de Radboud Universiteit 
Nijmegen, gecombineerd met deelname aan het Honoursprogramma. Na een periode 
van reizen en vrijwilligerswerk in Zuid-Afrika behaalde zij haar doctoraalexamen in 2006 
(cum laude). Haar co-schappen doorliep zij in Nederland, waarna zij haar wetenschappelijke 
stage verrichtte aan het Sourasky Medical Centre te Tel Aviv, Israel, met een beurs van het 
Huygens Talentenprogramma. Onder supervisie van prof. Nir Giladi deed zij onderzoek 
naar vroege verschijnselen van de ziekte van Parkinson. Na haar artsexamen werkte 
Marjolein een jaar als arts-assistent op de Intensive Care van het Elizabeth Ziekenhuis 
in Tilburg. In 2009 startte zij haar promotieonderzoek naar het onderscheid tussen de 
ziekte van parkinson en atypische parkinsonismen in de klinische praktijk bij de afdeling 
Neurologie van het Radboud Universitair Medisch Centrum onder begeleiding van prof 
Bas Bloem, dr. ing. Marcel Verbeek en dr. Rianne Esselink. Begin 2011 startte zij, ook in 
Nijmegen, met de opleiding tot neuroloog onder supervisie van prof. GWAM Padberg. 
De afgelopen jaren combineerde zij onderzoek en opleiding. Marjolein is gehuwd met 
Marvin Berrevoets. Samen hebben zij een dochter, Lauke.
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